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Abstract Oncogenic activation of tyrosine kinases is a common feature in 
cancer, and its regulation represents an excellent antitumoral target. Tyrosine 
phosphorylation is also controlled by protein-tyrosine phosphatases (PTPs). 
Recent evidence has shown that PTPs can function as tumour suppressors. An 
improved understanding of how these enzymes function and how they are 
regulated might aid the development of new anticancer agents. 
It has been shown that cross-regulation of kinases/phosphatases and 
caspases allows for fine-tuning of the apoptotic threshold, as well as the 
opportunity to amplify apoptotic signals. The signaling pathways involved in 
the control of cell proliferation, adhesion and migration are governed by the 
balanced action of protein tyrosine kinases (PTKs) and protein-tyrosine 
phosphatases (PTPs). 
 
Keywords caspases, pathway, kinases, phosphatases. 
 
Abbreviations IAPs, Inhibitor of Apoptosis Proteins; TRADD, TNF 
receptor-associated death domain; FADD, Fas-associated death domain; 
DISC, death-inducing signaling complex; AIF, apoptosis inducing factor; 
Smac, second mitochondria-derived activator of caspase; TRAF2, TNF 
receptor associated factor 2; Erk, extracellular signal-regulated kinase; Cdk1, 
cyclin-dependent kinase; PTKs, protein tyrosine kinases; PTPs, protein-
tyrosine phosphatases; PTPRJ, Protein Tyrosine Phosphatase receptor like-j; 
CaMKII,                                          Ca
2+
/Calmodulin-dependent protein kinase II; GRK2, 
G-protein-coupled receptor kinase 2; FasL, Fas ligand; LOH, loss of 
heterozygosity; S2ED, heparin sulfate proteoglycan Syndecan-2; TSP1, 
Thrombospondin- 1; GPCRs, G protein coupled receptors; 2AR,2-




Cancer can be viewed as the result of a succession of genetic changes 
during which a normal cell is transformed into a malignant one while evasion 
of cell death is one of the essential changes in a cell that cause this malignant 
transformation.
1,2
 As early as the 1970’s, Kerr et al. had linked apoptosis to the 
elimination of potentially malignant cells, hyperplasia and tumour 
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 Hence, reduced apoptosis or its resistance plays a vital role in 
carcinogenesis.  
Apoptosis is a form of programmed cell death that eliminates individual 




However, it was not until the mid-1990s that apoptosis was linked to the 
activation of the cysteine-dependent aspartate driven proteases (caspases),
5,6
 
which cleave key intracellular substrates to promote cell death. Given the 
critical role that caspases play in dismantling the cell during apoptosis, their 
activation and subsequent activity are highly regulated. Failure of a cell to 
properly modulate caspase activity can cause aberrant or untimely apoptotic 




There are many ways through which a malignant cell can acquire reduction 
in apoptosis or apoptosis resistance. Generally, the mechanisms of the evasion 
of apoptosis can be broadly dividend into: 1) disrupted balance of pro-
apoptotic and anti-apoptotic proteins (like Bcl-2 family, p53 and Inhibitor of 
Apoptosis Proteins (IAPs); 2) reduced caspase function and 3) impaired death 
receptor signaling.  
 
1.1 Caspases, a family of cysteine proteases 
 
The caspases are a family of cysteine proteases that are constitutively 
present in most mammalian cells, and they reside in the cytosol as single chain 
proenzymes.  
The primary structure of a caspase is an amino-terminal prodomain and a 
carboxy-terminal protease domain, which contains the key catalytic cysteine 
residue. Caspases are categorized as initiator or effector caspases, based on 
their position in apoptotic signaling cascades. The initiator caspases (caspase-
2, -8, -9, and -10) act apically in cell death pathways and all share long, 
structurally similar prodomains.
9,10
 This group of enzymes is activated through 
“induced proximity” when adaptor proteins interact with the prodomains and 
promote caspase dimerization.
11 , 12
In contrast, the effector caspases 
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(caspase-3, -6, and -7) have shorter prodomains and exist in the cell as 
preformed, but inactive, homodimers. Following cleavage mediated by an 
initiator caspase, effector caspases act directly on specific cellular substrates to 
dismantle the cell. Although many individual caspase substrates have been 
implicated in specific aspects of cellular destruction (e.g., lamin cleavage is 
required for the efficient packaging of nuclei into small membrane-bound 
vesicles), recent proteomic approaches have greatly expanded the known 
repertoire of proteolytic products generated during apoptosis.
13
 Further work 
will be needed to confirm these findings and to determine how (or if) all of 
these substrates participate in the apoptotic process,
14
 especially as new details 
emerge on the relationship between posttranslational modifications, like 




1.2 Apoptotic pathways  
 
There are three pathways by which caspases can be activated. The two 
commonly described initiation pathways are the intrinsic (or mitochondrial) 
and extrinsic (or death receptor) pathways of apoptosis (Figure 1). Both 
pathways eventually lead to a common pathway or the execution phase of 





1.2.1 The extrinsic death receptor pathway  
 
The extrinsic death receptor pathway, as its name implies, begins when 
death ligands bind to a death receptor. Although several death receptors have 
been described, the best known death receptors is the type 1 TNF receptor 
(TNFR1) and a related protein called Fas (CD95) and their ligands are called 
TNF and Fas ligand (FasL) respectively.
17
 These death receptors have an 
intracellular death domain that recruits adapter proteins such as TNF receptor-
associated death domain (TRADD) and Fas-associated death domain (FADD), 
as well as cysteine proteases like caspase 8.
18
 Binding of the death ligand to 
the death receptor results in the formation of a binding site for an adaptor 
protein and the whole ligand-receptor-adaptor protein complex is known as the 
death-inducing signaling complex (DISC). DISC then initiates the assembly 
and activation of pro-caspase 8. The activated form of the enzyme, caspase 8 
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is an initiator caspase, which initiates apoptosis by cleaving other downstream 
or executioner caspases. 
 
1.2.2 The intrinsic mitochondrial pathway 
 
As its name implies, the intrinsic pathway is initiated within the cell. 
Internal stimuli such as irreparable genetic damage, hypoxia, extremely high 
concentrations of cytosolic Ca
2+
 and severe oxidative stress are some triggers 
of the initiation of the intrinsic mitochondrial pathway. Regardless of the 
stimuli, this pathway is the result of increased mitochondrial permeability and 
the release of pro-apoptotic molecules such as cytochrome-c into the 
cytoplasm.
19
 The intrinsic pathway is closely regulated by a group of proteins 
belonging to the Bcl-2 family, named after the BCL2 gene originally observed 
at the chromosomal breakpoint of the translocation of chromosome 18 to 14 in 
follicular non-Hodgkin lymphoma. There are two main groups of the Bcl-2 
proteins, namely the pro-apoptotic proteins (e.g. Bax, Bak, Bad, Bcl-Xs, Bid, 
Bik, Bim and Hrk) and the anti-apoptotic proteins (e.g. Bcl-2, Bcl-XL, Bcl-W, 
Bfl-1 and Mcl-1).
20
 While the anti-apoptotic proteins regulate apoptosis by 
blocking the mitochondrial release of cytochrome-c, the pro-apoptotic proteins 
act by promoting such release. It is not the absolute quantity but rather the 
balance between the pro- and anti-apoptotic proteins that determines whether 
apoptosis would be initiated. Other apoptotic factors that are released from the 
mitochondrial intermembrane space into the cytoplasm include apoptosis 
inducing factor (AIF), second mitochondria-derived activator of caspase 
(Smac), direct IAP Binding protein with low pI (DIABLO) and Omi/high 
temperature requirement protein A (HtrA2). Cytoplasmic release of 
cytochrome c activates caspase 3 via the formation of a complex known as 
apoptosome which is made up of cytochrome c, Apaf-1 and caspase 9.
21
 On 
the other hand, Smac/DIABLO or Omi/HtrA2 promotes caspase activation by 
binding to inhibitor of apoptosis proteins (IAPs) which subsequently leads to 
disruption in the interaction of IAPs with caspase-3 or -9.
22
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1.2.3 The common pathway 
 
The execution phase of apoptosis involves the activation of a series of 
caspases. The upstream caspase for the intrinsic pathway is caspase 9 while 
that of the extrinsic pathway is caspase 8. The intrinsic and extrinsic pathways 
converge to caspase 3. Caspase 3 then cleaves the inhibitor of the caspase-
activated deoxyribonuclease, which is responsible for nuclear apoptosis. In 
addition, downstream caspases induce cleavage of protein kinases, 
cytoskeletal proteins, DNA repair proteins and inhibitory subunits of 
endonucleases family. They also have an effect on the cytoskeleton, cell cycle 
and signaling pathways, which together contribute to the typical 






Figure 1. The intrinsic and extrinsic pathways of apoptosis. 
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1.2.4 The intrinsic endoplasmic reticulum pathway 
 
This intrinsic endoplasmic reticulum (ER) pathway is a third pathway and 
is less well known. It is believed to be caspase 12-dependent and 
mitochondria-independent.
24
 When the ER is injured by cellular stresses like 
hypoxia, free radicals or glucose starvation, there is unfolding of proteins and 
reduced protein synthesis in the cell, and an adaptor protein known as TNF 
receptor associated factor 2 (TRAF2) dissociates from procaspase-12, 
resulting in the activation of the latter. 
 
1.3 The bidirectional communication between caspases and 
kinases/phosphatases  
 
Although the cleavage of many caspase substrates is required for the 
structural packaging of cellular contents during apoptosis, a subset of caspase 
substrates are signaling molecules whose cleavage alters their signaling 
properties to affect the internal environment of the dying cell. In turn, 
signaling molecules can modulate caspase function to positively or negatively 
alter the trajectory of the cell death program. Given the millions of reversible 
phosphorylation events necessary to maintain cellular homeostasis and to 
allow cells to adapt nimbly to changing internal and external environments, 
the bidirectional communication between caspases and the 




With respect to phosphorylation, both the caspase activation process and 
intrinsic enzymatic activity are under the control of modifying kinases and 
phosphatases. This permits cellular flexibility in setting a threshold for the 
induction of apoptosis in response to alterations in the cellular environment 
(for example, after growth factor stimulation or changes in cellular 
metabolism) through changes in the activity of pro- or antiapoptotic kinases 
and phosphatases. Phosphorylation may also control caspase activity indirectly 
by controlling other apoptotic modulators (including caspase binding 
partners). If we consider that the control of caspases can be exerted via their 
direct phosphorylation, focused on caspase 9 we find that of caspase 9 may 
result in the failure of apoptotic induction. In particular the phosphorylation of 
caspase 9 by both Erk (extracellular signal-regulated kinase) and Cdk1 
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(cyclin-dependent kinase 1) suppresses caspase 9 activation.
26
 Given that the 
Erk pathway is upregulated in a variety of cancers, this inhibitory 
phosphorylation of caspase 9 may contribute to apoptotic (and therefore 
chemotherapeutic) resistance. It’s note that phosphorylation and inhibition of 
caspase 9 by ERK promotes cell survival during development and tissue 
homeostasis suggesting that phosphorylation of Thr 125 on caspase 9 may be 
an important mechanism through which growth factor and survival signals that 
activate the ERK-MAPK pathway can inhibit apoptosis. 
Therefore the apoptosis pathway could be regulated by a phosphorylation 
and a dephosphorylation event of apoptotic effectors.  
Cross-regulation of kinases/phosphatases and caspases allows for fine 
tuning of the apoptotic threshold, as well as the opportunity to amplify 
apoptotic signals. 
In the apoptotic process, the regulatory role of protein kinases is clearly 
established instead of the regulatory role of protein phosphatases is not clear. 
For this reason we are interested in the regulation of signaling responses of 
phosphatases. 
However, it has recently become apparent that protein phosphatases can no 
longer be viewed as passive housekeeping enzymes, but they partner with 
kinases in the regulation of signaling responses. The distinct but 
complementary function of these enzymes is emphasized by recent studies, in 
which kinases have been implicated in controlling the amplitude of signaling 
responses, whereas phosphatases are thought to have an important role in 
controlling the rate and duration of the response.
27,28   
 
In base to these considerations, my doctoral thesis aimed to identify 
chemical entities able to regulate the apoptotic process through the modulation 
of phosphatase and kinase activities. Therefore, I studied 1) PTPRJ, a protein 
tyrosine phosphatase receptor like j; 2) GRK2, G protein-coupled receptor 
kinase 2; and 3) CaMKII, Ca
2+
/Calmodulin-dependent protein kinase II. 
 
1.4 Protein Phosphatases 
 
The first PTP was purified in 1988, approximately 10 years after the 
discovery of tyrosine kinases. It is now known that PTPs constitute a large, 
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It is also clear that PTPs have both inhibitory and stimulatory effects on 
cancer associated signaling processes, and that deregulation of PTP function is 
associated with tumorigenesis in different types of human cancer. 
Among all protein tyrosine phosphatases, PTPRJ is of particular interest for 
its role in human and experimental tumorigenesis.
31
 In fact, after its 
discovery,
32
a consistent body of literature supports its tumor suppressor 
activity in several models. PTPRJ (also named DEP-1, HPTPη, or CD148) is 
down-regulated in mammary cancer cells, and its restoration blocks their 
proliferation; a similar behavior was described in both human and 
experimental models of thyroid tumorigenesis, where PTPRJ overexpression 
was able to interfere with cancer cells malignant phenotype both in vitro and 
in vivo.
33
 Moreover, down-regulation of PTPRJ expression operated by miR-
328 increases cell proliferation in HeLa and SKBr3 cell lines.
34
 
PTPRJ has been successfully used as a therapeutic gene in cancer gene 
therapy preclinical models of thyroid and pancreatic cancer.
35
 The role of 
PTPRJ in human tumorigenesis was also highlighted by Ruivenkamp et al.,
 36
 
who demonstrated that PTPRJ was affected by loss of heterozygosity (LOH) 
in colon, lung, and mammary tumors; a significant percentage of LOH was 
also described in human thyroid tumors.
37
 Moreover, a polymorphism in the 
mouse Ptprj locus (Scc1) is associated with colon cancer development, 
although Ptprj genetic ablation did not induce spontaneous tumors in mice.
38,39
 
The biochemical pathways negatively regulated by PTPRJ have been partly 
elucidated. Various reports indicate an inhibitory effect of PTPRJ on several 
players of the mitogenic signals in both normal and cancer cells. In fact, 
CD148 interacts with and dephosphorylates numerous receptor tyrosine 
kinases (RTKs) including PDGFR, HGFR,
 40,41
 RET, and EGFR
42,43
 whose 
aberration in cancer cells is responsible for self sufficiency cell growth.
44
 
PTPRJ is also a negative modulator of the signaling mediated by cytosolic 





 Noteworthy, the role of PTPRJ on the inhibition of RTKs was also 
extended to VEGFR-2,
48,49
 whose activity is required for the formation of new 
vessels in tumor progression. Lately, PTPRJ ligands have been discovered, 





 CD148 acts as key intermediary in S2ED 
mediated cell adhesion, by modulating downstream β1 integrin mediated 
adhesion and cytoskeletal organization, whereas TSP1, a glycoprotein that 
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mediates cell-cell and cell-matrix interactions, increases PTPRJ activity, 
influencing the dephosphorylation of its substrates. These findings make 
PTPRJ an interesting candidate for the generation of novel therapeutic 
strategies.  
 
1.4.1 PTPRJ regulates cell growth and cell cycle 
 
The tumor-suppressive role of PTPRJ was clearly displayed in experiments 
where highly malignant thyroid cells, after transduction by a retrovirus 
carrying CD148, appeared to acquire a normal phenotype and showed 
increased adhesion, restoration of differentiation, reduced proliferation and 
decreased tumorigenicity. The same report established that PTPRJ induced a 
G1 growth arrest by suppressing the degradation of the cyclin-dependent 
kinase inhibitor p27kip1 protein. 
Therefore, synthetizing PTPRJ agonists could be one of a possible approach 
in cancer therapy. 
The receptor-like PTP phosphatase DEP-1 opposes various oncogenic 
receptor tyrosine kinases. Recently, DEP-1 agonists were isolated from a 
random peptide phage-display library.
52
  
Intriguingly, these agonists circularize in vitro via an intramolecular 
disulfide bridge and form stable dimers that induce the dimerization-mediated 
activation of DEP-1 (Figure 2). Consistent with the activation of DEP-1 as a 
tumor suppressor, these peptides reduced proliferation and triggered apoptosis 
of cancer cells.  
 
 
Figure 2. Small-molecule activators of protein phosphatases. 
 
Starting from these observations during my PhD I focused the attention on 
two peptides, recently identified by means of a phage display library, able to 
bind and activate PTPRJ ([Cys-His-His-Asn-Leu-Thr-His-Ala-Cys]-OH and 
[Cys-Leu-His-His-Tyr-His-Gly-Ser-Cys]-OH) designing and synthetizing new 
PTPRJ agonists with the aim to identify a more stable and active peptide 
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 These informations could help the design of peptidomimetics with 
PTPRJ agonistic properties.  
 
1.5 Protein kinases as drug targets 
 
Nearly every cellular process is controlled by phosphorylation of key 
regulatory proteins on specific serine (Ser), threonine  (Thr), or tyrosine (Tyr) 
residues. The covalent attachment of a bulky and negatively charged 
phosphate group by a kinase usually induces a conformational change that 
affects protein function. Mammalian genomes harbor more than 500 genes that 
encode protein kinases. Almost all of these belong to the same protein kinase 
superfamily and have a highly similar catalytic core and mechanism, implying 
that they originate from a common ancestor. In recent years protein kinases 
have become one of the most popular drug targets.
54
 
There are more than 518 human protein kinases recognized through their 
conserved sequence motifs. These constitute the third most populous protein 
family and represent 1.7% of the human genome. Of the total, 478 protein 
kinases are typical kinases, and 40 are atypical. The typical kinases are divided 
into those that phosphorylate serine or threonine residues (388 kinases) and 
those that phosphorylate tyrosine residues (90 kinases). These proteins have 
biochemical kinase activity but lack sequence similarity to the conventional 
eukaryotic kinases. 
A distinguishing feature of the protein kinase family is the different 
structures that they adopt between the active and inactive states. This family 
characteristic was first appreciated following the determination of the first 
protein kinase structures of protein kinase A (PKA) [Protein Data Bank (PDB) 
code 1ATP] in the active conformation and cyclin-dependent protein kinase 2 
(Cdk2) (PDB code 1HCK) in an inactive conformation. 
Deregulation of protein kinase activity through mutation to constitutively 
active forms, loss of negative regulators, and chromosomal rearrangements 
that lead to the formation of active fusion proteins are associated with a 
number of disorders. Protein kinases have become major targets for therapy, 
and protein kinase structures have had a significant impact on the development 
of selective and specific targeted therapy. Phosphorylation of protein 
substrates can have profound effects. Phosphorylation can result in enzyme 
activation, enzyme inhibition, the creation of recognition sites for recruitment 
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of other proteins, and transitions in protein state from order to disorder or 
disorder to order.  
 
1.5.1 Protein kinases in cancer 
 
During my PhD I studied two different protein kinases: Ca
2+
/Calmodulin-
dependent protein kinase II and GRK2, G-protein coupled receptor kinase 2.  
Aberrant protein kinase activity is linked to a range of diseases, most 
notably cancer.
55
 Recent large scale sequencing projects revealed that kinases 
are indeed the most frequently mutated proteins in tumors.
56,57
 
Why is that? Cancer is the malignant growth of cells and tissues, a 
development that requires independence from organism control in a spectrum 
of processes; as for example the proliferation, survival and migration of cells. 
All these functions are orchestrated by protein kinase signaling networks, 
making kinases a likely starting point for dysregulation. This can be achieved 
by alteration of expression levels, but also by introducing activity modulating 
mutations in the kinase domain. Hence it appears logical to fight cancer with 
kinase activity modulating drugs. 
 
The general structure of CaMKs includes an N-terminal kinase domain, an 
autoregulatory domain, an overlapping CaM-binding domain and, in 
phosphorylase kinase and CaMKII, a C-terminal association domain that is 
essential for multimerization and targeting.
58
 The best characterized CaM 
Kinase is CaMKII. 
 
1.5.1.1 CaMKII, Ca 
2+
/Calmodulin-dependent protein kinase II 
 
CaMKII is a serine/threonine protein kinase which plays an essential role in 
central nervous system function.
59 , 60
There are many types of CaMKII 





Therefore, CaMKII plays a variety of functions in different cell types.
63
 
One of the functions CaMKII plays is the control of apoptosis.
64,65
 
However, the mechanism by which CaMKII controls apoptosis remains to 
be determined. p27 was first identified as a cell cycle inhibitor and it was later 
revealed that p27 also functions as a positive cell cycle controller. 
Phosphorylation of serine 10 of p27 induces the translocation of p27 from 
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 Cytoplasmic p27 may control apoptosis.
68
 In 
particular CaMKII can directly bind to MEK1, activate the kinase activity of 
MEK/ERK, and enhance the phosphorylation of p27 protein, therefore 
promoting the S-G2/M transition of the cell cycle progression and then the 





Figure 3. Models depicting the roles of MEK/ERK signaling in CaMKII induced 
promotion of cell cycle progression. 
 
CaMKII also regulates apoptosis by inactivating Bad. One phosphorylation 
site on Bad, Ser170, is a potential CaMKII target, raising the possibility that 
CaMKII phosphorylates Bad directly.  
The mechanism by which CaMKII inactivates Bad involves multiple 
signaling pathways, and differs among cell types. CaMKII also suppresses 
nuclear translocation of histone deacetylase, thereby promoting neuronal 
survival.
69
 Indeed, CaMKII has been shown to activate the pro-survival 
transcriptional regulator NF-κB in T lymphocytes and in neurons.
70
 Because 
dominant-negative CREB constructs do not reduce the pro-survival effect of 
CaMKII, it is unlikely that CREB is the nuclear target of CaMKII. 
Starting from these observations synthetizing CaMKII antagonists could be 




Chapter 1       Programmed cell death pathways in cancer governed by the 
balanced action of PTKs and PTPs 
 
- 13 - 
 
1.5.1.2 GRK2, G-protein coupled receptor kinase 2 
 
Different functions of G-protein coupled receptor kinase 2. Cellular 
proliferation is regulated by specific membrane receptors, including receptor-
tyrosine kinases and G protein coupled receptors (GPCRs), among others. 
GPCRs initiate a variety of intracellular signaling cascades that can modulate 
cell division involving both G protein-dependent and independent 
mechanisms.
72
 Regarding the latter, G protein-coupled receptor kinases 
(GRKs) and β-arrestins, first identified as key molecules involved in the 
agonist-induced desensitization of multiple GPCRs, are emerging as 
alternative signal transducers with a direct or potential impact on cell growth 
and proliferation. 
Whereas β-arrestins can bring different signaling molecules into the 
receptor complex,
73
 a growing number of non-GPCR substrates and 
interacting proteins are being identified for GRKs, particularly for the 
ubiquitous GRK2 isoform. 
These include PDGF and EGF receptors, and a variety of proteins involved 
in pathways controlling cell migration and proliferation, such as p110-PI3K, 
p38Mapk, GIT, MEK, or AKT.
74
 
Consistently, GRK2 expression has been reported to have distinct impacts 
on cell proliferation, depending on both the cell type and the mitogenic stimuli 
analyzed.  
Such canonical role of GRK2 are to inhibit TGF mediated cell growth 
arrest and apoptosis in human hepatocarcinoma cells; to attenuate thyroid 
stimulating hormone- and PDGF-dependent proliferation of thyroid cancer cell 
lines and smooth muscle cells, respectively, whereas it increases mitogenic 
signaling pathways in response to EGF in osteoblasts or upon activation of the 
Smoothened receptor in fibroblasts. Increased GRK2 levels also potentiate 
migration of epithelial cells toward fibronectin and sphingosine-1-phosphate.
75
 
Besides these canonical role, GRK2 can also initiate alternative signaling 
pathways and participate in cellular processes related to cell cycle progression, 
survival, or cell migration by phosphorylating and interacting with non-GPCR 
partners.
76 , 77
 Interestingly, the GRK2 “interactome” in different cell types 
includes several actors in vascular homeostasis and remodeling.
78,79
 
Besides regulating chemokine GPCRs, GRK2 phosphorylates PDGF 
receptors
80
 and also modulates TGF-β signaling in epithelial cells
81
 or cardiac 
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 GRK2 inhibits PDGF-dependent chemotactic signaling in 
VSMCs
83
 and modulates both vasoconstrictory and vasodilatory responses of 
VSMCs,
84
 whereas increased GRK2 attenuates NO production by sinusoidal 
ECs in the context of liver injury.
85
 However, the role of GRK2 in vessel 
formation and stability in other pathophysiological settings has not been 
addressed. Its dosage is important in determining how ECs (Endothelial Cells) 
integrate different relevant physiological stimuli and to balance TGF-β 
signaling to downstream pathways. Furthermore, ablation of GRK2 
compromises postnatal angiogenesis and vascular remodeling in the retina and 
vasculogenesis during embryonic development as a result of defective vessel 
maturation, whereas GRK2 down regulation in ECs reduces pericyte coverage 
of tumoral vessels and potentiates tumor progression. 
 Rivas et al.,
78 
identified that GRK2 is involved in counterbalancing the 
action of different angiogenic growth factors responsible for the activation of 
ECs (Endothelial cells). 
GRK2 down regulation in ECs alters the endothelial barrier function and 
causes defective tube formation on Matrigel, a process that depends on profuse 
cellular polarization and morphogenetic rearrangements. Therefore, 
manipulation of tumor-associated angiogenesis represents a promising strategy 
to limit cancer progression and GRK2 down modulation could represent a 
novel marker for pathological vasculature. In particular GRK2 down 
regulation would be a relevant event in the angiogenic switch triggered by 
tumor cells by favoring a permissive microenvironment for tumor progression. 
Notably, GRK2 levels are also altered in different malignant mammary cell 
lines
86
 and enhanced GRK2 levels increase epithelial cell motility,
87 , 88
 
stressing that cell type–specific modulation of this kinase may participate in 
cancer development. As tumor progression is the result of the interplay 
between malignant cells themselves and their surrounding microenvironment, 
recent results suggest that opposite changes in GRK2 expression may occur in 
transformed epithelial cells and in the tumor endothelium to synergistically 
promote tumor cell invasiveness and intravasation. 
Degradation of G-protein-coupled receptor kinase 2. Such functional 
complexity predicts that alterations in GRK2 levels and/or activity may have 
important effects on cell signaling. Interestingly, several pathological 
conditions such as congestive heart failure, hypertension
89
 and rheumatoid 
arthritis (RA), among others, display altered GRK2 expression and   
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 Salcedo et al.,
 86 
described that GRK2 is rapidly degraded by the 
proteasome pathway, and that 2-adrenergic receptor (2AR) activation 
enhances GRK2 ubiquitination and turnover. It has been shown that agonist-
dependent binding of -arrestin to GPCRs supports GRK2 degradation by 
allowing the recruitment of c-Src and the phosphorylation of GRK2 on critical 
tyrosine residues.
92
 MAPK-mediated GRK2 phosphorylation also triggers 




Proteasome degradation requires the orchestrated activities of the ubiquitin-
activating enzyme (E1), ubiquitin conjugating enzymes (E2) and ubiquitin 
ligases (E3).
94
 The specificity of target protein selection is determined by 
ubiquitin ligases, which interact with their substrates either directly or by 
means of adaptor molecules. Interestingly, -arrestins are able to interact with 
Mdm2, a RING domain-containing E3-ubiquitin ligase involved in the control 
of tumor suppressor p53 activity.
95
 -Arrestin-mediated recruitment of Mdm2 
to several GPCR complexes leads to different -arrestin ubiquitination 
patterns,
 96
 which controls the characteristics of MAPK activation and receptor 
internalization.
97,98 
In this report, Alicia Salcedo et al.,
86
 identify Mdm2 as an 
E3-ubiquitin ligase for GRK2 that is critically involved in kinase 
ubiquitination and degradation. Moreover, they put forward a new Mdm2- 
mediated pathway for the modulation of GRK2 cellular levels by IGF-1. The 
Mdm2 oncoprotein is an E3-ubiquitin ligase best known by its role in 
controlling p53 degradation and transcriptional activity.
99,100
Growing evidence 




  and can be regulated 
by this ligase.
103,104 
It has been identified GRK2 as a new Mdm2 target. 
Several lines of evidence support the notion that Mdm2 serves as an E3 
ligase for GRK2 ubiquitination and is critical for modulating its degradation 
and cellular levels. 
Modulation of Mdm2 by the PI3K/Akt pathway upon IGF1-R stimulation 
alters GRK2 degradation and augments kinase cellular levels, putting forward 
a new mechanism for controlling GRK2 expression. Mdm2 has been shown to 




2AR stimulation leads to the recruitment of Mdm2 to the receptor 
complex in a -arrestin-dependent manner. Both -arrestin1 and -arrestin2 
are able to interact with Mdm2 and therefore to bring this ligase to the vicinity 
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of activated receptors. It has been reported that -arrestin1 also plays a role in 
GRK2 degradation by facilitating the -agonist-triggered GRK2/Mdm2 
association. -arrestin might deliver Mdm2 to the receptor complex in an 
active form that is suitable to interact with and promote GRK2 ubiquitination, 
as has been reported for other targets. Mdm2 shuttles back and forth between 
the nucleus and the cytoplasm as a result of its interaction with different 
proteins. In this regard, it has been reported that -arrestin2 promotes Mdm2 
cytoplasmic relocation, whereas -arrestin1 might cooperate with -arrestin2 
in the maintenance of an accessible cytosolic pool of Mdm2 for degradation of 
targets such as GRK2 in response to specific stimuli. 
GRK2 and cancer. Interestingly, in addition to its reported alteration in 
cardiovascular and inflammatory pathologies emerging data indicate changes 
in GRK2 expression in certain tumors.
107
 The fact that general but not cardiac-
specific GRK2 knockout mice are embryonic lethal
108
 further supports the 
notion that this protein could play a central, general role in key cellular 
processes as proliferation or migration. However, the potential involvement of 
this kinase in the cell cycle has not been addressed. Given that the control of 
the turnover of key kinases throughout the cell cycle represents a major 
regulatory mechanism in cell proliferation,
109
 recently Penela et al. reported 
that phosphorylation of GRK2 by cyclin-dependent kinase 2 (CDK2) and 
subsequent interaction with the Pin1 prolyl-isomerase promotes its transient 
down-regulation in the G2 phase, and that this event is critical for adequate 
cell cycle progression and control.
92
 
In particular GRK2 protein levels progressively decay during G2 as a result 
of a degradation process triggered by the CDK2-dependent phosphorylation of 
GRK2 at residue S670. Inhibition of endogenous GRK2 phosphorylation by 
CDK2 or expression of a mutant unable to be phosphorylated at this residue 
(GRK2-S670A) completely prevents GRK2 down-regulation and delays cell 
cycle progression. Importantly, such “default” down-regulation is blocked 
upon activation of the G2 checkpoint, and the resultant accumulation of GRK2 
protein levels inversely correlates with the extent of activation of the p53-
dependent apoptotic responses. 
 
In the last year, identification of GRK2 modulators/inhibitors is a very 
active fields of research.
110,111
 
Chapter 1       Programmed cell death pathways in cancer governed by the 
balanced action of PTKs and PTPs 
 
- 17 - 
 
Different small molecules inhibitors of GRK2 activity are currently 
available,
112 , 113
 even if they are characterized by low sensitivity and 
specificity.
114,115
 Strategies to selectively inhibit the GRK2 activity have been 
attempted
116
 using shorter peptides
117,118
 or RNA aptamers.
119
 In particular, 
Anis et al. demonstrated that myristyl or lauryl glycine derivatives of short 
peptides derived from HJ loop of GRK2 are potent inhibitor of the kinase and 
possess hypoglycemic effect in animal models of Type 2 diabetes. 
Starting from these peptides during my PhD I focused the attention on 
synthesis of new compounds with the aim to identify more potent and 
selective GRK2 antagonists. 
 
 
                                                          
1
 Hanahan, D.; Weinberg, RA. The hallmarks of cancer. Cell 2000, 100, 57-70. 
2
  Wong, R. SJ. Apoptosis in cancer: from pathogenesis to treatment. Journal 
of Experimental & Clinical Cancer Research 2011, 30, 87. 
3
 Kerr, JFR.; Wyllie, AH.; Currie AR. Apoptosis: a basic biological 
phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 
1972, 26, 239-257. 
4
 Parrish, AB.; Freel, CD.; Kornbluth, S. Cellular Mechanisms Controlling 
Caspase Activation and Function. Cold Spring Harb Perspect Biol 2013, 5. 
5
 Cerretti, DP.; Kozlosky, CJ.; Mosley, B.; Nelson, N.; Van Ness, K.; 
Greenstreet, TA.; March, CJ.; Kronheim, SR.; Druck, T.; Cannizzaro, LA. 
Molecular cloning of the interleukin-1  converting enzyme. Science 1992, 
256, 97-100. 
6
Thornberry, NA.; Lazebnik, Y. Caspases: Enemies within. Science 1998, 281, 
1312-1316. 
7
 Yuan, J.; Yankner, BA. Apoptosis in the nervous system. Nature 2000, 407, 
802-809. 
8
 Li, J.; Yuan, J. Caspases in apoptosis and beyond. Oncogene 2008, 27, 6194-
6206. 
9
 Boatright, KM.; Renatus, M.; Scott, FL.; Sperandio, S.; Shin, H.; Pedersen, 
IM.; Ricci, JE.; Edris, WA.; Sutherlin, DP.; Green, DR.; Salvesen, GS. A 
unified model for apical caspase activation. Mol Cell 2003, 11, 529-541. 
10
 Baliga, BC.; Read, SH.; Kumar, S. The biochemical mechanism of caspase-
2 activation. Cell Death Differ 2004, 11, 1234-1241. 
11
 Pop, C.; Timmer, J.; Sperandio, S.; Salvesen, GS. The apoptosome activates 
caspase-9 by dimerization. Mol Cell 2006, 22, 269-275. 
12
 Riedl, SJ.; Salvesen, GS. The apoptosome: Signaling platform of cell death. 
Nat Rev Mol Cell Biol 2007, 8, 405-413. 
Chapter 1       Programmed cell death pathways in cancer governed by the 
balanced action of PTKs and PTPs 
 
- 18 - 
 
                                                                                                                                                        
13
 Mahrus, S.; Trinidad, JC.; Barkan, DT.; Sali, A.; Burlingame, AL.; Wells, 
JA. Global sequencing of proteolytic cleavage sites in apoptosis by specific 
labeling of protein N termini. Cell 2008, 134, 866-876. 
14
 Poreba, M.; Strozyk, A.; Salvesen, GS.; Drag, M. Caspase substrates and 
inhibitors. Cold Spring Harb Perspect Biol 2013, 5, a008680. 
15
 Dix, MM.; Simon, GM.; Wang, C.; Okerberg, E.; Patricelli, MP.; Cravatt, 
BF. Functional interplay between caspase cleavage and phosphorylation 
sculpts the apoptotic proteome. Cell 2012, 150, 426-440. 
16
 O’ Brien, MA.; Kirby, R. Apoptosis: a review of pro-apoptotic and 
antiapoptotic pathways and dysregulation in disease. J Vet Emerg Crit Care 
2008, 18, 572-585. 
17
 Hengartner, MO. Apoptosis: corralling the corpses. Cell 2000, 104, 325-
328. 
18
 Schneider P.; Tschopp, J. Apoptosis induced by death receptors. Pharm 
Acta Helv 2000, 74, 281-286. 
19
 Danial, NN.; Korsmeyer, SJ. Cell death: critical control points. Cell 2004, 
116, 205-219. 
20
Reed, JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance 
in haematologic malignancies. Semin Haematol 1997, 34, 9-19. 
21
Kroemer, G.; Galluzzi, L.; Brenner, C. Mitochondrial membrane 
permeabilisation in cell death. Physiol Rev 2007, 87, 99-163. 
22
 LaCasse, EC.; Mahoney, DJ.; Cheung, HH.; Plenchette, S.; Baird, S.; 
Korneluk, RG. IAP-targeted therapies for cancer. Oncogene 2008, 27, 6252-
6275. 
23
 Ghobrial, IM.; Witzig, TE.; Adjei, AA. Targeting apoptosis pathways in 
cancer therapy. CA Cancer J Clin 2005, 55, 178-194. 
24
 Szegezdi, E.; Fitzgerald, U.; Samali, A. Caspase-12 and ER stress mediated 
apoptosis: the story so far. Ann NY Acad Sci 2003, 1010, 186-194. 
25
 Kurokawa, M.; Kornbluth, S. Caspases and Kinases in a Death Grip. Cell 
2009, 138. 
26
 Allan, LA.; Clarke, PR. Phosphorylation of caspase-9 by CDK1/cyclin B1 
protects mitotic cells against apoptosis. Mol Cell 2007, 26, 301-310. 
27
 Heinrich, R.; Neel, BG.; Rapoport, TA. Mathematical models of protein 
kinase signal transduction. Mol Cell 2002, 9, 957-970. 
28
 Hornberg, JJ.; Bruggeman, FJ.; Binder, B.; Geest, CR.; de Vaate, AJ.; 
Lankelma, J.; Heinrich, R.; Westerhoff, HV. Principles behind the multifarious 
control of signal transduction. ERK phosphorylation and kinase/phosphatase 
control. FEBS J 2005,  272, 244-258.  
29
 Alonso, A.; Sasin, J.; Bottini, N.; Friedberg, I.; Osterman, A.; Godzik, A.; 
Hunter, T.; Dixon, J.; Mustelin, T. Protein tyrosine phosphatases in the human 
genome. Cell 2004, 117, 699-711. 
Chapter 1       Programmed cell death pathways in cancer governed by the 
balanced action of PTKs and PTPs 
 
- 19 - 
 
                                                                                                                                                        
30
 Anderson, JM.; Van Itallie, CM.; Fanning, AS.; Setting up a selective 
barrier at the apical junction complex. Curr Opin Cell Biol 2004, 16, 140-145. 
31
 Ostman, A.; Hellberg, C.;  Bohmer, FD. Protein tyrosine phosphatases and 
cancer. Nat Rev Cancer 2006, 6, 307-320. 
32
 Ostman, A.; Yang, Q.; Tonks, NK. Expression of DEP-1, a receptor-like 
protein-tyrosine-phosphatase, is enhanced with increasing cell density. Proc 
Natl Acad Sci U.S.A. 1994, 91, 9680-9684. 
33
 Trapasso, F.; Iuliano, R.; Boccia, A.; Stella, A.; Visconti, R.; Bruni, P.; 
Baldassarre, G.; Santoro, M.; Viglietto, G.; Fusco, A. Rat protein tyrosine 
phosphatase eta suppresses the neoplastic phenotype of retrovirally 
transformed thyroid cells through the stabilization of p27(Kip1). Mol Cell Biol 
2000, 20, 9236-9246. 
34
 Paduano, F.; Dattilo, V.; Narciso, D.; Bilotta, A.; Gaudio, E.; Menniti, M.; 
Agosti, V.; Palmieri, C.; Perrotti, N.; Fusco, A.; Trapasso, F.; Iuliano, R. 
Protein tyrosine phosphatase PTPRJ is negatively regulated by microRNA-
328. FEBS J 2013, 280, 410-412. 
35
 Trapasso, F.; Yendamuri, S.; Dumon, KR.; Iuliano, R.; Cesari, R.; Feig, B.; 
Seto, R.; Infante, L.; Ishii, H.; Vecchione, A.; During, MJ.; Croce, CM.; 
Fusco, A. Restoration of receptor-type protein tyrosine phosphatase eta 
function inhibits human pancreatic carcinoma cell growth in vitro and in vivo. 
Carcinogenesis 2004, 25, 2107-2114. 
36
 Ruivenkamp, C.; Hermsen, M.; Postma, C.; Klous, A.; Baak, J.; Meijer, G.; 
Demant, P. LOH of PTPRJ occurs early in colorectal cancer and is associated 
with chromosomal loss of 18q12−21. Oncogene 2003, 22, 3472-3474. 
37
 Iuliano, R.; Le Pera, I.; Cristofaro, C.; Baudi, F.; Arturi, F.; Pallante, P.; 
Martelli, M.L.; Trapasso, F.; Chiariotti, L.; Fusco, A. The tyrosine 
phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis. Oncogene 
2004, 23, 8432-8438. 
38
 Trapasso, F.; Drusco, A.; Costinean, S.; Alder, H.; Aqeilan, RI.; Iuliano, R.; 
Gaudio, E.; Raso, C.; Zanesi, N.; Croce, C. M.; Fusco, A. Genetic ablation of 
Ptprj, a mouse cancer susceptibility gene, results in normal growth and 
development and does not predispose to spontaneous tumorigenesis. DNA Cell 
Biol 2006, 25, 376-382. 
39
 Zhu, JW.; Brdicka, T.; Katsumoto, TR.; Lin, J.; Weiss, A. Structurally 
distinct phosphatases CD45 and CD148 both regulate B cell and macrophage 
immunoreceptor signaling. Immunity 2008, 28, 183-196. 
40
 Kovalenko, M.; Denner, K.; Sandstrom, J.; Persson, C.; Gross, S.; Jandt, E.; 
Vilella, R.; Bohmer, F.; Ostman, A. Site-selective dephosphorylation of the 
platelet-derived growth factor beta-receptor by the receptor-like protein-
tyrosine phosphatase DEP-1. J Biol Chem 2000, 275, 16219-16226. 
Chapter 1       Programmed cell death pathways in cancer governed by the 
balanced action of PTKs and PTPs 
 
- 20 - 
 
                                                                                                                                                        
41
 Palka, HL.; Park, M.; Tonks, NK. Hepatocyte growth factor receptor 
tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase 
DEP-1. J Biol Chem 2003, 278, 5728-5735. 
42
 Iervolino, A.; Iuliano, R.; Trapasso, F.; Viglietto, G.; Melillo, RM.; 
Carlomagno, F.; Santoro, M.; Fusco, A. The receptor type protein tyrosine 
phosphatase J antagonizes the biochemical and biological effects of RET-
derived oncoproteins. Cancer Res 2006, 66, 6280-6287. 
43
 Berset, TA.; Hoier, EF.; Hajnal, A. The C. elegans homolog of the 
mammalian tumor suppressor Dep-1/Scc1 inhibits EGFR signaling to regulate 
binary cell fate decisions. Genes Dev 2005, 19, 1328-1340. 
44
 Hanahan, D.; Weinberg, RA. The hallmarks of cancer. Cell 2000, 100, 57-
70. 
45
 Baker, JE.; Majeti, R.; Tangye, SG.; Weiss, A. Protein tyrosine phosphatase 
CD148-mediated inhibition of T-cell receptor signal transduction is associated 
with reduced LAT and phospholipase C gamma1 phosphorylation. Mol Cell 
Biol 2001, 21, 2393-2403. 
46
 Omerovic, J.; Clague, MJ.; Prior, IA. Phosphatome profiling reveals 
PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation 
in Ras-mutated cancer cells. Biochem J 2010, 426, 65-72. 
47
 Tsuboi, N.; Utsunomiya, T.; Roberts, RL.; Ito, H.; Takahashi, K.; Noda, M.; 
Takahashi, T. The tyrosine phosphatase CD148 interacts with the p85 
regulatory subunit of phosphoinositide 3-kinase. Biochem J 2008, 413, 193-
200. 
48
 Lampugnani, GM.; Zanetti, A.; Corada, M.; Takahashi, T.; Balconi, G.; 
Breviario, F.; Orsenigo, F.; Cattelino, A.; Kemler, R.; Daniel, TO.; Dejana, E. 
Contact inhibition of VEGF induced proliferation requires vascular endothelial 
cadherin, betacatenin, and the phosphatase DEP-1/CD148. J Cell Biol 2003, 
161, 793-804. 
49
 Chabot, C.; Spring, K.; Gratton, JP.; Elchebly, M.; Royal, I. New role for 
the protein tyrosine phosphatase DEP-1 in Akt activation and endothelial cell 
survival. Mol Cell Biol 2009, 29, 241-253. 
50
 Whiteford, JR.; Xian, X.; Chaussade, C.; Vanhaesebroeck, B.;  Nourshargh, 
S.; Couchman, JR. Syndecan-2 is a novel ligand for the protein tyrosine 
phosphatase receptor CD148. Mol Biol Cell 2011, 22, 3609-3624. 
51
 Takahashi, K.; Mernaugh, RL.; Friedman, DB.; Weller, R.; Tsuboi, N.; 
Yamashita, H.; Quaranta, V.; Takahashi, T. Trombospondin-1 acts as a ligand 
for CD148 tyrosine phosphatase. Proc Natl Acad Sci U.S.A. 2012, 109, 1985-
90. 
52
 Paduano, F.;  Ortuso, F.; Campiglia, P.; Raso, C.; Iaccino, E.; Gaspari, M.; 
Gaudio, E.; Mangone, G.; Carotenuto, A.; Bilotta, A.; Narciso, D.; Palmieri, 
C.; Agosti, V.; Artese, A.; Gomez-Monterrey, I.; Sala, M.; Cuda, G.; Iuliano, 
Chapter 1       Programmed cell death pathways in cancer governed by the 
balanced action of PTKs and PTPs 
 
- 21 - 
 
                                                                                                                                                        
R.; Perrotti, N.; Scala, G.; Viglietto, G.; Alcaro, S.; Croce, CM.; Novellino, E.; 
Fusco, A.; Trapasso, F. Isolation and functional characterization of peptide 
agonists of PTPRJ, a tyrosine phosphatase receptor endowed with tumor 
suppressor Activity. ACS Chem Biol 2012, 7, 1666-1676. 
53 Ortuso, F.; Paduano, F.; Carotenuto A.; Gomez, IM.; Bilotta, A.; Gaudio, E.; 
Sala, M.; Artese, A.; Vernieri, E.; Dattilo, V.; Iuliano, R.; Brancaccio, D.; 
Bertamino, A.; Musella, S.; Alcaro, S.; Grieco, P.; Perrotti, N.; Croce, CM.; 
Novellino, E.; Fusco, A.; Campiglia, P.; Trapasso, F. Discovery of PTPRJ 
Agonist Peptides That Effectively Inhibit in Vitro Cancer Cell Proliferation 
and Tube Formation. ACS Chem Biol 2013, 8, 1497-1506. 
54 Endicott, JA.; Noble, ME.; Johnson, LN. The structural basis for control of 
eukaryotic protein kinases. Annu Rev Biochem 2012, 81, 587−613. 
55  Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature 2001, 
411, 355-365. 
56 Lin, J.; Gan, CM.; Zhang, X.; Jones, S.; Sjöblom, T.; Wood, LD.; Parsons, 
DW.; Papadopoulos, N.; Kinzler, KW.; Vogelstein, B.; Parmigiani, 
G.; Velculescu, VE. A multidimensional analysis of genes mutated in breast 
and colorectal cancers. Genome Research 2007, 17, 1304-1318. 
57
 Wood, LD.; Parsons, DW.; Jones, S.; Lin, J.; Sjöblom, T.; Leary, RJ.; Shen, 
D.; Boca, SM.; Barber, T.; Ptak, J.; Silliman, N.; Szabo, S.; Dezso, Z.; 
Ustyanksky, V.; Nikolskaya, T.; Nikolsky, Y.; Karchin, R.; Wilson, PA.; 
Kaminker, JS.; Zhang, Z.; Croshaw, R.; Willis, J.; Dawson, D.; Shipitsin, M.; 
Willson, JK.; Sukumar, S.; Polyak, K.; Park, BH.; Pethiyagoda, CL.; Pant, 
PV.; Ballinger, DG.; Sparks, AB.; Hartigan, J.; Smith, DR.; Suh, E.; 
Papadopoulos, N.; Buckhaults, P.; Markowitz, SD.; Parmigiani, G.; Kinzler, 
KW.; Velculescu, VE.; Vogelstein, B. The genomic landscapes of human 
breast and colorectal cancers. Science 2007, 318, 1108-1113. 
58
 Rusciano, MR.; Maione, AS.; Illario, M. Sisters Acts: Converging Signaling 
Between CaMKII and CaMKIV, Two Members of the Same Family. Transl 
Med UniSa 2012, 4, 66-72. 
59
 Ryutaro, K.; Fukushige, S.; Norifumi, S.; Tanabe, K.; Fukunaga, K.; Inui, S. 
CaMKII phosphorylates serine 10 of p27 and confers apoptosis resistance to 
HeLa cells. Biochemical and Biophysical Research Communications  2010, 
401, 350-355. 
60  Griffith, LC. Calcium/calmodulin-dependent protein kinase II: An 
unforgettable Kinase. J Neurosci 2004, 8391-8393. 
61  Strack, S.; Barban, MA.; Wadzinski, BE.; Colbran, RJ. Differential 
inactivation of postsynaptic density-associated and soluble Ca
2+
/calmodulin-
dependent protein kinase II by protein phosphatase 1 and 2A. J Neurochem 
1997, 68, 92119-92128. 
Chapter 1       Programmed cell death pathways in cancer governed by the 
balanced action of PTKs and PTPs 
 
- 22 - 
 
                                                                                                                                                        
62
 Braun, AP.; Schulman, H. The multifunctional calcium/calmodulin-
dependent protein kinase: from form to function. Annu Rev Physiol 1995, 57, 
417-445. 
63
 Zhang, T.; Brown, JH. Role of Ca
2+
/calmodulin-dependent protein kinase II 
in cardiac hypertrophy and heart failure. Cardiovasc Res 2004, 63, 476-486. 
64 Rokhlin, O.; Taghiyev, AF.;  Bayer, KU.; Bumcrot, D.; Kotelianski, VE.; 
Glover, RA.; Cohen, MB. Calcium/calmodulin-dependent kinase II plays an 
important role in prostate cancer cell survival. Cancer Biol Ther 2007, 6, 732-
742. 
65
 Mishra, S.; Mishra, JP.; Gee, K.; McManus, DC.; LaCasse, EC.; Kumar, A. 
Distinct role of calmodulin and calmodulin-dependent protein kinase-II in 
lipopolysaccharide and tumor necrosis factor-a-mediated suppression of 
apoptosis and antiapoptotic c-IAP2 gene. J Biol Chem 2005, 280, 37536-
37546. 
66
 Guan, X.; Chen, L.; Wang, J.; Geng, H.; Chu, X.; Zhang, Q.; Du, L.; De, W. 
Mutations of phosphorylation sites Ser10 and Thr187 of p27Kip1 abolish 
cytoplasmic redistribution but do not abrogate G0/1 phase arrest in the HepG2 
cell line. Biochem Biophys Res Commun 2006, 347, 601-607. 
67
 Fujita, N.; Sato, S.; Katayama, K.; Tsuro, T.; Akt-dependent 
phosphorylation of p27Kip promotes binding to 14-3-3 and cytoplasmic 
localization. J Biol Chem 2002, 277, 28706-28713. 
68
 Conqueret, O. New roles for p21 and p27 cell-cycle inhibitors: a function for 
each cell compartment?. Trends Cell Biol 2003, 13, 65-70. 
69 Midorikawa, R.; Takei, Y.; Hirokawa, N. KIF4 motor regulates activity-
dependent neuronal survival by suppressing PARP-1 enzymatic activity. Cell 
2006, 125, 371-383. 
70 Sherr, CJ. G1 phase progression: cycling on cue. Cell 1994, 79, 551-555. 
71
 Gomez, IM.; Sala, M.; Rusciano, MR.; Monaco, S.; Maione, AS.; Iaccarino, 
G.; Tortorella, P.; D’Ursi, AM.; Scrima, M.; Carotenuto, A.; De Rosa, G.; 
Bertamino, A.; Vernieri, E.; Grieco, P.; Novellino, E.; Illario, M.; Campiglia, 
P. Characterization of a selective CaMKII peptide inhibitor. European Journal 
of Medicinal Chemistry 2013, 62, 425-434. 
72  Luttrell, LM. Composition and function of g protein-coupled receptor 
signalsomes controlling mitogen-activated protein kinase activity. J Mol 
Neurosci 2005, 26, 253-264. 
73
 DeWire, SM.; Ahn, S.; Lefkowitz, RJ.; Shenoy, SK. Beta-arrestins and cell 
signaling. Annu Rev Physiol 2007, 69, 483-510. 
74 Ribas, C.; Penela, P.; Murga, C.; Salcedo, A.; García-Hoz, C.; Jurado-Pueyo, 
M.; Aymerich, I.; Mayor, Jr. F. The G protein-coupled receptor kinase (GRK) 
interactome: role of GRKs in GPCR regulation and signaling. Biochim 
Biophys Acta 2007, 1768, 913-922. 
Chapter 1       Programmed cell death pathways in cancer governed by the 
balanced action of PTKs and PTPs 
 
- 23 - 
 
                                                                                                                                                        
75
 Penela, P.; Rivas, V.; Salcedo, A.; Mayor, Jr. F. G protein-coupled receptor 
kinase 2 (GRK2) modulation and cell cycle progression. Proc Natl Acad Sci U 
S A 2010, 107, 1118-1123. 
76  Rivas, V.; Carmona, R.; Muñoz-Chápuli, R.; Mendiola, M.; Nogués, L.; 
Reglero, C.; Miguel-Martín, M.; García-Escudero, R.; Dorn II, GW.; 
Hardisson, D.; Mayor F Jr.; Penela, P. Developmental and tumoral 
vascularization is regulated by G protein–coupled receptor kinase 2. J Clin 
Invest. 2013, 123, 4714-4730. 
77
 Penela, P.; Murga, C.; Ribas, C.; Lafarga, V.; Mayor, Jr. F. The complex G 
protein-coupled receptor kinase 2 (GRK2) interactome unveils new 
physiopathological targets. Br J Pharmacol 2010, 160, 821-832. 
78 Kiefer, F.; Siekmann, AF. The role of chemokines and their receptors in 
angiogenesis. Cell Mol Life Sci 2011, 68, 2811-2830. 
79
 Hellberg, C.; Ostman, A.; Heldin, CH. PDGF and vessel maturation. Recent 
Results Cancer Res 2010, 180, 103-114. 
80
 Wu, JH.; Goswami, R.; Kim, LK.; Miller, WE.; Peppel, K.; Freedman, NJ. 
The platelet-derived growth factor receptor-beta phosphorylates and activates 
G protein-coupled receptor kinase-2. A mechanism for feedback inhibition. J 
Biol Chem 2005, 280, 31027-31035. 
81 Ho, J.; Cocolakis, E.; Dumas, VM.; Posner, BI.; Laporte, SA.; Lebrun, JJ. 
The G protein-coupled receptor kinase-2 is a TGFβ-inducible antagonist of 
TGFβ signal transduction. EMBO J 2005, 24, 3247-3258. 
82  D’Souza, KM.; Malhotra, R.; Philip, JL.; Staron, ML.; Theccanat, T.; 
Jeevanandam, V.; Akhter, SA. G protein-coupled receptor kinase-2 is a novel 
regulator of collagen synthesis in adult human cardiac fibroblasts. J Biol Chem 
2011, 286, 15507-15516. 
83 Peppel, K.; Zhang, L.; Huynh, TT.; Huang, X.; Jacobson, A.; Brian, L.; 
Exum, ST.; Hagen, PO.; Freedman, NJ. Overexpression of G protein-coupled 
receptor kinase-2 in smooth muscle cells reduces neointimal hyperplasia. J 
Mol Cell Cardiol 2002, 34, 1399-1409. 
84  Morris, GE.; Nelson, CP.; Standen, NB.; Challiss, RA.; Willets, JM. 
Endothelin signalling in arterial smooth muscle is tightly regulated by G 
proteincoupled receptor kinase 2. Cardiovasc Res 2010, 85, 424-433. 
85 Liu, S.; Premont, RT.; Kontos, CD.; Zhu, S.; Rockey, DC. A crucial role for 
GRK2 in regulation of endothelial cell nitric oxide synthase function in portal 
hypertension. Nat Med 2005, 11, 952-958. 
86 Salcedo, A.; Mayor, Jr. F.; Penela, P. Mdm2 is involved in the ubiquitination 
and degradation of G-protein- coupled receptor kinase 2. EMBO J 2006, 25, 
4752-4762. 
87 Penela, P.; Ribas, C.; Aymerich, I.; Eijkelkamp, N., Barreiro, O.; Heijnen, 
CJ., Kavelaars, A.; Sánchez-Madrid, F.; Mayor, Jr. F. G protein-coupled 
Chapter 1       Programmed cell death pathways in cancer governed by the 
balanced action of PTKs and PTPs 
 
- 24 - 
 
                                                                                                                                                        
receptor kinase 2 positively regulates epithelial cell migration. EMBO J 2008, 
27, 1206-1218. 
88 Lafarga, V.; Aymerich, I.; Tapia, O.; Mayor, Jr. F.; Penela, P. A novel 
GRK2/HDAC6 interaction modulates cell spreading and motility. EMBO J 
2012, 31, 856-869. 
89 Penela, P.; Murga, C.; Ribas, C.; Tutor, AS.; Peregrin, S.; Mayor, Jr. F. 
Mechanisms of regulation of G-protein-coupled receptor kinases (GRKs) and 
cardiovascular disease. Cardiovasc Res 2006, 69, 46-56. 
90  Penela, P.; Ribas, C.; Mayor, Jr. F. Mechanisms of regulation of the 
expression and function of G protein-coupled receptor kinases. Cell Signal 
2003, 15, 973-981. 
91 Metaye, T.; Gibelin, H.; Perdrisot, R.; Kraimps, JL. Pathophysiological roles 
of G-protein-coupled receptor kinases. Cell Signal 2005, 17, 917-928. 
92
 Penela, P.; Elorza, A.; Sarnago, S.; Mayor, Jr. F. Beta-arrestin- and c-Src-
dependent degradation of G-protein-coupled receptor kinase 2. EMBO J 2001, 
20, 5129-5138. 
93  Elorza, A.; Penela, P.; Sarnago, S.; Mayor, Jr. F. MAPK-dependent 
degradation of G protein-coupled receptor kinase 2. J Biol Chem 2003, 278, 
29164-29173. 
94  Pickart, CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 
2001, 70, 503-533. 
95
 Weissman, AM. Themes and variations on ubiquitylation. Nat Rev Mol Cell 
Biol 2001, 2, 169-178. 
96
 Shenoy, SK.; McDonald, PH.; Kohout, TA.; Lefkowitz, RJ. Regulation of 
receptor fate by ubiquitination of activated beta 2-adrenergic receptor and 
beta-arrestin. Science 2001, 294, 1307-1313. 
97  Shenoy, SK.; Lefkowitz, RJ. Receptor-specific ubiquitination of beta-
arrestin directs assembly and targeting of seven-transmembrane receptor 
signalosomes. J Biol Chem 2005, 280, 15315-15324. 
98 Wang, P.; Gao, H.; Ni, Y.; Wang, B.; Wu, Y.; Ji, L.; Qin, L.; Ma, L.; Pei, G. 
Beta-arrestin 2 functions as a G-protein-coupled receptoractivated regulator of 
oncoprotein Mdm2. J Biol Chem 2003, 278, 6363-6370. 
99
 Yang, Y.; Li, CC.; Weissman, AM. Regulating the p53 system through 
ubiquitination. Oncogene 2004, 23, 2096-2106. 
100  Bond, GL.; Hu, W.; Levine, AJ. MDM2 is a central node in the p53 
pathway: 12 years and counting. Curr Cancer Drug Targets 2005, 5, 3-8. 
101
 Lin, FT.; Chen, W.; Shenoy, S.; Cong, M.; Exum, ST.; Lefkowitz, RJ. 
Phosphorylation of beta-arrestin2 regulates its function in internalization of 
beta(2)-adrenergic receptors. Biochemistry 2002, 41, 10692-10699. 
Chapter 1       Programmed cell death pathways in cancer governed by the 
balanced action of PTKs and PTPs 
 
- 25 - 
 
                                                                                                                                                        
102 Girnita, L.; Girnita, A.; Larsson, O. Mdm2-dependent ubiquitination and 
degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci 
USA 2003, 100, 8247-8252. 
103 Iwakuma, T.; Lozano, G. MDM2, an introduction. Mol Cancer Res 2003, 1, 
993-1000. 
104
 Jin, Y.; Lee, H.; Zeng, SX.; Dai, MS.; Lu, H. MDM2 promotes 
p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J 
2003, 22, 6365-6377. 
105
 Pan, Y.; Chen, J. MDM2 promotes ubiquitination and degradation of 
MDMX. Mol Cell Biol 2003, 23, 5113-5121. 
106
 Uchida, C.; Miwa, S.; Kitagawa, K.; Hattori, T.; Isobe, T.; Otani, S.; Oda, 
T.; Sugimura, H.; Kamijo, T.; Ookawa, K.; Yasuda, H.; Kitagawa, M. 
Enhanced Mdm2 activity inhibits pRB function via ubiquitin dependent 
degradation. EMBO J 2005, 24, 160-169. 
107  Métayé, T.; Gibelin, H.; Perdrisot, R.; Kraimps, JL. Pathophysiological 
roles of G-protein-coupled receptor kinases. Cell Signal 2005, 17, 917-928. 
108
 Matkovich, SJ.; Diwan, A.; Klanke, JL.; Hammer, DJ.; Marreez, Y.; Odley, 
AM.; Brunskill, EW., Koch, WJ.; Schwartz, RJ.; Dorn, GW 2nd. Cardiac-
specific ablation of G-protein receptor kinase 2 redefines its roles in heart 
development and beta-adrenergic signaling. Circ Res 2006, 99, 996-1003. 
109
 Nigg, EA. Mitotic kinases as regulators of cell division and its checkpoints. 
Nat Rev Mol Cell Biol 2001, 2, 21-32. 
110
 Gomez-Monterrey, I.; Carotenuto, A.; Cipolletta, E.; Sala, M.; Vernieri, 
E.; Limatola, A.; Bertamino, A.; Musella, S.; Grieco, P.; Trimarco, 
B.; Novellino, E.; Iaccarino, G.; Campiglia, P. SAR study and 
conformational analysis of a series of novel peptide G protein-coupled 
receptor kinase 2 (GRK2) inhibitors. Byopolimers 2014, 101, 121-128.  
111
 Carotenuto, A.; Cipolletta, E.; Gomez-Monterrey, I.; Sala, M.; Vernieri, E.; 
Limatola, A.; Bertamino, A.; Musella, S.; Sorriento, D.; Grieco, P.; Trimarco, 
B.; Novellino, E.; Iaccarino, G.; Campiglia, P. Design, synthesis and efficacy 
of novel G protein-coupled receptor kinase 2 inhibitors. Eur J Med Chem 
2013, 69, 384-92. 
112 Setyawan, J.; Koide, K.; Diller, TC.; Bunnage, ME.; Taylor, S.; Nicolai, K. 
C.; Brunton, LL. Mol Pharmacol 1999, 56, 370-376. 
113 Iino, M.; Furugori, T.; Mori, T.; Moriyama, S.; Fukuzawa, A.; Shibano, T. J 
Med Chem 2002, 45, 2150-2159. 
114
 Benovic, JL.; Stone, WC.; Caron, MG.; Lefkowitz, RJ. J Biol Chem 1989, 
264, 6707-6710. 
115  Takeda Pharmaceuticals Company Limited, Ikeda, S., kaneko, M., 
Fujiwara, S. World patent WO2007034846.  
Chapter 1       Programmed cell death pathways in cancer governed by the 
balanced action of PTKs and PTPs 
 
- 26 - 
 
                                                                                                                                                        
116
 Winstel, R.; Ihlenfeldt, HG.; Jung, G.; Krasel, C.; Lohse, M. J Biochem 
Pharmacol 2005, 70, 1001-1008. 
117
 Niv, MY.; Rubin, H.; Cohen, J.; Tsirulnikov, L.; Licht, T.; Peretzman-
Shemer, A.; Cnàan, E.; Tartakovsky, A.; Stein, I.; Albeck, S.; Weinstein, I.; 
Goldenberg-Furmanov, M.; Tobi, D.; Cohen, E.; Laster, M.; Ben-Sasson, S. 
A.; Reuveni, H. J Biol Chem 2004, 279, 1242-1255. 
118
 Anis, Y.; Leshem, O.; Reuveni, H.; Wexler, I.; Ben Sasson, R.; Yahalom, 
B.; Laster, M.; Raz I.; Ben Sasson, S.; Shafrir, E.; Ziv, E. Diabetologia, 2004, 
47, 1232-1244. 
119
 Mayer, G.; Wulffen, B.; Huber, C.; Brockmann, J.; Flicke, B.; Neumann, 















Synthesis, characterization and biological evaluation of PTPRJ 







Chapter 2       Synthesis, characterization and biological evaluation of PTPRJ 
(protein tyrosine phosphatase receptor like-j) agonists 
 
- 28 - 
 
 
Abstract PTPRJ is a receptor protein tyrosine phosphatase involved in both 
physiological and oncogenic pathways. Our work group previously reported 
that its expression is strongly reduced in the majority of explored cancer cell 
lines and tumor samples; moreover, its restoration blocks in vitro cancer cell 
proliferation and in vivo tumor formation. By means of a phage display library 
screening, we recently identified two peptides able to bind and activate 
PTPRJ, resulting in cell growth inhibition and apoptosis of both cancer and 
endothelial cells. Here, on a previously discovered PTPRJ agonist peptide, 
[CHHNLTHAC], we synthetized and assayed a panel of nonapeptide 
analogues with the aim to identify specific amino acid residues responsible for 
peptide activity. These second-generation nonapeptides were tested on both 
cancer and primary endothelial cells (HeLa and HUVEC, respectively). 
Interestingly, one of them ([CHHALTHAC]) was able to both dramatically 
reduce cell proliferation and effectively trigger apoptosis of both HeLa and 
HUVECs compared to its first-generation counterpart. Moreover this peptide 
significantly inhibited in vitro tube formation on Matrigel. Our compound 
inhibited ERK1/2 phosphorylation and cell proliferation in breast cancer cells 
(MCF-7 and SKBr3), while no effects were observed on primary normal 
human mammary endothelial cells (HMEC). Molecular modeling and NMR 
studies on these peptides reporting the possibility of self-aggregation states 
and highlighting new hints of structure-activity relationship. Thus, our results 
indicate that this nonapeptide might represent a great potential lead for the 
development of novel targeted anticancer drugs. 
Furthermore and in order to enhance the potency of this peptide, we performed 
different modification on this hit, including changes to disulfide bridge with 
lactam bridge, changes in specific position and changes to Cysteine with its 
analog (Penicillamine). 
 
Keywords PTPRJ, Ala scan peptide, disulfide bridge, lactam bridge, 
microwave, HeLa cells, HUVEC cells, Molecular Modeling. 
 
Abbreviations Abbreviations used for amino acids and designation of 
peptides follow the rules of the IUPACIUB Commission of Biochemical 
Nomenclature in J Biol Chem 1972, 247, 977-983. Amino acid symbols 
denote L-configuration unless indicated otherwise. 
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The following additional abbreviations are used: 
DCM, dichloromethane; DIPEA, N,N-diisopropylethyl-amine; DMF, N,N-
dimethylformamide; iPr3SiH, or TIS triisopropylsilane; TFA, trifluoroacetic 
acid; Fmoc, 9-fluorenyl-methoxycarbonyl; HOBt, Nhydroxy- benzotriazole; 
HBTU, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluoro -
phosphate; Trt, trityl; Pbf, 2,2,4,6,7–pentamethyldihydro benzofuran-5-
sulfonyl; RP HPLC, reversed-phase high performance liquid chromatography; 
ESI, electrospray ionization; LCQ, liquid chromatography quadrupole mass 




Reversible tyrosine phosphorylation, which is governed by the balanced 
action of protein tyrosine kinases (PTKs) and protein-tyrosine phosphatases 
(PTPs), regulates important signaling pathways that are involved in the control 
of cell proliferation, adhesion and migration. 
The distinct but complementary function of these enzymes is emphasized 
by recent studies, in which kinases have been implicated in controlling the 
amplitude of signaling responses, whereas phosphatases are thought to have an 
important role in controlling the rate and duration of the response.
1,2
 
The first PTP was purified in 1988, approximately 10 years after the 
discovery of tyrosine kinases.
3
 It is now known that PTPs constitute a large, 
structurally diverse family of tightly regulated,
 4




It is also clear that PTPs have both inhibitory and stimulatory effects on 
cancer associated signaling processes, and that deregulation of PTP function is 
associated with tumorigenesis in different types of human cancer. 
The PTP-superfamily includes 109 genes, compared to 90 human PTK 
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1.1 Protein Tyrosine Phosphatases 
 
PTPs are broadly divided into receptor-like forms and non-receptor forms.
7
  
The receptor-like PTPs have a single transmembrane domain and variable 
extracellular domains.  
The intracellular parts of most of the receptor-like PTPs contain two 
tandem PTP domains (D1 and D2) with most, if not all, of the catalytic 
activity residing in D1. In many cases, the extracellular domains include 
immunoglobulin like domains and fibronectin type III domains, similar to the 
extracellular domains of cellular adhesion molecules. Non-receptor PTPs have 
striking structural diversity and often contain sequences that target them to 
specific subcellular locations or enable their binding to specific proteins 
(Figure 1). The catalytic PTP domain spans approximately 280 amino acids 
and contains a highly conserved active site with a Cysteine residue that is 
required for catalytic activity. Dephosphorylation of substrates occurs through 
a two-step mechanism consisting of the formation of a covalent PTP-
phosphate intermediate that is subsequently hydrolysed. 
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Figure 1. Schematic view of the domain composition of all RPTP family 
members. The intracellular part consists of one catalytically active PTP domain (blue) 
and, in some subfamilies, a PTP domain with little or no catalytic activity (red), 
which is likely to have a regulatory function. 
 
CD148 or PTPRJ is a type-III RPTP with a broad pattern of tissue 
expression. It is expressed on fibroblasts and endothelium, as well as epithelial 
and hematopoietic cells.
8,9
 The CD148 gene, also known as Ptprj, is located on 
chromosome 11p11.12 in humans, and consists of 25 exons distributed over 
150 Kb of genomic DNA. The protein contains a bulky extracellular domain 
of 970 amino acids organized in eight fibronectin type III repeats, a 25-amino 
acid long transmembrane domain and a 342 amino acid cytoplasmic portion 
with a single catalytic domain. Its mass varies from 200 to 250 KDa 
depending on different N- or O-glycosylations in the extracellular domain. 
Chapter 2       Synthesis, characterization and biological evaluation of PTPRJ 
(protein tyrosine phosphatase receptor like-j) agonists 
 




Figure 2. Schematic view of the CD148 molecule. 
 
1.2 Biochemical Activity of CD148 
 
As mentioned above, the activity of many PTPs may be regulated by 
phosphorylation, and this seems to occur in the case of CD148. Jallal et al.
10
 
reported that CD148 is tyrosine-phosphorylated after stimulation with 
epithelial growth factor (EGF), although no change in phosphatase activity 
was documented. Even if it does not affect CD148 phosphatase activity, this 
phosphorylation event might have an important role in promoting interactions 
with SH2-containing proteins involved in the metabolic networks in which 
CD148 signal transduction pathways participate. Although protein 
dimerization is a key mechanism that simulates PTK activity, PTPs are 
generally not regulated in this way. Some lines of evidence, however, suggest 
that CD148 could indeed dimerize. In fact, the transmembrane domain 
contains the same dimerization consensus sequence
11
 found in RPTP, whose 
dimerization inhibits its phosphatase activity.
12
 It is not clear if dimerization 
inhibits or induces CD148 phosphatase activity, since experimental data lead 
to conflicting results. For example, in lymphocytes CD148 dimerization 
(induced by cross-linking) was shown to induce proliferation; on the contrary, 
in endothelial cells dimerization induced by a bivalent antibody seems to act in 
an opposite way, promoting CD148 activation.
13
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1.3 CD148 acts as a Tumor Suppressor 
 
Like many phosphatases, PTPRJ plays a role in cancer, its down-regulation 
being documented in different kinds of tumors. Additionally, in cultured breast 
cancer cells CD148 re-expression led to a five- to ten-fold reduction in cell 
growth.
14






CD148 re-expression was also described to induce differentiation in breast 
and thyroid undifferentiated tumor cells.
18
 To understand the role of CD148 in 
cancer, many studies were carried out to analyze Ptprj gene status in human 
tumors. The most thorough analysis identified Ptprj as the functional gene at 
the mouse colon-cancer susceptibility locus, Scc1.
16
 This locus was originally 
defined based on its segregation with colon cancer susceptibility after crossing 
cancer-resistant and cancer-susceptible mouse strains. Sequence differences in 
Ptrpj between the cancer-susceptible and cancer-resistant strains were also 
identified, supporting the theory that tumor susceptibility is conferred by 
certain Ptprj variants. 
PTPRJ status has also been analyzed in human tumors.
19
Loss of 
heterozygosity, occurring in the absence of acquired mutation in the remaining 
allele, has been found in breast, colon, lung and thyroid cancers, implicating 
Ptprj haploid insufficiency as a transforming mechanism in humans. 
In association with these studies, different allelic variants of human Ptprj 
were identified; these variations result in CD148 proteins that have differences 




1.3.1 CD148 Regulates Cell Growth and Cell Cycle 
 
The tumor-suppressive role of CD148 was clearly displayed in experiments 
where highly malignant thyroid cells, after transduction by a retrovirus 
carrying CD148, appeared to acquire a normal phenotype and showed 
increased adhesion, restoration of differentiation, reduced proliferation and 
decreased tumorigenicity.
15
 The same report established that CD148 induced a 
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G1 growth arrest by suppressing the degradation of the cyclin-dependent 
kinase inhibitor p27kip1 protein. 
Therefore, it could be assumed that CD148 is a cell regulator that maintains 
cells in a controlled proliferation state. When CD148 is overexpressed, cells 
show a reduction in cell proliferation,
21
 while when there is a deficiency in 
CD148 cells proliferate uncontrollably. 
For this reason we designed and synthetized a library of peptides agonist of 
this phosphatase in order to stimulate PTPRJ overexpression. 
 




 identified PTPRJ-binding peptides from a combinatorial 
phage display library in a cell free assay. Two peptide, whose specificity were 
tested in vitro, were also responsible of both biochemical and biological 
PTPRJ mediated effects, as we observed both dephosphorylation of PTPRJ 
targets and cell growth inhibition of HeLa and HUVEC cells. In particular, it 
has been described the isolation and characterization of synthetic peptides that 
interact with PTPRJ ectodomain and are able to trigger its signaling. 
In this context and as part of a wide research program aimed to the 
identification of new PTPRJ-targeted anticancer agents, I focused the attention 
on PTPRJ 19 (named peptide 1 in the Table 1) and PTPRJ 24 that in vitro, 
were shown to be responsible for both biochemical and biological PTPRJ-
mediated effects. In fact, the administration of both PTPRJ 19 ([Cys-His-His-
Asn-Leu-Thr-His-Ala-Cys]-OH) and PTPRJ 24 ([Cys-Leu-His-His-Tyr-His-
Gly-Ser-Cys]-OH) peptides to human cervical HeLa cancer cell line and 
human umbilical vein endothelial cells (HUVECs) dramatically reduced the 
extent of both MAPK phosphorylation, a critical mediator of mitogenic 
signals, and total phospho-tyrosine levels and, conversely, induced a 
significant increase of the cell cycle inhibitor p27Kip1. Moreover, these 
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Therefore, during my PhD, I considered PTPRJ 19 (peptide 1) as a valuable 
starting point for the development of a novel class of potential 
chemotherapeutic agents. 
Several general approaches to development different libraries of peptides 
have been used: (a) L- Ala scanning analysis to check the contribution of the 
various amino acid residues to the agonist activity of peptide 1; (b) 
implementation of various global and local conformational constraints via 
peptide cyclizations and employment of constrained amino acids; and (c) 
manipulation of steric factors that influence protein-ligand interactions.  
 
2.1 Alanine scanning approach (peptides 1-10) 
 
In a first classical approach, a series of L-Ala substituted analogues of 
peptide 1 were synthetized in order to evaluate the amino acid side chains 
involved in the interaction with the target molecule (peptides 1-10, Table 1). 
 
Table 1. Structure, inhibition activities, and analytical data of peptides 1-10. 
PTPRJ 
peptides 
Sequence HPLC ESI MS % of cell growth inhibitionb 
k’a Found Calc. 24h 48h 72h 
1 [CHHNLTHAC] 3.34 1931.2 1033.5 - 4.5±.1.4 19±2.82 
2 CHHNLTHAC 3.28 1035.1 1035.7 - - 4±1.4 
3 AHHNLTHAC  3.22 1003.1 1003.7 -             - - 
4 [CAHNLTHAC] 3.56 967.1 967.6 16.5±2.12 30±2.82 32.0±4.2 
5 [CHANLTHAC] 3.56 967.1 967.4 28±5.5 46±4.2 51±1.4 
6 [CHHALTHAC] 3.44 990.1 990.4 48.0±2.82 62.5±4.9 66.5±2.12 
7 [CHHNATHAC] 3.26 991.0 991.4 - 2±1.5 19±4.2 
8 [CHHNLAHAC] 3.45 1003.1 1003.2 - - 19±4.2 
9 [CHHNLTAAC] 3.56 967.1 967.6 - 4.5±2.13 20±1.4 
10 CHHNLTHAA 3.22 1003.1 1003.5 - - - 
a
k’=[(peptide retention time-solvent retention time)/solvent retention time].
b
The 
relative cell growth was expressed as a percentage of the growth observed in 
untreated cells at 24, 48, and 72h. 
b
The results are presented as mean values ± SD of 
at least three independent experiments. 
Here, it has been demonstrated that peptide 6, a derivative of peptide 1, 
generated through an Ala Scan analysis, was able to (a) reduce the 
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phosphorylation of ERK1/2; (b) inhibit HeLa cancer cell proliferation, and (c) 
trigger apoptosis in a much more efficient way than its lead compound.
23 
 
HUVEC cell proliferation was also inhibited by peptide 6, although to a 
lower extent compared to HeLa cells. Moreover, it effectively blocked in vitro 
HUVEC tube formation (see Results and Discussion session). These results 
strongly encourage the pursuit of this path for the development of a novel class 
of targeted anticancer drugs. 
At the same time, we decided to consider peptide 1 a valuable starting point 





Cys ring with lactam bridges to provide varying size 
of the ring by substituting with different bridging residues. 
 
2.2 Lactam cyclic peptides (peptides 11-17) 
 
Taking in mind that any attempt to design a peptide for therapeutic use 
would then be aided by a clear understanding of the structural elements that 
are responsible for its interaction with biological target, we have begun a study 
to address the roles of the disulfide bridge in the activity of peptide lead, 
compound 1.  
Herein, we present the synthesis and the biological activities of new 
analogues containing a more stable lactam bridge with the aim to implement 
the global conformational constraint and the ring size. These strategies, 







HIV gp41 antigenic loop,
27
 will 
allow to evaluate the structural importance of both ring size and bridge 
chemical nature on the biological activity for the new analogues.  
In particular, the Cysteines at positions 1 and 9 were replaced by amino 
acids bearing an amino ((2,3)-diaminopropionic acid (Dap), ornithine (Orn) or 
lysine (Lys)) and carboxylic (Asp or Glu) functions on the side chain, 
respectively; these two side chains were subsequently linked to form the 
lactam bridge (peptides 11-17, Table 2). 
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Table 2.  Structure, inhibition activities, and analytical data of peptides 11-17. 
PTPRJ 
peptides 
Sequence HPLC ESI MS % of cell growth inhibitionb 
k’a Found Calc. 24h 48h 72h 
11 [KHHNLTHAD] 3.26 1054.7 1054.1 5±4.3 10±4.3 10±5.5 
12 [OrnHHNLTHAD] 3.19 1041.7 1041.2 1.18±5.5 1.88±2.2 13±3.2 
13 [KHHNLTHAE] 3.25 1068.6 1068.1 - 2±3.30 4.0±3.3 
14 [OrnHHNLTHAE] 3.29 1054.6 1054.2 - 10±1.10 10±1.3 
15 [DapHHNLTHAE] 3.31 1026.7 1026.6 - 9 9 
16 [DHHNLTHAK] 3.23 1054.4 1054.2 1±4.5 2±4.5 3±1.1 
17 [EHHNLTHAK] 3.26 1068.5 1068.3 4.3±6.6 20±5.6 19.7±3.4 
a
k’=[(peptide retention time-solvent retention time)/solvent retention time].
b
The 
relative cell growth was expressed as a percentage of the growth observed in 
untreated cells at 24, 48, and 72h. 
b
The results are presented as mean values ± SD of 
at least three independent experiments. 
 
2.3 Alanine scanning approach (peptides 18-24) 
 
Once that the biological investigations of the first series of compounds were 
completed (paragrafe 2.1), we realized that it was necessary to evaluate if 
there are other amino acid side chains involved in the interaction with the 
target molecule. Therefore, being interested in the development of analogues 
with higher inhibitory potency, we decided to apply for the second time an 
Alanine scanning approach to the most active peptide, peptide 6 
([CHHALTHAC]) (peptides 18-24, Table 3). 
 
Table 3.  Structure, inhibition activities, and analytical data of peptides 18-24. 
PTPRJ 
peptides 
Sequence HPLC ESI MS % of cell growth inhibitionb 
k’a Found Calc. 24h 48h 72h 
18 AHHALTHAC 3.54 960.4 958.1 3.7±2.2 10.0±.3.2 10.0±4.4 
19 [CAHALTHAC] 3.33 922.2 921.1 - 10.0±3.4 9.5±3.2 
20 [CHAALTHAC  3.75 922.4 921.1 - 25.0±3.5 25.0±2.2 
21 [CHHAATHAC] 3.25 945.4 945.1 2.7±2.6 18.5±2.3 19.0±1.1 
22 [CHHALAHAC] 3.76 958.1 957.1 9.76±3.5 7.9±2.4 28.0±3.2 
23 [CHHALTAAC] 3.56 922.2 921.1 9.76±2.5 20.1±2.2 42.1±2.9 
24 CHHALTHAA 3.26 960.1 958.1 4.3±2.1 20.0±2.3 19.7±3.7 
a
k’=[(peptide retention time-solvent retention time)/solvent retention time].
b
The 
relative cell growth was expressed as a percentage of the growth observed in 
untreated cells at 24, 48, and 72h. 
b
The results are presented as mean values ± SD of 
at least three independent experiments. 
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Here, it has been demonstrated that no one compound generated through 
the second Ala scan analysis, was able to inhibit HeLa cancer cell proliferation 
in a greater extent of peptide 6. 
 
2.4 Changes to disulfide bridge (peptides 25-29) 
 
Interestingly, peptide 6 was responsible for a 66.5% reduction of cell 
proliferation versus 20% of the lead peptide, compound 1. Therefore, it was 
considered as a valuable starting point to design new analogues containing 
both a modified disulfide bridge (series 1, Table 4) and changes in position 
four, from Alanine to the most simple and no chiral amino acid (Glycine) and 
a restricted amino acid (Proline) to assest if it is important both the chirality 
and steric size (series 2, Table 4). 
 
Table 4.  Structure, inhibition activities, and analytical data of peptides 25-29.  
PTPRJ 
peptides 
Sequence HPLC ESI MS % of cell growth inhibitionb 
k’a Found Calc. 24h 48h 72h 
25 [PenHHALTHAPen] 3.24 1043.3 1043.2 5.0±2.1 20.0±.5.4 30.0±3.8 
26 [PenHHALTHACys] 3.55 1016.3 1015.2 5.0±3.4 10.0±4.6 30.0±1.4 
27 [CysHHALTHAPen] 3.75 1016.6 1015.2 - 4.4±6.2 30.0±5.2 
28 [CHHGLTHAC] 3.21 976.5 975.1 50.3±5.6 72.3±.1.4 75.1±2.82 
29 [CHHPLTHAC] 3.36 1016.3 1016.1 38.5±2.12 40.2±2.82 70.0±3.2 
a
k’=[(peptide retention time-solvent retention time)/solvent retention time].
b
The 
relative cell growth was expressed as a percentage of the growth observed in 
untreated cells at 24, 48, and 72h. 
b
The results are presented as mean values ± SD of 
at least three independent experiments. 
Although peptide cyclization generally induces structural constraints, the 
size of cyclization can affect the binding affinity of cyclic peptides. In this 
case, the substitution of Cysteine with Penicillamine (a superior analogue) 
bring a loss of activity compared with peptide 6. 
Interestingly, we found a peptide with a significant increase in inhibitory 
activity. Peptide 28 was responsible for a 75.1% reduction of cell proliferation 
versus 66.5% of peptide 6. Instead peptide 29 had an inhibitory activity similar 
to peptide 6. The substitution of Alanine with Glycine leads to the loss of 
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chirality in side chain. It suggests it is not necessary the chirality in four 
residue. 
The cyclic structure of Proline forces the ϕ angle to -65°+/-15°, thus 
preventing the formation of a α-helix, and promoting the formation of a β-turn. 
Besides, while the barrier to secondary amide cis/trans isomerization is about 
10 kcal/mol, the presence of Proline reduces the barrier to just 2 kcal/mol, 
hence influencing the biological behaviour of peptides.
28
 
In this case, the substitution of Alanine with Proline does not lead an 
increase in the inhibitory activity, moreover it is maintained. 
 
2.5 Changes to increase stability of peptides (peptides 30-33) 
 
The introduction of D-amino acids
29
 in a sequence can give the peptide an 
increased stability, since only a few enzymes that effectively hydrolyse 
peptide bonds involving D-amino acids have been discovered and 
characterized in multicellular organisms.  
Moreover, D-residues often enforce a different conformation of the 
peptide,
30
 and strongly influence receptor affinity and selectivity. 
Focused on peptide 6 we decided to change L-Alanine in four with its D-
analogue and with D-Proline, to assess the importance of conformation and 
chirality (peptides 31-32, Table 5). 
Moreover, the most promising peptide, compound 6, was also investigated 
by solution NMR in water solution. NMR parameters of the peptide indicated 
high conformation flexibility illustrated, for example, by the absence of 
medium range diagnostic NOEs apart from a weak signal between Hβs of 
4
Ala 
and HN of 
6





Leu is present in a population of conformers. Upfield shift of 




Thr, confirms this hypothesis being 
indicative of the presence of H-bonds involving these amide protons. For this 




Leu to test the 
importance of H-bonds. 
The reduction of the cycle often increases the stability of peptides, which 
can prolong their biological activity. For this reason we wanted to check if the 
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reduction of ring size could improve the inhibitory activity of peptide. 
Therefore, we decided to eliminate 
8
Ala to reduce the ring size and also to 
check if it is an essential residue (peptide 30). 
 
Table 5.  Structure, inhibition activities, and analytical data of peptides 28-31. 
PTPRJ 
Peptides 
Sequence HPLC ESI MS 
k’
a
 Found Calc. 
30 [CHHGLTHC] 3.33 905.2 905.0 
31 [CHHaLTHAC] 3.24 990.3 990.1 
32 [CHHpLTHAC] 3.28 1016.3 1016.2 
33 [CHHNGTHAC] 3.26 977.3 977.1 
a
k’=[(peptide retention time-solvent retention time)/solvent retention time]. 
At the same time, we decided to design a new library of peptides, starting 
from biological results mentioned above with the aim to increase the affinity 
and stability of peptide, manipulating steric factors that influence protein-
ligand interactions. 
 
2.6 Changes in specific position (peptides 34-42) 
 
To extend structure-activity relationships for these series of inhibitors, 
analyzing the inhibitory activity of peptides 1-10 (Table 1), we decided to 
bring forward two different approaches: a) changes 
4
Ala with aliphatic, 
positive and negative charged and aromatic amino acid; b) changes 
3
His with 
aliphatic, positive and negative charged and aromatic amino acid. 
In particular, we focused on peptides 5 and 6 that showed an inhibitory 
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Table 6.  Structure, inhibition activities, and analytical data of peptides 34-42. 
PTPRJ 
Pepides 
Sequence HPLC ESI MS 
k’
a
 Found Calc. 
34 [CHHLLTHAC] 3.44 1033.1 1032.7 
35 [CHHVLTHAC] 3.42 1019.1 1018.2 
36 [CHHDLTHAC] 3.41 1034.4 1034.2 
37 [CHHFLTHAC] 3.46 1067.4 1066.3 
38 [CHLALTHAC] 3.32 967.3 966.2 
39 [CHVALTHAC] 3.33 953.4 952.1 
40 [CHDALTHAC] 3.37 969.5 968.3 
41 [CHFALTHAC] 3.39 1001.6 1000.3 
42 [CHOrnALTHAC] 3.26 968.1 967.5 
a
k’=[(peptide retention time-solvent retention time)/solvent retention time]. 











Phe. The same approach was 





(peptide 42).  The biological activity assays are in progress. 
 
2.7 Changes in lactam bridge (peptides 43-45) 
 
Valuating the biological results obtained with peptides 11-17, the only one 
that seems to have an inhibitory activity similar than peptide lead, compound 
1, is the peptide 17 (19.7% versus 19%) containing a lactam bridge between 
Glutamic acid and Lysine. Considering the importance of amino acid in four 
position we wanted to check if the activity of this compound increased with 
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Table 7.  Structure and analytical data of peptides 43-45. 
PTPRJ 
peptides 
Sequence HPLC ESI MS 
k’
a
 Found Calc. 
43 [EHHALTHAK] 3.25 1026.1 1025.4 
44 [EHHGLTHAK] 3.20 1012.3 1011.4 
45 [EHHPLTHAK] 3.34 1070.3 1069.4 
a
k’=[(peptide retention time-solvent retention time)/solvent retention time]. 
The biological activity assays are in progress. 
 
2.8 An improvement in the synthesis of PTPRJ analogue, peptide 6  
 
A first attempt to prepare peptide 6 by a standard Fmoc procedure using 
Wang resin as starting material clearly showed that optimization would be 
required. For this reason we prepared this compound on acid-labile 2Cl-Trt 
resin by solid-phase synthesis of linear peptide sequences. 
We obtained significant difference in PTPRJ analogue synthesis (see 
Chemistry section, paragraph 3.4 and Appendix B). 
In view of this, common problems during peptide synthesis, purification, 
and handling can be minimized. Several tips should be taken into 
consideration whenever possible in the design of a peptide. Chemically 
synthetized peptides carry free amino and carboxy termini, being electrically 
charged in general. In order to remove this electric charge, peptide ends are 
often modified by N-terminal acetylation and/or C-terminal amidation.  
 
Table 8.  Structure and analytical data of peptides 46. 
PTPRJ 
Pepides 
Sequence HPLC ESI MS 
k’
a
 Found Calc. 
46 Ac[CHHALTHAC]NH2 3.35 1031.4 1031.2 
a
k’=[(peptide retention time-solvent retention time)/solvent retention time]. 
For internal sequences derived from native proteins, it may be necessary to 
cap either or both the N- and C-termini to avoid introducing a charge where 
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there is none in the native sequence. The C-terminus and N-terminus can be 
capped as an amide (peptide amide-CONH2 instead of peptide acid-COOH) 
and acetyl group respectively. Sometimes synthetizing a peptide modified by 
N-terminal  acetylation and/or C-terminal amidation increases its stability and 
quality. 
In fact there are some advantages: 
- peptide ends are uncharged, compared to standard synthetic peptides, so 
modified peptide more closely mimic the native protein. This increases their 
ability to permeate cells. Therefore, these modifications are required for 
intracellular, in-vivo assays and in-vitro functional studies; 
- stability toward digestions by aminopeptidases is enhanced therefore these 
peptides can be used as substrate in enzyme assays; 
- peptide ends are blocked against synthetase activities; 
- acetylated peptides serve as optimized enzyme substrates amidation of 
peptides enhances activity of peptide hormones and it also prolongs their shelf 
life. 
Having some problems about synthesis and purification of disulfide 
peptides: the overall quality of the material was rather low due to a sticky 
peptide therefore a difficult characterization with the first oxidative method 
(see paragraph 3.2.1), we check if N-terminal acetylation and/or C-terminal 
amidation lead to an improvement in the yield (Table 8). 
These improvements can be combined to produce a linear precursor clean 
enough to be oxidized as a crude product, thus increasing the efficiency of the 
synthetic approach. 
In conclusion, these changes resulted in a product with and HPLC profile 




3.1 General procedure for synthesis 
 
The synthesis of peptides (1-46) was performed according to the solid 
phase approach using standard Fmoc methodology in a manual reaction 
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 The first amino acid, N𝛼Fmoc-Xaa-OH, was linked onto the Wang 
resin and was attached to the resin using HOBt/HBTU as an activating agent 
and a catalytic amount of DMAP. 
Fmoc-Cys(Trt)-Wang resin was used to avoid the use of DMAP and 
collateral reactions due to its. 
The following protected amino acids were then added stepwise. Each 
coupling reaction was accomplished using a HBTU and HOBt as coupling 
reagents in the presence of DIEA. The N𝛼-Fmoc protecting groups were 
removed by treating the protected peptide resin with a 25% solution of 
piperidine in DMF (1 × 5min and 1 × 25min).  
For peptide 46, the last N
α
-Fmoc was removed and the amino group was 
acetylated with acetic anhydride and DIPEA in DCM/DMF for 1h and 30 min. 
In addition, after each step of deprotection and after each coupling step, 
Kaiser test was performed to confirm the complete removal of the Fmoc 
protecting group, respectively, and to verify that complete coupling has 
occurred on all the free amines on the resin. Then Kaiser test was performed to 
confirm the acetylation reaction. 
The N-terminal Fmoc group was removed as described above, and the 
peptide was released from the resin with TFA/iPr3SiH/H2O (90:5:5) for 3 h. 
The resin was removed by filtration, and the crude peptide was recovered by 
precipitation with cold anhydrous ethyl ether to give a white powder and then 
lyophilized. 
 
3.2 General method of disulfide bridge formation 
 
3.2.1 Oxidative method with Potassium Ferrocyanide 
 
Oxidation of cysteinyl peptides to form cyclic disulfide-bonded peptides is 
generally carried out using dilute solutions of peptide in aqueous or 
aqueous/organic media at weakly basic pH. The classical oxidizing agent 
K3Fe(CN)6 was used in our procedure with the principle that a low 
concentration of the linear (reduced) peptide is necessary for oxidation.
32
 
Thus, oxidation was performed by slow dropping of a solution of the peptide 
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into a reaction vessel containing an excess (1.2 eq.) of the oxidizing agent in 
aqueous solution. The concentration of the reduced peptide was regulated by 
controlling the speed of addition of the peptide with the help of an automated 
syringe pump (Scheme 1). 
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Scheme 1. Synthesis and oxidative folding of peptide 6 (1). 
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Progress of the folding reaction was monitored by analytical HPLC and, 
once completed, the target products were purified to homogeneity by 
preparative RP-HPLC, and subsequently lyophilized. Analytical purity and 
molecular weight were determined by analytical RP-HPLC and ESI mass 
spectrometry. 
This first attempt to prepare peptide 6 clearly showed that optimization 
would be required. The overall quality of the material was rather low due to a 
sticky peptide therefore a difficult characterization. A different oxidative 
approach was used with the aim to improve the overall quality. 
 
3.2.2 Oxidative method with NH4HCO3 / isopropyl alcohol 
 
Air oxidation was carried out by dissolving the lyophilized crude peptide in 
NH4HCO3/isopropyl alcohol (pH 8.25) with vigorous stirring at RT for 1 h. 
Prior to purification, the solution was acidified to pH 3 with TFA and analyzed 
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Scheme 2. Synthesis and oxidative folding of peptide 6 (2). 
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In contrast, replacement of the first oxidative method with this one resulted 
in a product with and HPLC profile significantly cleaner than the previous 
attempt and with better resolution (Figure 3). 
 
  
Figure 3. HPLC preparative crude profile of peptide 6 with different oxidative 
methods. 
 
3.3 Synthesis of lactam analogues (peptides 11-17, 43-45) 
 
The preparation of cyclic peptides, 11-17 and 43-45 through a side-chain-
to-side-chain cyclization, was carried out after removal of the Allyl/Alloc 
protection according to strategy reported by Grieco et al.
34
 Peptide analytical 
data are reported in Table 2 and 7. 
 
3.4 Synthesis of disulfide cyclic peptides with 2Cl-Trt resin (peptides 6, 
28-29) 
 
A first approach to prepare PTPRJ analogues by a standard Fmoc procedure 
using Wang resin or Fmoc-Cys(Trt)-Wang resin, as starting material clearly 
showed that optimization would be required. Accordingly, while LC-MS 
analysis of the crude product showed the expected peptide without Alanine-
Cysteine in C-terminal (m/z 818) as the main peak (Figure 4), the overall 
quality of the material was rather low.  
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Figure 4. HPLC crude profile of peptide 6 and ESI-MS spectrum of peptide 6: 
[M+2H]
2+




Cys  (m/z 818). 
 
The synthesis of compounds 6, 28 and 29 were prepared on acid-labile  
2Cl-Trt resin by solid-phase synthesis of linear peptide sequences, using the 
Fmoc protection strategy, followed by cyclization with NH4HCO3/isopropyl 
alcohol as previously described. 
At this point it was clear that the replacement of Wang resin with 2Cl-Trt 
resin had meant a significant difference in PTPRJ analogue synthesis.  
2-Chlorotrityl chloride resin is an acid labile resin for peptide 
synthesis using Fmoc-amino acids. The steric bulk and mild acid conditions 
for cleavage make 2-chlorotrityl resins useful in many applications. 
Additionally, Fmoc-amino acids can be attached to 2-chlorotrityl chloride 
resin with essentially no racemization. Amino acid 2-chlorotrityl resins can be 
alternatives to Fmoc-amino acid Wang resins where racemization of the first 
Fmoc-amino acid is common as with Cys and His. The steric size of 2Cl-Trt 
group not allow the formation of diketopiperazine. Therefore, the formation of 
diketopiperazine for intramolecular bond of ammine group of the second 




-Fmoc amino acid and DIPEA were dissolved in dry 
dichloromethane (DCM) containing, if necessary, a small amount of dry DMF 
(enough to facilitate dissolution of the acid). This was added to the resin and 
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stirred for 30-120 min. Other N





General procedure for cyclization: A solution of the linear protected 
peptide was added at room temperature to a reaction flask containing a 
solution of HOBt, HBTU  and DIPEA in DMF. The mixture was stirred for 24 
h at room temperature and monitored by TLC.  
 
3.5 Purification and characterization 
 
All crude peptides were purified by RP-HPLC on a preparative C18-bonded 
silica column using a Shimadzu SPD 10A UV/VIS detector, with detection at 
215 and 254 nm. 
All peptides were characterized with analytical RP-HPLC and peptides 
molecular weights were determined by ESI mass spectrometry and  LC-MS in 
a LC-MS 2010 instrument fitted with a C18 column. All analogues showed 
>97% purity when monitored at 215 nm. Homogeneous fractions, as 
established using analytical HPLC, were pooled and lyophilized. 
 
3.5.1 Chromatographic optimization 
 
During my PhD, an improvement for purification and characterization of 
peptides were done. 
The choice of the chromatographic column is a crucial step for an efficient 
chromatographic separations with better resolution, higher sensitivity and 
improved peak capacities. 
For this reason, we used the core shell technology to increase resolution, 
reducing time processing. 
Core-shell particle technology provides striking increases in peak capacity 
and resolution at lower backpressure, giving chromatographers the ability to 
achieve ultra-high performance on any system, HPLC or UHPLC. 
A uniform porous silica layer is grown around a solid, spherical silica core, 
providing effective retention and selectivity with improved resolution, speed, 
and recovery. Next, optimizing the pore size and shell thickness for intact 
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proteins or smaller peptide fragments provides well-defined depth penetration 
of biomolecules leading to maximum separation power. 
Concerning chromatographic columns for preparative HPLC, the Jupiter 
HPLC column portfolio, including Jupiter 300 and Jupiter Proteo, offers 
optimized reversed phase solutions for protein characterization and 
purification. With these columns, one can identify, purify, and analyze almost 
any protein. In particular, 300 Å column designed for intact protein 
purification and analysis allowed a separation of proteins ≥ 10,000 MW 
producing excellent peak shape and resolution of protein samples. Instead 90 
Å column engineered for peptide mapping and  peptide separations allowed a 
separation of proteins and peptides ≤ 10,000 MW, increasing peak capacity 
and resolution. Specifically, we used a preparative Jupiter Proteo column for 
all PTPRJ analogues and GRK2 inhibitors instead Jupiter 300 column for 
other compounds we will see in the third chapter. 
 For all these reasons, an alternative oxidative method together with an 
improvement in HPLC purification and characterization allowed us to achieve 
the amount of solid pure product ca. 5 times higher than with the standard 
procedure. 
 
4. Results and discussion 
4.1 PTPRJ Ala scan peptide derivatives inhibit HeLa cancer cell 
proliferation 
Through a phage display library screening, Trapasso et al., recently 
identified two nonapeptides (named PTPRJ 19 and 24, peptide 1 and 2) with 
the ability to bind and trigger PTPRJ activity; these peptides could induce 
MAPK dephosphorylation and inhibit cell growth of HeLa and HUVEC cells, 
although to a low extent.
23
 Here, in order to generate PTPRJ peptide agonists 
with improved biological activity, we (a) investigated the role of the peptide 
circularization, synthesizing a peptide 1 derivative deprived of the disulfide 
bridge between the first and the last Cysteine residues, and then (b) pursued an 
Ala scan procedure consisting in the systematic substitution of each peptide 1 
residue with a L-Alanine (Table 1). 
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This latter approach resulted in the generation of a panel of nine peptides, 
named peptide 1 to 10. All new derivatives were tested in HeLa cancer cells 
for the assessment of their ability to inhibit cell proliferation; cells were 
treated with 160 μM concentration of each compound, and cell count was 
performed 24, 48, and 72 h after treatment. Interestingly, peptide 6 was 
responsible for a reduction of cell proliferation up to 66.5% versus 20% of 
peptide lead (Figure 5). Values of cell growth inhibition for all tested peptides 




Figure 5. Cell growth inhibition induced by PTPRJ peptides in HeLa cells. 
Relative cell growth (as a percentage of the growth observed in untreated cells) at 
different intervals of treatments (from 24 to 72 h) is reported. HeLa cells were treated 
once with PTPRJ peptides for 24 h (white columns) or treated every 24 h for 48 h 
(gray columns) and for 72 h (black columns). Results represent the mean ± SD of 
three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 compared to 
untreated cells by unpaired two-tailed Student’s t test. 
 
The above-reported data suggested important structure-activity 
relationships for this small library of derivatives. First, the disulfide bridge 
appears to have effect upon cell growth inhibition as demonstrated by our 
previous work.
23
 In fact, all three linear compounds used, namely, peptide 2 
(that only differs from PTPRJ 19 for the absence of the disulfide bridge) and 
peptide 3 and peptide 10 (which incorporate an Ala residue at position 1 and 9, 
respectively), lost their ability to activate PTPRJ (Table 1). 
Second, the most interesting result was obtained with peptides modified at 




Asn into the 
cyclic peptide 1 by Ala produced a dramatic increase in the biological activity 
of the corresponding analogues (peptide 5 or peptide 6), resulting in a cell 
Chapter 2       Synthesis, characterization and biological evaluation of PTPRJ 
(protein tyrosine phosphatase receptor like-j) agonists 
 
- 54 - 
 
growth inhibition ranging from two to three times higher compared to their 
lead compound. In particular, the observed effect was time dependent, 
generating a 48%, 62.5%, and 66.5% reduction of HeLa cell number at 24, 48, 
and 72 h, respectively for peptide 6. These data suggest that either a lack of 
polar side chains in these positions or the introduction of low hindrance, 
lipophilic features is well accepted. 






His residues by Ala (peptide 7, 
8 and 9) did not modify the weak cell growth inhibition levels exhibited by 
peptide lead. 
 
4.1.1 Ala scan PTPRJ 19 (peptide 1) derivatives negatively modulate 
ERK1/2 phosphorylation and induce apoptosis of HeLa cancer cells 
 
According to recent published results,
23
 treatment of HeLa cells with 160 
μM peptide 1 resulted in a dramatic reduction of the ERK1/2 phosphorylation; 
the dephosphorylation effect reported in previous investigation was rapid and 
transient and reached its peak within 15 min after treatment. In order to test the 
effects of the newly Ala scan generated derivatives on ERK1/2 
phosphorylation, we used the same approach as previously reported.
23
 HeLa 
cells were treated with 160 μM concentration of the most potent 
antiproliferative compounds described in the previous section (peptides 4-6). 
As shown in Figure 6A, peptides 4 and 5 reduced the ERK1/2 phosphorylation 
extent in a short term; these results are comparable to those observed with 
their precursor. Interestingly, the treatment with peptide 6 induced a time-
dependent reduction of ERK1/2 phosphorylation that reached its maximum at 
60 min. ERK1/2 phosphorylation was also assessed 12, 24, and 48 h after 
peptide 6 treatment of HeLa cells; as shown in Figure 6B, we observed a slight 
reduction of ERK1/2 phosphorylation extent in all cases. To further expand 
the concept of functional specificity of the peptide 6/PTPRJ interaction, we 
knocked-down endogenous PTPRJ protein with specific siRNAs in HeLa 
cells. Forty-eight hours after transfection, cells were treated with either peptide 
6 and scramble peptide (tipically used as a negative controls to show that a 
specific sequence is critical to the protein function or activity), and 1 h later 
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we evaluated the ERK1/2 phosphorylation extent. Interestingly, ERK1/2 
phosphorylation of PTPRJ knocked-down cells treated with peptide 6 was 
higher compared to control treated with peptide 6 alone, suggesting that 




Figure 6. Peptides 4-6 synthetic peptides suppress phosphorylation of ERK1/2 
and induce cell death of HeLa cancer cells. (A) HeLa cells were seeded in 6-well 
plates and, 24 h later, treated with 160 μM peptides 4-6, lead compound, or scrambled 
peptide at 0, 15, 30, and 60 min. Cell lysates were subjected to immunoblotting using 
a phospho-specific ERK1/2 (p-ERK) antibody. Blots were stripped and reprobed for 
total ERK1/2 as a loading control. (B) HeLa cells were treated either with 160 μM 
peptide 6 or scrambled peptide, and cells were collected at the indicated intervals (12, 
24, and 48 h). Cell lysates were subjected to immunoblots using phospho-specific 
ERK1/2 (p-ERK). Blots were stripped and reprobed for total ERK1/2 antibody as a 
loading control. (C) HeLa cells were transfected with either 100 nM PTPRJ or 
scrambled siRNAs and 48 h later were treated with either 160 μM peptide 6 or 
scrambled peptide for 1 h. Cell lysates were subjected to immunoblotting using an 
anti-PTPRJ antibody and a phospho-specific ERK1/2 (p-ERK) antibody. Blots were 
stripped and reprobed for total ERK1/2 as a loading control.( D) Representative 
experiment of cell cycle analysis of HeLa cells treated with 4-6 synthetic peptides. 
The percentage of sub-G1 population is reported on the top of each histogram. Data 
analysis was performed with ModFit LTTM cell cycle analysis software. 
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We also evaluated cell cycle perturbations induced by peptides 4-6 on HeLa 
cells. Twenty four hours after treatment, cells were collected and investigated 
by flow cytometric analysis; in Figure 6D is indicated the percentage of a sub-
G1 population, suggestive of apoptotic cell death. 
Interestingly, while the administration of peptide 4 was able to trigger cell 
death only in 6.1% of cell population, HeLa cells treated with peptide 5 and 6 
showed a 17.5% and 27.3% of dead cells, respectively.  
 
4.1.2 Peptide 6 partly inhibits cell proliferation of HUVECs and blocks in 
vitro tube formation 
 
In order to investigate the biological effects of peptide 6 on normal 
endothelial cells, HUVECs were treated with 160 μM peptide. Similarly to 
what observed with HeLa cells, peptide 6 significantly reduced the ERK1/2 
phosphorylation extent in HUVEC cells in a time-dependent manner (Figure 
7A). No differences in ERK1/2 phosphorylation were observed in HUVEC 
cells after a scramble peptide administration (data not shown). Instead, cell 
growth assessment performed 24, 48, and 72 h after treatment showed a 
different behavior in HUVEC compared to HeLa cells. In fact, no significant 
differences were noticed 24 h after treatment compared to the control, while a 
48% inhibition was reported with HeLa cells. Moreover, we only observed a 
28% and 32% of cell growth inhibition 48 and 72 h after treatment, 
respectively (Figure 7B) versus 62.5% and 66.5% described 48 and 72 h after 
treatment of HeLa cells, respectively (see Table 1). To investigate the role of 
VEGFR2 on peptide 6-mediated ERK1/2 dephosphorylation and cell growth 
inhibition on HUVECs, we assayed the phosphorylation state of VEGFR2 in 
VEGF stimulated HUVECs treated with or without peptide 6. As reported in 
Figure 7C, we observed a significant reduction of phospho-VEGFR2, thus 
suggesting an impaired signaling by this receptor in cells treated with peptides 
6. The production of tubular structures is an important step in angiogenesis; 
therefore, as PTPRJ activity antagonizes VEGFR2 function,
36
 we investigated 
the role of peptide 6 on HUVEC tube formation. As shown in Figure 7D, 
control HUVEC cells, plated on Matrigel and incubated either with control 
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medium or a scramble peptide, formed lumen-like structures, while HUVEC 





Figure 7. Peptide 6 negatively modulates ERK1/2 phosphorylation and inhibits 
both cell proliferation and tube formation of HUVEC endothelial cells. (A) Peptide 6 
suppresses phosphorylation of ERK1/2 in HUVECs; cells were treated with 160 μM 
peptide 6 and collected at the indicated intervals (15−60 min). Cell lysates were 
subjected to immunoblots using phospho-specific ERK1/2 (p-ERK). Blots were 
stripped and reprobed for total ERK1/2 antibody as a loading control. (B) Cell growth 
inhibition induced by peptide 6 in HUVECs at 24 h (white columns), treated every 24 
h for 48 h (gray columns) and every 24 h for 72 h (black column). Results represent 
the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01 compared to 
scrambled peptide by unpaired two-tailed Student’s t test. (C) HUVECs were serum 
starved, stimulated with 20 ng/mL of VEGF, treated 15 min with or without peptide 
6, and then lysed. VEGFR2 phosphorylation levels were detected by immunoblotting 
with a phospho-specific VEGFR2 (Y1054/1059) antibody. Membranes were stripped 
and immunoblotted with a VEGFR2 antibody. (D) Peptide 6 inhibits tube formation 
of primary endothelial cells on Matrigel. Representative photograph of antitube 
formation activity of peptide 6. HUVECs (2.5 × 104/well) were untreated or 
preincubated either with peptide 6 or scrambled peptide (100 μM) for 30 min before 
being seeded onto the solidified Matrigel for 18 h. (scale bar: 200 μM). 
Chapter 2       Synthesis, characterization and biological evaluation of PTPRJ 
(protein tyrosine phosphatase receptor like-j) agonists 
 
- 58 - 
 
4.1.3 Peptide 6 negatively modulates ERK1/2 phosphorylation and 
reduces cell proliferation of mammary 
 
Cancer Cells. To evaluate if the effects of peptide 6 on HeLa cells could be 
considered a general event in cancer cells, we also included in our 
investigation two mammary cancer cell lines, MCF-7 and SKBr3, which both 
express endogenous PTPRJ (data not shown). Both cell lines were treated with 
160 μM peptide 6, as previously described, and both ERK1/2 phosphorylation 
and growth rate were assessed. This compound negatively modulated ERK1/2 
phosphorylation extent in the short term (Figure 8A); moreover, we observed a 
significant cell growth inhibition resulting in a reduction of about 40% 
compared to controls in both cell lines (Figure 8C) at 72 h. 
To check if peptide 6 administration was toxic to normal cells, the above-
described experiments were also carried out on primary human mammary 
epithelial cells (HMECs). Intriguingly, no effects on both ERK1/2 
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Figure 8. Peptide 6 negatively modulates ERK1/2 phosphorylation and reduces 
cell proliferation of human mammary cancer cells. (A) MCF-7 and SKBr3 cells were 
seeded in 6-well plates and, 24 h later, treated with either 160 μM peptide 6 or 
scrambled peptide, and lysed at 0, 15, 30, 60 min. Cell lysates were subjected to 
immunoblotting using a phospho-specific ERK1/2 (p-ERK) antibody. Blots were 
stripped and reprobed for total ERK1/2 as a loading control. B) HMECs were treated 
with 160 μM peptide 6 or scrambled peptide, and cells were collected at the indicated 
intervals. Cell lysates were subjected to immunoblots using phospho-specific ERK1/2 
(p-ERK). Blots were stripped and reprobed for total ERK1/2 antibody as a loading 
control. (C) Cell growth rate of MCF7, SKBr3, and HMECs by peptide 6 peptide. 
Relative cell growth (as a percentage of the growth observed in cells treated with 
scrambled peptide) at different intervals of treatments (from 24 to 72 h) is reported. 
Cells were treated once with peptide 6 and scrambled peptides for 24 h (white 
columns) or treated every 24 h for 48 h (gray columns) and for 72 h (black columns). 
Results represent the mean ± SD of three independent experiments. *P < 0.05, **P 
< 0.01 compared to scrambled peptide by unpaired two-tailed Student’s t test. 
 
4.1.4 Molecular Modeling of Ala scan PTPRJ-binding derivatives 
suggests supramolecular aggregation states 
 
Monte Carlo (MC) conformational search, docking experiments, 
thermodynamics, and statistical analyses were performed with the aim to 
rationalize at molecular level the biological properties of our PTPRJ agonist 
peptides comparing their structural features to those of the lead compound, 
peptide 1 (see Experimental section for further details). 
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As in the case of other PTPRJ peptide binders, the MC search of peptide 1 
to -10 revealed a large number of local minimum energy conformers (data not 
shown). Following the same computational approach reported in recent 
communication,
23
 the self-aggregation trend of the new peptides was 
investigated by means of docking simulation coupled to thermodynamics and 
statistical analyses (see Experimental section). Results clearly indicate that all 
peptides formed multiple conformation self aggregates with 1:1 stoichiometry 
(data not shown). 
Peptides 3-5 and 7-10 reported an overall complexes stabilization (ΔG) 
notably weaker than that of peptide 1. Only peptide 6 maintained a 
thermodynamic profile comparable to the lead compound. Statistic data, 
obtained by coupling Boltzmann population and clustering analyses, revealed 
for all new derivatives, excluding peptide 5, a number of possible geometry 
clusters larger than peptide lead and, with the exception of derivative 3, 
increased population of the global minimum energy structures. 
Graphic inspection of the most stable complexes and their α carbons 
alignment onto peptide lead strongly indicated that only the derivative 6 could 
be related to the lead compound (Figure 9), while all other derivatives were 




Figure 9. Graphic comparison of peptide lead (on the left) and peptide 6 (on the 
right) most stable self-aggregates. Peptides are depicted in polytube, and complex 
subunits are colored in CPK and green carbons, respectively. 
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4.1.5 NMR analysis indicates that peptide 6 folds as a β-Turn and shows 
propensity to dimerization 
 
The most promising peptide, derivative 6, was also investigated by solution 
NMR in water solution. Similarly to its precursor, peptide lead, the spectra 
showed splitting of the signals. Complete 
1
H NMR chemical shift assignments 
were achieved for the most intense signal pattern according to the W thrich 
procedure
37
(data not shown). NMR parameters of the peptide indicated high 
conformation flexibility illustrated, for example, by the absence of medium 
range diagnostic NOEs apart from a weak signal between Hβs of 
4
Ala and HN 
of 
6









Thr, compared to the corresponding in peptide 1 and 
relatively low temperature coefficient of HN-6 (-Δδ/ΔT = 4.3 ppb/K), 
confirms this hypothesis being indicative of the presence of H-bonds involving 
these amide protons. Unfortunately, diagnostic Hα-HN i,i+2 NOE signal 
between residues 4 and 6 could not be observed due to overlapping. This turn 
structure is in accordance with the molecular modeling results (Figure 9). 
Furthermore, to check the aggregation state of peptide 6 under the NMR 
conditions, STD-NMR experimentswere recorded (data not shown).
 38
  As for 
peptide lead, on-resonance irradiation induces detectable STD signals with 
relative STD effect of about 1% (0.7% was found for peptide 1), suggesting 
that aggregation properties of the two peptides are similar with high propensity 
to dimerization. 
 
4.2 Lactam cyclic peptide derivatives action on HeLa cancer cell 
proliferation (peptides 11-17) 
 
Peptide cyclization is a well established approach to improve peptide 
biological activity
39
 which stems from reduced conformational freedom of the 
parent peptide and thus a better defined secondary structure required for 
efficient receptor-ligand interaction, i.e., “bioactive conformation”.
40
 It has 
been previously noted that the success of a peptide cyclization depends 
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strongly on the probability of juxtaposition of the reactive groups of the linear 
peptide precursor, and is usually encumbered by side reactions, most notably, 
oligomerizations and cyclo oligomerizations. 
Depending on its functional groups, a peptide can be cyclized in four 
different ways: head-to-tail (C-terminus to N-terminus), head-to-side chain, 
side chain-to-tail or side-chain-to-side-chain. Of the various methods of 
synthesizing cyclic peptides, most often the final ring-closing reaction is a 
lactamization, a lactonization or the formation of a disulfide bridge. For 
example, an effective side-chain-to-side-chain macrocyclization involves a 
condensation reaction between side chains of aspartic or glutamic acid and 
lysine residues.
41
 Therefore, the replacement of the disulfide bridge by a 
chemically more stable moiety appeared as an attractive alternative. 
In this case, in order to generate PTPRJ peptide agonists with improved 
biological activity, we investigated the role of the peptide circularization, 
synthesizing a peptide 1 derivatives. These compounds derived of the lactam 
bridge with the aim to implement the global conformational constraint and the 
ring size (Table 2). 
This latter approach resulted in the generation of a panel of seven peptides, 
named peptide 11 to 17. All new derivatives were tested in HeLa cancer cells 
for the assessment of their ability to inhibit cell proliferation; cells were 
treated with 160 μM concentration of each compound, and cell count was 
performed 24, 48, and 72 h after treatment. Interestingly, no one peptides were 
responsible for a reduction of cell proliferation greater of peptide 6 (Figure 
10). Values of cell growth inhibition for all tested peptides in this experiment 
are reported in Table 2. 
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Figure 10. Cell growth inhibition induced by PTPRJ peptides in HeLa cells. 
Relative cell growth (as a percentage of the growth observed in untreated cells) at 
different intervals of treatments (from 24 to 72 h) is reported. HeLa cells were treated 
once with PTPRJ peptides for 24 h (white columns) or treated every 24 h for 48 h 
(gray columns) and for 72 h (black columns). Results represent the mean ± SD of 
three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 compared to 
untreated cells by unpaired two-tailed Student’s t test. 
 
The above-reported data suggested important structure-activity 
relationships for this small library of derivatives. First, disulfide bridge 
appears to have more effect upon cell growth inhibition respect to lactam 
bridge. In fact, six compounds lost their ability to activate PTPRJ except 
peptide 17. This compound presents a lactam bridge with a negative charged 
in side chain in N-terminal residue and a positive charged in side chain in C- 
terminal residue. These substitutions produce an increase in the biological 
activity of the corresponding analogues (peptides 11-16), resulting in a cell 
growth inhibition ranging from one to two times higher compared to other 
lactam cyclic peptides. In particular, the observed effect was time dependent, 
generating a reduction of HeLa cell number only at 48 and 72 h (20 and 19.7 
% respectively) resulting in an improvement at 48h in term of reduction of 
HeLa cell number. Instead at 72h the activity we get more or less similar with 
respect to the peptide lead, peptide 1. This data suggest that either an acid side 
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4.3 PTPRJ Ala scan peptide 6 derivatives action on HeLa cancer cell 
proliferation 
 
Through Alanine scanning procedure, we wanted to evaluate if there are 
amino acid side chains involved in the interaction with the target molecule. 
Therefore, being interested in the development of analogues with higher 
inhibitory potency, we decided to apply for the second time an Alanine 
scanning approach to the most active peptide, compound 6. 
This latter approach resulted in the generation of a panel of seven peptides, 
named 18-24. All new derivatives were tested in HeLa cancer cells for the 
assessment of their ability to inhibit cell proliferation; cells were treated with 
160 μM concentration of each compound, and cell count was performed 24, 
48, and 72 h after treatment (Figure 11). 
 
Figure 11. Cell growth inhibition induced by PTPRJ peptides in HeLa cells. 
Relative cell growth (as a percentage of the growth observed in untreated cells) at 
different intervals of treatments (from 24 to 72 h) is reported. HeLa cells were treated 
once with PTPRJ peptides for 24 h (white columns) or treated every 24 h for 48 h 
(gray columns) and for 72 h (black columns). Results represent the mean ± SD of 
three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 compared to 
untreated cells by unpaired two-tailed Student’s t test. 
Interestingly, compound 23 was responsible for a reduction of cell 
proliferation up to 40% versus 20% of peptide 1. 
In particular, the observed effect was time dependent, generating a 20.1% 
and 42.1% reduction of HeLa cell number at 48 h and 72 h respectively. These 
data suggest that either a lack of polar and positive charged in side chains 
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His) in this position or the introduction of low hindrance, lipophilic features 
is well accepted. 
 
4.4 Peptides 25-29 action on HeLa cancer cell proliferation 
 
Although peptide cyclization generally induces structural constraints, the 
size of cyclization within the sequence can affect the binding affinity of cyclic 
peptides. In this case, the substitution of Cysteine with Penicillamine (a 
superior analogue) brings a loss of activity compared to peptide 6 (30.0% 
versus 66.5%). 
Interestingly, we find a peptide with a significant increase in inhibitory 
activity. Peptide 28 was responsible for a 75.1% reduction of cell proliferation 
versus 66.5% of the peptide 6. Instead compound 29 has an inhibitory activity 
similar to peptide 6 (70.0% versus 66.5%) (Figure 12). 
 
 
Figure 12. Cell growth inhibition induced by PTPRJ peptides in HeLa cells. 
Relative cell growth (as a percentage of the growth observed in untreated cells) at 
different intervals of treatments (from 24 to 72 h) is reported. HeLa cells were treated 
once with PTPRJ peptides for 24 h (white columns) or treated every 24 h for 48 h 
(gray columns) and for 72 h (black columns). Results represent the mean ± SD of 
three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 compared to 
untreated cells by unpaired two-tailed Student’s t test. 
All new derivatives were tested in HeLa cancer cells for the assessment of 
their ability to inhibit cell proliferation; cells were treated with 160 μM 
concentration of each compound, and cell count was performed 24, 48, and   
72 h after treatment. 
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In particular, the observed effect was time dependent, like previous results, 
like generating a 75.1% and 70.0% reduction of HeLa cell number only at 72 
h, for peptide 28 and 29 respectively. These data suggest that either a lack of 
chirality in side chain (
4
Gly) or the introduction of steric hindrance increase 
the activation of the target. 






 protein phosphatases represent a very interesting 
target for the development of novel therapeutics. The ability of PTPRJ to 
counteract the signaling from several protein kinases either transmembrane or 
soluble involved in the aberrant mitogenic signals
43 , 44
makes this protein 
tyrosine phosphatase receptor a particularly intriguing target for the generation 
of a novel class of protein kinase inhibitors as anticancer drugs
45,46
 in addition 




Being interested in the development of small-molecule agonists of PTPRJ, 
we focused our attention on PTPRJ 19 (peptide 1) that in vitro, was shown to 
be responsible for both biochemical and biological PTPRJ-mediated effects. 
Several general approaches to development different libraries of peptides have 
been used and in particular from L-Ala scanning analysis it was identified 
peptide 6 as a potent agonist of PTPRJ. It showed ability in blocking the 
organization of HUVECs into tubular structures in Matrigel; this finding 
further supports the idea that peptide 6 could be a useful tool in the design and 
discovery of additional agents that can inhibit pathologic neovascularization. 
We were interested to modify the structure of the most active peptide with the 
aim to generate peptidomimetics to be used in cancer treatment. Therefore, 
recent results on analogues of peptide 6 demonstrate that compound 28 
inhibits cell proliferation of 75.1% instead 66.5% of peptide lead. In 
conclusion, our study represents a significant advancement in the structure-
activity relationship knowledge related to the presented class of PTPRJ agonist 
peptides; moreover, our findings strongly encourage the applications of further 
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chemical modifications to PTPRJ peptides with the aim to create a novel class 
of small molecules with improved biological activity with the final goal to 
translate them into clinical practice. 
 
6. Experimental section  
 
6.1 Synthesis of Ala scan PTPRJ derivatives 
 
The synthesis of PTPRJ analogues was performed according to the solid 





-Fmoc-protected amino acids, Wang-resin, Fmoc-Cys(Trt)-Wang 
resin, 2Cl-Trt resin, HOBt, HBTU, DIEA, DMAP, Piperidine, and 
trifluoroacetic acid were purchased from Iris Biotech (Germany). Peptide 
synthesis solvents, reagents, and CH3CN for HPLC were reagent grade and 
were acquired from commercial sources and used without further purification 





-Fmoc-Pen(Trt)-OH was coupled to Wang resin (0.2 


































Each coupling reaction was accomplished using a 3-fold excess of amino 
acid with HBTU and HOBt in the presence of DIEA (6 equiv). The N
α
-Fmoc 
protecting groups was removed by treating the protected peptide resin with a 
25% solution of Piperidine in DMF (1 × 5 min and 1 × 25 min). 
The peptide resin was washed three times with DMF, and the next coupling 
step was initiated in a stepwise manner. The peptide resin was washed with 
DCM (3×), DMF (3×), and DCM (3×), and the deprotection protocol was 
repeated after each coupling step. 
The N-terminal Fmoc group was removed as described above, and the 
peptide was released from the resin with TFA/iPr3SiH/H2O (90:5:5) for 3 h. 
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The resin was removed by filtration, and the crude peptide was recovered by 
precipitation with cold anhydrous ethyl ether to give a white powder and then 
lyophilized. 
 
6.2 General method of disulfide bridge formation 
 
6.2.1 Method of disulfide bridge formation with Potassium Ferrocyanide  
 
A solution of K3Fe(CN)6 was prepared as follows: 1 mmol (330 mg) of 
K3Fe(CN)6 was dissolved in a mixture of water (100 mL) and CH3CN (20 
mL), a saturated solution of ammonium acetate (20 mL) was added to it and 
the pH was adjusted to 8.5 with concentrated ammonium hydroxide.
14
 
A solution of the linear peptide (0.25 mmol) in 20% aqueous CH3CN was 
added to the above solution dropwise overnight with the help of a push±pull 
syringe. After the overnight reaction, glacial acetic acid was added to the 
reaction mixture to obtain pH 4.0, followed by 20 mL of Amberlite IRA-68 
anion-exchange resin (pre-equilibrated with 2.0 m HCl) and the suspension 
was stirred for 30 min until the solution turned colorless and the resin turned 
yellow. The resin was suction-filtered and the filtrate rotoevaporated using 1-
butanol to form a water/1-butanol azeotrope. The residual oil was lyophilized 
overnight to yield a pale yellow solid. 
 
6.2.2 Method of disulfide bridge formation with NH4HCO3/isopropyl 
alcohol 
 
Air oxidation was carried out by dissolving 50 mg of the lyophilized crude 
peptide in 90 mL of 1:1 0.1 M NH4HCO3/isopropyl alcohol (pH 8.25) with 
vigorous stirring at RT for 1 h. Prior to purification, the solution was acidified 
to pH 3 with TFA and analyzed by analytical HPLC. The solution was 
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6.3 Synthesis of lactam analogues (peptides 11-17, 43-45) 
 
 The corresponding linear peptides were synthetized as described above and 









-Fmoc- Orn(Alloc)-OH and N

-Fmoc- Dap(Alloc)-
OH were used as lactam precursors. After linear assembly, the N-Alloc and 
the Allyl groups were removed according to the following procedure: 200 mg 
of peptide resin was washed with dichloromethane (DCM) under Ar and a 
solution of PhSiH3 (24 equiv) in 2 mL of DCM was added. Subsequently a 
solution of Pd(PPh3)4 (0.25 equiv) in 6 mL of DCM was added and the 
reaction was allowed to proceed under Ar for 30min. The peptide resin was 
washed with DCM (3x), DMF (3x) and DCM (4x), and the deprotection 
protocol was repeated (3x). The macrocyclic lactam ring formation was 
mediated by addition of HBTU (6 equiv), HOBt (6 equiv) and DIPEA (12 
equiv) for 2 h.
24
 The process was repeated if necessary (Kaiser test used to 
monitor completion). The N-terminal Fmoc group was removed and the 
peptide was released from the resin as described above. 
 
6.4 Synthesis of disulfide cyclic peptides with 2-Cl Trt resin (peptides 6, 
28-29) 
 
 The title peptides were synthetized using a 2-chlorotrityl chloride resin. 
The first N

-Fmoc amino acid (0.6–1.2 equiv relative to the resin for 2-
chlorotrityl resin) and DIPEA (4 equiv relative to amino acid) were dissolved 
in dry dichloromethane (DCM) (approx. 10 mL per gram of resin) containing, 
if necessary, a small amount of dry DMF (enough to facilitate dissolution of 
the acid). This was added to the resin and stirred for 30-120 min. After 
stirring, the resin was washed with 3×DCM/MeOH/DIPEA (17:2:1), 3×DCM, 
2×DMF and 2×DCM. Other N

-Fmoc amino acids (4 equiv.) were 
sequentially coupled as previously described. The final cleavage with 
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6.5 Purification and characterization of PTPRJ derivatives 
 
All crude cyclic peptides were purified by RP-HPLC on a preparative C18-
bonded silica column (Phenomenex, Jupiter Proteo 90Å, 100 mm × 21.2 mm, 
10m) using a Shimadzu SPD 10A UV−Vis detector, with detection at 210 
nm and 254 nm. The column was perfused at a flow rate of 15 mL/min with 
solvent A (10%, v/v, water in 0.1% aqueous TFA), and a linear gradient from 
10% to 90% of solvent B (80%, v/v, acetonitrile in 0.1% aqueous TFA) over 
15 min was adopted for peptide elution. Analytical purity and retention time 
(tR) of each peptide were determined using HPLC conditions in the above 
solvent system (solvents A and B) programmed at a flow rate of 1 mL/min 
using a linear gradient from 10% to 90% B over 15 min, fitted with 
Phenomenex, Aeris XB-C18 column (150 mm × 4.60 mm, 3.6 μm). All 
analogues showed >97% purity when monitored at 215 nm. Homogeneous 
fractions, as established using analytical HPLC, were pooled and lyophilized. 
At the same time, LC-MS was performed in a LC-MS 2010 instrument 
(Shimadzu) fitted with a C-18 column (Phenomenex, Aeris XB-C18 column 
(150 mm × 4.60 mm, 3.6 μm) eluted with a 10-90% linear gradient of B into A 
for all compounds. 
To check and to have a confirmation of peptides molecular weights were 
used ESI mass spectrometry. ESI-MS analysis in positive ion mode, were 
made using a Finnigan LCQ Deca ion trap instrument, manufactured by 
Thermo Finnigan (San Jose, CA, USA), equipped with the Excalibur software 
for processing the data acquired. The sample was dissolved in a mixture of 
water and methanol (50/50) and injected directly into the electrospray source, 
using a syringe pump, which maintains constant flow at 5 μL/ min. The 
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6.6 Biological section  
 
6.6.1 Cell lines and transfections 
 
HeLa cervical cancer cells and MCF-7 and SKBr3 mammary cancer cells 
were purchased from the American Type Culture Collection (ATCC). Cells 
were cultured in RPMI medium 1640 supplemented with 10% heat-inactivated 
FBS (Invitrogen). 
Human umbilical vein endothelial cells (HUVEC) (Clonetics) were 
cultured in M199 medium (Sigma-Aldrich) supplemented with 10% FBS, 
heparin (100 μg/mL; Sigma-Aldrich), and 10 ng/mL endothelial cell growth 
factor. Human mammary epithelial cells (HMECs) were purchased from 
Invitrogen and cultured as recommended by the manufacturer. Transfections 
were made with Lipofectamine 2000 (Invitrogen) by following the 
manufacturer’s instructions; 4 × 105 cells were seeded in 6-well plates and 




Human recombinant VEGF165 was purchased from ORF Genetics. 
 
6.6.2 Cell survival assay 
 
To assess peptides-mediated inhibition of cell proliferation, HeLa and 
HUVECs were treated once with peptides for 24 h or treated every 24 h for 48 
h and every 24 h for 72 h at the concentration of 160 μM. At the end of 
treatments, cells were trypsinized and counted, and cell viability was 
determined by the trypan blue dye exclusion test. The results were expressed 
as percent variation in the number of viable cells treated with PTPRJ-peptides 
compared with control peptide treated cells. 
 
6.6.3 Antibodies and Western Blot analysis 
 
 ERK1/2, VEGFR2, and phospho-ERK1/2 antibodies were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). Phospho-VEGFR2 Y1054/59 
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was purchased by Invitrogen. Horseradish peroxidase (HRP)-conjugated anti-
goat and anti-rabbit immunoglobulins were also from Santa Cruz 
Biotechnology. Cells were scraped in ice-cold phosphatase-buffered saline 
(PBS) and lysed in NP-40 lysis buffer containing 50 mM Tris- HCl, pH 7.5, 
150 mM NaCl, 1% NP-40, one protease inhibitor mixture tablet per 10 mL of 
buffer (Completet, Roche Diagnostics), 1 mM Na3VO4, and 50 mM NaF. 
Lysates were passed several times through a 21-gauge needle and incubated 
for 30 min on ice. Cellular debris was pelleted by centrifugation at 10,000g for 
15 min at 4°C. Protein concentrations were determined using the Bradford 
protein assay dye (Bio-Rad Laboratories, Hercules, CA). Total cell lysates 
were separated by SDS−PAGE and transferred to PVDF membranes. 
Membranes were blocked in 5% nonfat dry milk (Bio-Rad) and then probed 
for about 2 h with primary antibodies. After incubation with specific (HRP)- 
conjugated secondary antibodies, protein bands were revealed by the ECL 
detection system (Santa Cruz Biotechnology).  
 
6.6.4 Cell cycle distribution analysis 
 
 The cells were plated at 0.5 × 106 cells/60 mmdish and sequential treated 
every 24 h for 72 h with 160 μM peptides (Invitrogen, Carlsbad, CA). Cells 
were harvested and fixed with cold 70% ethanol. Before analysis, cells were 
washed with PBS and stained with a solution containing 50 μg/mL propidium 
iodide, 250 μg/mL RNAase, and 0.04% Nonidet P40 (NP40) for 30 min at RT 
in the dark. 
The fluorescence of stained cells was analyzed by flow cytometry using a 
FACSCanto (Becton Dickinson). A flow cytometric sub-G1 peak was detected 
on DNA plots using ModFit LT cell cycle analysis software (Verity software 
House). 
 
6.6.5 Endothelial cell tube formation assay 
 
 Unpolymerized Matrigel (Becton Dickinson, Mountain View, CA) was 
placed (50 μL per well) in a 96-well microtiter plate (0.32 cm
2
 per well) and 
polymerized for 1 h at 37°C. HUVECs (2.5 × 104 well) were preincubated 
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with peptide 6 or scrambled peptide (100 μM) for 30 min before being seeded 
onto the solidified Matrigel. After incubating in media for 18 h, cells were 
fixed, and tube formation was analyzed by light microscopy (Leica, Germany). 
Two random fields were chosen in each well. 
 
6.7 NMR spectroscopy 
 
 Samples for NMR spectroscopy were prepared by dissolving the 
appropriate amount of peptide in 0.55 mL of 
1
H2O and 0.05 mL of 
2
H2O or 
0.60 mL of 
2
H2O containing phosphate-buffered saline (50 mM) at pH 4.0 and 
5°C. NMR spectra were recorded on a Varian INOVA 700 MHz spectrometer 
equipped with a z-gradient 5 mm triple-resonance probe head. Spectra were 
calibrated relative to TSP (0.00 ppm) as internal standard. One-dimensional 
(1D) NMR spectra were recorded in the Fourier mode with quadrature 
detection. 







 spectra were 
recorded in the phase-sensitive mode using the method from States et al.
53
 
Data block sizes were 2048 addresses in t2 and 512 equidistant t1 values. 
Before Fourier transformation, the time domain data matrices were multiplied 
by shifted sin2 functions in both dimensions. A mixing time of 70 ms was 
used for the TOCSY experiments. NOESY experiments were run with mixing 
time of 200-600 ms. The quantitative analysis of NOESY spectra was obtained 
using the interactive program package XEASY.
54
 The temperature coefficients 
of the amide proton chemical shifts were calculated from TOCSY experiments 
performed at different temperatures in the range 5-15°C by means of linear 
regression. STD-NMR (25) experiments were performed in 2H2O solution 
with on-resonance and off-resonance saturation at δ = −2 and −16 ppm, 
respectively. Typically, 512 scans were recorded for each STD spectrum 
(saturation time = 2 s). The relative STD effect (STD%) was calculated as the 
ratio between the intensity (expressed as S/N ratio) of the signals in the STD 
spectrum and that of the signals in the 
1
H NMR spectrum. 
6.7.1 Molecular Modeling 
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3D theoretical models of all peptides were built by means of L series 
residues using ver. 9.1 of the Maestro GUI.
55
 
Using the Monte Carlo (MC) search, implemented in MacroModel ver. 
9.843,
56
 for each compound, by randomly rotate all possible dihedral angles, 
one million of conformations were generated. EachMC structure was 
optimized using 10000 steps of the Polak Ribiere Conjugate Gradient 
algorithm and energy evaluated with the all atoms notation of AMBER* force 
field.
57
 Water solvent effects were mimicked according to the GB/SA implicit 
model.
58
 Conformers with similar internal energies, within 4.184 kJ/mol, were 
geometrically compared one each other by computing the root-mean-square 
deviation (RMSd) onto their not hydrogen atoms and were considered 
duplicate if the RMSd value was lower than 0.05 Å. Boltzman population 
analysis was performed, at 300° K, onto all MC sampled structures reporting 
internal energy within 50 kJ/mol from the global minimum. MC ensembles 
were submitted to cluster analysis using an RMSd cutoff distance equal to 0.5 
Å, computed onto the non-hydrogen atoms.
59
 Boltzman population data were 
considered for weighting the cluster analysis results. Aggregation processes 
were investigated using our in house docking software MolInE
60 , 61
 that 
automatically generated bimolecular complexes. Each MC conformer with a 
Boltzman population larger than 0.1% was considered as both host and guest. 
According to MolInE methodology, the autorecognition of our peptides was 
systematically explored by rigid body roto-translation of the guest, with 
respect to the host. Docking configurations were energy evaluated using the all 
atoms notation of the AMBER* force field. Water environment was mimicked 
by defining the dielectric constant equal to 80. TheMolInE grid resolution 
(GR) and van der Waals compression factor (x) were fixed to 6 and 0.6, 
respectively. The same force field, environment, and deduplication criterion, 
previously described for the MC search, were adopted for taking into account 
induced fit phenomena and to discard equivalent structures. The 
thermodynamics module of MolInE was used to evaluate the stability of the 
complexes calculating the corresponding binding energies. 
6.7.2 Statistical methods and data analysis 
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All experiments were performed in triplicate from at least three 
independent experiments, and data shown are the means ± standard deviation 
(SD). When only two groups were compared, statistical differences were 
assessed with unpaired two-tailed Student’s t test. Statistical analyses were 
performed using GraphPad Prism 5 software. For all analyses, differences 
were considered significant if P < 0.05. 
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Abstract G protein-coupled receptor kinase 2 (GRK2) is a relevant 
signaling node of the cellular transduction network, playing major roles in the 
physiology of various organs/tissues including the heart and blood vessels. 
Emerging evidence suggests that GRK2 is up regulated in pathological 
situations such as heart failure, hypertrophy, hypertension and is involved in 
the progression of cellular cycle. Therefore its inhibition offers a potential 
therapeutic solution to these diseases like hypertension, heart failure and 
cancer. We performed a SAR study and a NMR conformational analysis of 
peptides derived from HJ loop of GRK2 and able to selectively inhibit GRK2. 
Moreover, we explored the GRK2 inhibitory activity of a library of cyclic 
peptides derived from the HJ loop of G protein-coupled receptor kinases 2 
(GRK2). The design of these cyclic compounds was based on the 
conformation of the HJ loop within the X-ray structure of GRK2. One of these 
compounds, potently and selectively inhibited the GRK2 activity, being more 
active than its linear precursor. 
In a cellular system, this peptide confirms the beneficial signaling properties 
of a potent GRK2 inhibitor. Preferred conformations of the most potent 
analogue were investigated by NMR spectroscopy. 
 
Keywords GRK2 inhibitors, cardiovascular system, peptide Ala scan, 
cyclic peptides, peptidomimetics, NMR conformational analysis. 
 
Abbreviations Abbreviations used for amino acids and designation of 
peptides follow the rules of the IUPACIUB Commission of Biochemical 
Nomenclature in J Biol Chem 1972, 247, 977-983. Amino acid symbols 
denote L-configuration unless indicated otherwise.  
The following additional abbreviations are used: 
DPC, dodecylphosphocholine; SAR, structure-activity relationship; DCM, 
dichloromethane; DIPEA, N,N-diisopropylethyl-amine; DMF,                       
N,N-dimethylformamide; iPr3SiH, or TIS triisopropylsilane; TFA, 
trifluoroacetic acid; Fmoc, 9-fluorenyl-methoxycarbonyl; HOBt, Nhydroxy- 
benzotriazole; HBTU, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluoro -phosphate; Trt, trityl; Pbf, 2,2,4,6,7–pentamethyldihydro 
benzofuran-5-sulfonyl; RP HPLC, reversed-phase high performance liquid 
chromatography; ESI, electrospray ionization; LCQ, liquid chromatography 
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quadrupole mass spectrometry; ATP, adenosine triphosphate; EDTA, 
Ethylenediaminetetraacetic acid; EGTA, ethylene glycol tetraacetic acid; 




The G protein-coupled receptor kinase family (GRKs) constitutes a group 
of seven protein kinases that specifically recognize and phosphorylate agonist-
activated G protein-coupled receptors (GPCRs).
1
 GRKs-mediated receptor 
phosphorylation triggers the binding of arrestin proteins
2
 that uncouple 
receptors from G proteins leading to rapid desensitization.
3,4
 As a result of β-
arrestin binding, phosphorylated receptors are also targeted for clathrin-
mediated endocytosis, a process that classically serves to re-sensitize and 
recycle receptors back to the plasma membrane.
5
 
In addition, both arrestins and GRKs participate in signal propagation, 
cooperating in the assembly of macromolecular complexes in the receptor 
environment and interacting with different components of signal transduction. 
The seven mammalian GRKs family can be divided into three subfamilies 
based on sequence and functional similarity: visual GRK subfamily (GRK1 
and GRK7), the -adrenergic receptor kinase (GRK2/GRK3), and the GRK4 
subfamily (GRK4, GRK5 and GRK6).
6
 All GRKs share a common structural 
architecture that includes a N-terminal regulator of G protein signaling 
homology domain (RH), a central kinase catalytic domain, and a C-terminal 
region containing a pleckstrin homology domain (PH).
7
 The best-characterized 
member of this family is the ubiquitously expressed GRK2, also known as -
adrenergic receptor kinase 1 (-ARK1).
8
 
In the past 20 years, GRK2 emerges as a key node in signal transduction 
pathway playing a major role in the agonist-specific desensitization of several 
metabolism-related GPCRs, including the β-adrenergic, melanocortin, 
endothelin, and glucose-dependent insulinotropic polypeptide receptors.
9,10
 
GRK2 can also phosphorylate other membrane receptors,
11
 as well as non-
receptor substrates, acting as effector in the regulation of diverse cellular 
phenomena from cardiovascular and immune cell functionality
12
 to migration 
Chapter 3           SAR studies and conformational analysis of a series of novel 
peptides G protein–coupled receptor kinase 2 (GRK2) inhibitors 
 
- 82 - 
 
and cell cycle progression.
13,14
 Furthermore, GRK2 may also contribute to 
modulate cellular responses in a phosphorylation-independent manner thank to 
its ability to interact with a plethora of proteins involved in signaling and 
trafficking.
15
 All these functional interactions predict that alterations in GRK2 
levels and/or activity may have important effects in human diseases,
16
 as  








In this regard, many attentions are focused on the role for GRK2 as both an 
extrinsic and intrinsic cell-cycle regulator (Figure 1). GRK2 expression has 
been reported to have distinct impacts on cell proliferation and mitogenic 
signaling depending on both the cell type and the mitogenic stimuli analysed. 
GRK2 inhibits TGF-mediated cell growth arrest and apoptosis in human 
hepatocarcinoma cells.
21
 On the other hand, GRK2 attenuates serum- or 
PDGF-induced proliferation of thyroid cancer cell lines
22
 and smooth muscle 
cells,
23
 respectively, whereas its expression increases MAPK signaling in 
response to EGF in HEK-293 cells
24
 and GRK2 kinase activity is required for 
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Figure 1. GRK2 interactome involved in the modulation of cell cycle progression. 
GRK2 is linked to diverse regulatory networks acting at specific stages of the cell 
cycle. In response to both extrinsic and intrinsic cues, GRK2 protein plays a critical 
role in driving cell progression through G1/S and G2/M transitions in a kinase-
dependent and independent manner. GRK2 is part of an intrinsic pathway that ensures 
timely progression of cell cycle at G2/M by means of its functional interaction with 
CDK2/cyclinA and Pin1.
13
 Such pathway is disrupted upon DNA damage, when 
GRK2 appears to turn into a pro-arresting factor that promotes increased cell survival 
and to dampen p53-dependent responses by mechanisms that remain to be established 
(dotted lines/question mark). On the other hand, GRK2 contributes to the 
Hedgehog/Smoothened-triggered control of cell proliferation by promoting Smo 
activity and relieving the Patched-dependent inhibition of cyclin B. CDK, cyclin-
dependent kinase; GRK, G protein-coupled receptor kinase. 
 
In addition, GRK2 has been recently shown to establish a complex network 
of novel functional interactions during cell cycle progression that are critical 
for timely G2/M transition. It has found that GRK2 levels are controlled 
intrinsically by the cell-cycle machinery under normal conditions and in 
response to DNA damage, and differentially contribute either to cell cycle 
progression or cell arrest in a receptor-independent manner. GRK2 protein 
levels are transiently down-regulated during the G2/M transition by a 
mechanism involving CDK2-mediated phosphorylation of GRK2 at S670, 
what drives binding to the prolyl-isomerase Pin1 and subsequent degradation. 
Preventing GRK2 phosphorylation at this residue impedes normal GRK2 
down regulation and markedly delays cell cycle progression.
13
 Interestingly, 
the ‘default’ GRK2 protein decay in G2 is prevented in the presence of DNA 
damaging agents that trigger cell cycle arrest such as doxorubicin. Moreover, 
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in cells with higher steady-state levels of the kinase, increased stabilized 
GRK2 levels in such conditions inversely correlate with the p53 response and 
the induction of apoptosis, strongly suggesting that GRK2 contributes to 
orchestrate G2/M checkpoint mechanisms, helping to restrict the apoptotic fate 
of arrested cells. As it has been reported that GRK2 is up-regulated in the 
context of oncogenic signaling,
26,27
 it is tempting to suggest that inhibition of 
GRK2 expression might sensitize cells to drug-induced DNA damage. 
The increasingly complex GRK2 ‘interactome’ puts forward this kinase is a 
relevant signaling node of the cellular transduction network. The intricacy of 
this network of functional interactions and the participation of this protein in 
basic cellular processes as migration and cell cycle progression or 
cardiovascular cell functionality predicts that alterations in GRK2 levels 
and/or activity, as those reported in several relevant cardiovascular, 
inflammatory or cancer pathologies, may have important effects in human 
disease. This makes of this kinase a potentially interesting diagnostic marker 
and therapeutic target. 
In the last year, identification of GRK2 modulators/inhibitors is a very 
active fields of research. 
Different small molecules inhibitors of GRK2 activity are currently 
available, even if they are characterized by low sensitivity and specificity.
28,29
 
Strategies to selectively inhibit the GRK2 activity have been attempted using 
shorter peptides
30,31
 or RNA aptamers.
32,33 In particular, Anis et al.
31 
demonstrated that myristyl or lauryl glycine derivatives of short peptides 
derived from HJ loop of GRK2, such as KRX-683107 and KRX-683124 (Table 
1), are potent inhibitor of the kinase and possess hypoglycemic effect in 
animal models of Type 2 diabetes. The peptide fragments of these compounds 
closely resemble the catalytic fragment 383-390 KLLRGHSP of GRK2. This 
fragment is composed by the last part of the α-helix F (residues 383-386) and 
the first part of a strand (residues 387-390) within the HJ loop. Several 
crystallographic and mutational studies, have pointed to HJ-αG residues as 
being involved in substrate binding and in binding to upstream activators. 
Based on these findings, this fragment and, more concretely, compounds 1 and 
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2 appeared to be valuable starting points for the development of novel specific 
and more potent GRK2 inhibitors. 
 
Table 1. Different peptide fragments considered in this study. 
Peptide Sequence 
383-390HJ loop GRK2 K L L R G H S P 
KRX-683107 Myristyl G L L R r H S 
KRX-683124 Lauryl    G L L R r H S I 
1                G L L R r H S 
2                G L L R r H S I 
 
2. Aim of work 
 
Previous results obtained by Anis et al.,
31
 point to the selected peptides, 1 
and 2, as interesting lead compounds for the development of a novel class of 
effective chemotherapeutic agents. 
 
2.1 Alanine scanning approach and changes in 
5
D-Arg (peptides 3-18) 
 
First of all, we decided to apply to peptide leads L-Alanine scanning 
approach, a classical chemical approach to check the relevance of each residue 
for the biological activity of the peptide (peptides 3-15, Table 2). To verify the 
effect of chirality, the D-Arg at position 5 was also replaced by D-Ala 
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1 GLLRrHS 1.70 836.97 837.66 47.6±5.5 54.2±6.1 
3  GALRrHS 1.68 793.89 795.52 <5 <5 
4  GLARrHS 1.68 793.89 795.52 <5 <5 
5  GLLArHS 1.74 751.86 752.61 42.2±9.7 38.2±4.5 
6  GLLRAHS 1.74 751.86 752.52 <5 <5 
7  GLLRrAS 1.76 770.91 771.60 13.5±6.4 25.6±5.7 
8  GLLRrHA 1.68 821.91 821.60 22.3±5.4 28.8±9.2 
2 GLLRrHSI 1.72 950.13 950.70 49.6±6.3 60.2±5.0 
9  GALRrHSI 1.72 908.05 908.55 45.7±12.3 54.5±9.1 
10  GLARrHSI 1.72 908.05 908.68 46.6±12.3 47.7±7.2 
11  GLLArHSI 1.78 865.02 865.50 45.7±6.2 42.1±7.8 
12  GLLRAHSI 1.78 865.62 865.53 <5 <5 
13  GLLRrASI 1.80 884.07 884.65 <5 <5 
14  GLLRrHAI 1.78 934.13 934.82 <5 <5 
15  GLLRrHSA 1.72 908.05 908.48 <5 <5 
16  GLLRaHS 1.74 751.86 752.48 55.5±4.7 54.2±3.2 
17  GLLRaHSI 1.78 865.62 865.50 63.2±9.7 55.5±6.0 
18 GLLRRHS 1.74 836.86 837.79 20.5±5.7 28.4±3.5 
 
a
Data represent mean values (±SD) of three independent determinations. 
b
GRK2 
purified protein activity (50 ng) was tested on rod outer segments (ROS) in presence 
or absence of 1M inhibitors.  
c
GRK2 purified protein activity (50 ng) was tested on 
Myelin Basic Protein (MBP) in presence or absence of  inhibitors. 
d
k’=[(peptide 
retention time-solvent retention time)/ solvent retention time]. 
 
The effectiveness of these peptides to inhibit GRK2 kinase activity was 
assessed by in vitro assay using GRK2 purified protein and the G protein-
coupled receptor rod outer segments (ROS) as a substrate (Table 2) in 
presence of [γ-
32
P]- adenosine triphosphate (ATP). 
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With a quick scan we found that peptide 1 causes a 47.6±5.5% inhibition of 
GRK2 activity on ROS. We found that indeed, substitution with a neutral D-
amino acid such as Alanine maintained the inhibitory properties of the 
resulting peptide 16 (55.5±4.7%). 
A similar approach was assessed for peptide 2. First of all, 2 causes a 
49.6±6.3% decrease in GRK2 activity. Similarly to peptide 1, the reinstallation 
of D-chirality in residue 5 restores the inhibitory properties of resulting 
peptide 17 on GRK2 (63.2±9.7%) which showed the highest GRK2 inhibition 
potency of the series.
34
 
To test the specificity of the peptides for GRK2 rather than for the 
substrate, we also repeated the same experiment using as substrate Myelin 
Basic Protein (MBP). MBP is an ideal model substrate, since this basic protein 
can be phosphorylated at multiple sites (Ser-11, Ser-55, Ser-8, Ser-132, Ser- 
55, Ser-161, and Ser-46) from several kinase types.
35
 Therefore, in this study 
we have used the myelin basic protein as conventional substrate for in vitro 
kinase assay. With this substrate, we observed a similar inhibition pattern as 
for ROS (Table 2). 
Furthermore, to better understand the importance of chirality in residue 5 
we synthetized an analogue of peptide 1 with 
5
L-Arg (peptide 18). This 
compound causes a 20.5±5.7% inhibition of GRK2 activity instead of 
47.6±5.5% for peptide lead suggested an important role of chirality. 
Furthermore, conformational analysis of these peptides clearly indicated that 
their structures are very similar to the X-ray structure of the fragment 
encompassing the HJ loop of the GRK2, indicating that the isolated peptide 
could keep the 3D structure of the protein segment. Based on these results, we 
designed, synthetized, and evaluated the GRK2 inhibitor activities of a small 
libraries of cyclic peptides. 
 
2.2 Design of cyclic peptides (peptides 19-24) 
 
The attention was focused on peptides lead, 1 and 2, that selectively inhibit 
GRK2 in vitro. Their NMR solution conformations are very similar to the 
crystal structure of the fragment encompassing the HJ loop of the GRK2 (pdb 
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entry 3CIK, Figure 2). Hence, it can be hypothesized that the active 
conformation of the peptides resemble the HJ loop crystal structure. 
Accordingly, the stabilization of the peptide 3D structure by, for example, 
the cyclization of these linear compounds can be considered as a valid 
approach to the identification of more potent, (stable and selective) 
compounds. As evident from Figure 2, N- and C-terminal sides of the loop 
fragment are relatively close (~5 Å), hence we first carried out a head-to-tail 
cyclization of peptides 1 and 2 leading to peptides 19 and 20, respectively 
(Table 3). 
The design of a second group of cyclic peptides is based on the 
consideration that, in the GRK2 crystal structure, the amino group of Lys383 
side chain points towards the Ser389 side chain (Figure 2). 
 
 
Figure 2. Stereoview of the crystal structure of the fragment 383-390 of GRK2 (1, 
pdb entry 3CIK). Heavy atoms are shown with different colours (carbon, green; 
nitrogen, blue; oxygen, red). Hydrogen atoms are not shown for clarity. Cyclization 
strategies are shown as dotted lines. 
 
Hence, the stabilization of the peptide structure was also sought through a 
side chain-to-side chain cyclization approach. The cyclic peptides 21 and 22 
(Table 3) were synthetized from linear peptides which contain the original 
residue Lys383 of GRK2 instead of 
1
Gly and an Asp residue in place of 
7
Ser 
residue. These two residues are linked by a side chain amide bond. For 
comparative purpose the analogues 23 and 24, containing the original Gly387 
residue at the position 5, were also synthetized and tested for their activity to 
inhibit GRK2.
36 
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The effectiveness of these peptides to inhibit GRK2 kinase activity was 
assessed by in vitro assay using GRK2 (GRK5) purified protein and the G 
protein–coupled receptor rod outer segments (ROS) as a substrate (Table 3) in 
presence of [γ-
32
P]- adenosine triphosphate (ATP). 
 





















 GLLRrHS 1.70 836.97 837.66 47.6±5.5 <5 
  2
 d
 GLLRrHSI 1.72 950.13 950.70 49.6±6.3 <5 
19 [GLLRrHS] 1.70 819.96 820.53 47.8±6.0 <5 
20 [GLLRrHSI] 1.85 933.12 933.80 37.2±10.7 <5 
21 [KLLRrHD] 1.72 919.09 920.13 36.3±4.4 <5 
22 [KLLRrHD]I 1.75 1032.25 1033.11 55.3±4.6 <5 
23 [KLLRGHD] 1.76 819.47 820.51 47.2±4.5 <5 
24 [KLLRGHD]I 1.78 933.12 933.68 33.7±7.8 <5 
a
Data represent mean values (±SD) of three independent determinations. 
b
GRK2 and 
GRK5 purified proteins activity (50 ng) were tested on rod outer segments (ROS) in 
presence or absence of 1 mM inhibitors. 
c
k’=[(peptide retention time-solvent retention 
time)/ solvent retention time]. 
d
Already reported in reference 11. 
 
2.2.1 NMR Analysis of cyclic peptide 22 
 
NMR analysis of peptide 22 was performed in water and DPC micelle 
solutions. No standard -helix or -sheet structure from HαCSI (chemical 
shift index) values,
37
 and no unambiguous medium- or long-range backbone 
NOE connectivities were found in the NOESY spectrum of the peptides. In 
contrast, several NMR parameters indicate that peptides are better structured 
in DPC solution and that they share very similar conformations. 
Superposition of the 10 lowest energy conformers of 22 is shown in Figure 
3. 
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Figure 3. Stereoview of the 10 lowest energy conformers of 22. Structures were 
superimposed using the backbone heavy atoms. Heavy atoms are shown with 
different colors (carbon, green; nitrogen, blue; oxygen, red). Hydrogen atoms are not 
shown for clarity.  
 
The first -turn structure is stabilized by a hydrogen bond between the 
carbonyl oxygen of 
1
Lys and the amide hydrogen of 
4
Arg. Residues 6 and 7 
are in extended conformations, residue 8 is more flexible. The side chain are 









Leu side chains establish a hydrophobic surface pointing in 
the opposite direction. 
At the same time, we decided to consider peptide 1 and 2 as a valuable 
starting point for the development of a novel class of potential 
chemotherapeutic agents carrying out N- and C- terminal deletions with the 
aim to identify more potent and selective peptide derivatives. 
 
2.3 Design of a small truncation library and di-Ala approach (peptides 
25-30) 
 
Truncation library can be used to identify the shortest amino acid sequence 
needed for the peptide activity. The truncation process is carried out via a 
systemic reduction of residues from each flank of the original peptide. With 
the knowledge of the positions of key residues elucidated through Alanine 
Scanning library, the construction of the truncation library could also be 
centered around these key amino acid residues. 
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Ala scan results (Table 2) indicated that, while C-terminal residues are 






are important only for the shorter peptide 1. 
4
Arg side chain is of little 
importance for the activity of both the peptides, in contrast the substitution 
with a neutral D-amino acid such as Alanine does not change the inhibitory 
properties of peptides 1 and 2, thus suggesting an important role for the 
chirality of amino acid 5 rather than for the side chain. 
For this reason, we synthetized peptides 25-26 obtained from N- and C- 
terminal deletions of peptide 1. Considering that only C-terminal residues are 
important for the activity of peptides 2 we synthetized compound 28 
containing only C-terminal residues. 
To investigate the importance of C-terminal residues, in term of charges 
and steric hindrance, we used a di-Alanine scanning approach (peptides 29-
30). It is an important tool for peptide sequence optimization. It identifies 
amino acids of interest at a given position and substitutes the amino acid(s) 
near this position with the smallest chiral amino acid, Alanine, to explore side-
chain contributions of near amino acid to the interaction.  
 




















 GLLRrHS 1.70 836.97 837.66 47.6±5.5 <5 
  2
 d
 GLLRrHSI 1.72 950.13 950.70 49.6±6.3 <5 
25 LRrH 1.54 579.69 580.12 38.2±6.0 <5 
26 LLRr 1.65 555.71 556.23 50.5±9.7 <5 
27 rHS 1.43 397.42 398.41 10.3±4.4 <5 
28 rHSI 1.67 510.58 511.41 35.4±4.6 <5 
29 GLLArAS 1.74 685.21 686.13 35.7±6.4 <5 
30 GLLRrAA 1.76 754.92 755.35 22.6±4.7 <5 
a
Data represent mean values (±SD) of three independent determinations. 
b
GRK2 and 
GRK5 purified proteins activity (50 ng) were tested on rod outer segments (ROS) in 
presence or absence of 1 mM inhibitors. 
c
k’=[(peptide retention time-solvent retention 
time)/ solvent retention time]. 
d
Already reported in reference 11. 
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The effectiveness of these peptides to inhibit GRK2 kinase activity was 
assessed by in vitro assay using GRK2 (GRK5) purified protein and the G 
protein-coupled receptor rod outer segments (ROS) as a substrate (Table 4) in 
presence of [γ-
32
P]- adenosine triphosphate (ATP). 
From previous preliminary results we observed an improvement on 
inhibitory activity of tetrapeptide, compound 26 than peptide lead, 1. 
 
2.4 Design of cyclic peptides starting from tetrapeptide (peptides 26-40) 
 
Compound 22, a lactam cyclic peptide, remains the most active peptide and 
above it leads to an increase in 2AR density, in HEK-293 cells, consistent 
with an effective inhibition of GRK2. 
Being interested to identify the most active and at the same time the most 
stable peptide, we decided to apply two different approaches: 
i) Stabilization of tetrapeptide, compound 26, through a head-to tail 
cyclization approach; 
ii) Enhancement of ring size synthetizing lactam bridge analogues, 
starting from peptide 26. 
Head-to-tail cyclic peptides, important targets in peptide synthesis over 
decades, have attracted considerable interest in recent years. The reason for 
this interest stems from the observation that constraining of the highly flexible 
linear peptides by cyclization induces or stabilizes the bioactive conformation 
of peptides. Furthermore, cyclic peptides are more resistant to proteolysis than 
their linear counterparts due to the lack of exopeptidase cleavage sites.
38
  
i) The synthesis of peptide 31 allows us to have a more rigid structure of 
side chain-to-side chain cyclization. Furthermore, head-to tail cyclization 
allows us to have a peptide with minor possible conformers. 
ii) We decided to stabilize the peptide with the introduction of lactam 
bridge. Therefore, we designed a library of lactam cyclic derivatives from 
tetrapeptide, peptide 26. 
In particular, in N-terminal and C-terminal domain at positions 1 and 6 
amino acids bearing an amino ((2,3)-diaminopropionic acid (Dap), ornithine 
(Orn) or lysine (Lys)) and carboxylic (Asp or Glu) functions on the side chain, 
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respectively, were added; these two side chains were subsequently linked to 
form the lactam bridge (peptides 32, 34-40 Table 5). 
 
Focused on inhibitory activity of compound 21 and 22 we found that 
peptide 22, containing a 
8
Ile inhibits GRK2 activity of 55.3% instead of 36.3% 
for peptide 21. It suggests an important role of 
8
Ile. For this reason we decided 
to synthetize peptide 33, [KLLRrD]I. 
 
















1.72 950.13 950.70 
22 [KLLRrHD]I 1.75 1032.25 1033.11 
26 LLRr 1.65 555.71 556.23 
31 [LLRr] 1.71 538.75 539.60 
32 [KLLRrD] 1.77 780.91 781.64 
33 [KLLRrD]I 1.86 894.13 894.72 
34 [KLLRrE] 1.75 794.98 795.23 
35 [OrnLLRrD] 1.79 767.02 768.13 




37 [DapLLRrD] 1.81 738.54 739.86 
38 [OrnLLRrE] 1.78 780.93 781.25 
39 [DabLLRrE] 1.72 766.76 767.23 
40 [DapLLRrE] 1.74 752.43 753.79 
a
k’=[(peptide retention time solvent retention time)/ solvent retention time]. 
b
Already reported in reference 32. 
 
Recently,  peptides 31-33 were tested to verify if they inhibit GRK2 kinase 
activity. Peptide 31 and 33 appear to inhibit GRK2 activity in a similar manner 
to peptide 2. Peptide 32 causes a 25.3±1.2% inhibition of GRK2 activity 
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2.5 Design of peptidomimetic 
 
Use of peptidomimetics is one of the most recent methods of drug design 
and development in medicinal chemistry. Peptidomimetics typically are small 
protein-like molecules designed to mimic natural peptides or proteins.
39
 
They typically arise either from modification of an existing peptide, or by 
designing similar systems that mimic peptides, such as peptoids and β-
peptides. These mimetics, whose structures were mainly derived from natural 
peptides, should have the ability to bind to their natural targets in the same 
way of the natural sequences and hence should produce the same biological 
effects. 
It is possible to design these molecules in such a way that they show the 
same biological effects as their peptide role models, but with enhanced 
properties like a higher proteolytic stability, higher bioavailability and also 
often with improve selectivity or potency.
40
 
Moreover it is known that the isosteric replacement of a peptide bond 
represents an important and general tool in design of peptidomimetics together 
with the incorporation of conformationally restricted units, such as rings, into 




In peptidomimetics, alterations to the side chain groups or the peptide 
backbone are used to improve the peptide’s stability and/or biological activity. 
Since most linear peptides can easily be degraded by enzymatic proteolysis, 
altering the peptide backbone can help reduce their rate of degradation. The 
highly charged side chain groups on peptidomimetics provide greater binding 
affinity and selectivity of the receptors towards these peptidomimetics which 
will reduce unwanted side effects and improve the therapeutic effects. As a 
result of their properties, peptidomimetics are of high interest as bioactive 
agents and as drugs having pharmacological activities. 
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 N-Substituted glycine oligomers (NSG), otherwise referred to as α-
peptoids, belonged to peptidomimetics class and are a readily accessible class 
of synthetic, non-natural peptide mimic of modular design into which a 
plethora of structural elements can be readily incorporated.
42
 The first NSG 
reports came from Zuckermann et al. in 1992.
43
 They are mimics of -
peptides in which the side chains are attached to the backbone N

-amide 
nitrogen instead of C

-atom. The schematic comparison of peptides and 
peptoids, provided in Figure 4, shows the similarities in the spacing of the side 
chains and the carbonyl groups, and the differences in the chirality of the two 
monomers. 
 
Figure 4.  Schematic comparison between peptides and peptoids showing the 
similarity of spacing of the side chains, and the lack of stereochemistry of the peptoid 
monomers. 
 
NSG’s were originally anticipated as a source of lead structure 
development in the pharmaceutical industry through the preparation of 
combinatorial libraries of short oligomers.
44
 
Hence, focused on tetrapeptide peptide 26 we decided to synthetize the 
peptoid analogue (compound 41, Figure 5).  
Recently, the peptoid was tested to verify if it inhibits GRK2 kinase 
activity. It appears not inhibit notably GRK2 activity compared to peptide 2. 
Specifically, peptoid 41 causes a 20.5±3.2% inhibition of GRK2 activity 
instead of 49.6±6.3 for peptide 2 (data not shown). 
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3.1 General procedure for synthesis 
 
The synthesis of peptides (1-18, 25-30) was performed according to the 
solid phase approach using standard Fmoc methodology in a manual reaction 
vessel.
45
 The first amino acid, was linked onto the Rink resin (100–200 mesh, 
1% DVB, 0.75 mmol/g) previously deprotected by a 25% piperidine solution 
in N,N-dimethylformamide (DMF) for 30 min. 
The following protected amino acids were then added stepwise.  Each 
coupling reaction was accomplished using a 3-fold excess of amino acid with 
HBTU and HOBt in the presence of DIPEA. The N
α
-Fmoc protecting groups 
was removed by treating the protected peptide resin with a 25% solution of 
piperidine in DMF. 
In addition, after each step of deprotection and after each coupling step, 
Kaiser test was performed to confirm the complete removal of the Fmoc 
protecting group, respectively, and to verify that complete coupling has 
occurred on all the free amines on the resin. 
The N-terminal Fmoc group was removed as described above, and the 
peptide was released from the resin with trifluoroacetic acid (TFA)/ 
triisopropylsilane(iPr3SiH)/H2O (90:5:5) for 3 h. The resin was removed by 
filtration, and the crude peptide was recovered by precipitation with cold 
anhydrous ethyl ether to give a white powder and then lyophilized. 
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3.2 Synthesis of lactam analogues (peptides 21-24, 32-40) 
 
The corresponding linear peptides were synthetized as described above. 
The preparation of cyclic peptides, 21-24, 32-40 through a side-chain-to-side-
chain cyclization, was carried out after removal of the Allyl/Alloc protection 
according to strategy reported by Grieco et al. (Scheme 1).
46
 
Structure, inhibition activities, and analytical data of peptides are in Table 3 
and Table 5. 
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Scheme 1. Synthesis and folding of peptide 21. 
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3.3 Synthesis of head-to-tail cyclic peptides (peptides 19-20, 31)  
 
The title peptides were synthetized using a 2-chlorotrityl chloride resin. The 
first N

-Fmoc amino acid and DIPEA were dissolved in dry dichloromethane 
containing, if necessary, a small amount of dry DMF. This was added to the 
resin and stirred for 30-120 min. Other N

-Fmoc amino acids were 
sequentially coupled as previously described. The final cleavage with 
AcOH/MeOH/DCM (1:1:8) resulted in protected peptides.
47
 
General procedure for cyclization: A solution of the linear protected 
peptide was added at room temperature to a reaction flask containing a 
solution of HOBt, HBTU and DIPEA in DMF. The mixture was stirred for 24 
h at room temperature and monitored by TLC.  
 
3.4 Synthesis of peptoid (compound 41) 
 
In the solid-phase synthesis of peptoid-peptide hybrids, two different 
approaches can be used to introduce an N-alkylglycine (peptoid residue) on 
the growing peptide chain: (i) the N-substituted glycine derivative, suitably 
protected at the tertiary nitrogen atom, can be separately prepared and directly 
utilized as building block in the solid phase procedure (monomer method),
48,49
 
or (ii) the peptoid residue is built during the peptide chain elongation by a 
combination of two submonomers, an R-haloacetic acid and a primary amine 
(submonomer method).
43
 In both cases to achieve a N-Arg peptoid residue, a 
suitable NG-protected-3-guanidinopropanamine has to be synthetized in 
advance.
50
 To speed up the synthesis of N-Arg containing peptoid-peptide 
hybrids, we optimized a procedure based on the submonomer method, which 
makes possible a direct assembling of the functionalized peptoid residue 
starting from commercially available reagents. 
For the synthesis of compound 41, the peptoid residue is built during the 
peptide chain elongation by a combination of two submonomers, an R-
haloacetic acid and a primary amine (submonomer method). 
Bromoacetic acid was coupled to the NH2-peptide resin in the presence of 
N,N’-diisopropylcarbodiimide (DIC).  
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Initially the Rink resin was deprotected by a 25% piperidine solution in 
N,N-dimethylformamide (DMF) for 30 min. 
Bromoacetic acid was then coupled to the NH2-peptide resin in the presence 
of N,N’-diisopropylcarbodiimide (DIC), and the halogen was displaced with a 
large excess of 1,3-diaminopropane. The resulting N-(3-aminopropyl)glycine 
(a precursor of NArg) was then selectively protected at the side chain amino 




Further elongation of the peptide chain was carried out according to the 
standard protocol,
52
 with the addition of Bromo acetic acid and the appropriate 
amine. The last N-alkylglycine residue was Boc protected with Boc anhydride 
which is orthogonal to the Dde group. This one was removed from the peptoid 
side chain by treatment with 2% hydrazine in DMF, and the resulting δ-amino 
function was on-resin guanidinylated with N,N’-di-Boc-1H-pyrazole-1-
carboxamidine. Simultaneous deprotection and cleavage of peptides from the 
resin gave the peptoid-peptide hybrids in high yield (70-80%). 
The synthesis is illustrated in Scheme 2: 
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Scheme 2. Synthesis of compound 41. 
 
3.5 Synthesis of labeled peptides (Fl-2, Fl-22) 
 
The starting peptides 2 and 22 were synthetized as described above. Then 
Fmoc-deprotected, resin-bound peptides, were reacted with 5(6)-
carboxyfluorescein, N,N’-diisopropyl carbodiimide and 1-
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hydroxybenzotriazol at RT. Completeness of N-terminal acylation was 
confirmed using the Kaiser test. 
 
3.6  Purification and Characterization 
 
All crude peptides were purified by RP-HPLC on a preparative C18-bonded 
silica column using a Shimadzu SPD 10A UV/VIS detector, with detection at 
215 and 254 nm. 
All peptides were characterized with analytical RP-HPLC and peptides 
molecular weights were determined by ESI mass spectrometry and  LC-MS in 
a LC-MS 2010 instrument (Shimadzu) fitted with a C-18 column. All 
analogues showed >97% purity when monitored at 215 nm. Homogeneous 
fractions, as established using analytical HPLC, were pooled and lyophilized. 
 
4. Results and discussion  
 
4.1 Inhibitory activity of peptides 3-18 
 
The first part of the work focused on a SAR study and a NMR 
conformational analysis of peptides 1 and 2 which are able to selectively 
inhibit GRK2.
32, 34
 Ala scan results (Table 2) indicated that, while C-terminal 




Leu are important only for the shorter peptide 1. Since the 
conformational preferences in solution of the two peptides are very similar, a 
possible explanation of the different SAR observed is that hydrophobic 









Ile is lacking in peptide 1). 
4
Arg side chain is of little importance 
for the activity of both the peptides, in contrast, replacement of 
5
Arg with Ala 
completely abolishes the inhibitory activity. 
Since in the original sequence, the amino acid in position 5 is a D-
enantiomer, 
5
D-Arg was substituted by D-Ala, in order to discern the real role 
of molecular orientation from the effects of the amino acid side chain on the 
inhibitory activity. We found that substitution with a neutral D-amino acid 
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such as Alanine does not change the inhibitory properties of peptides 1 and 2, 
thus suggesting an important role for the chirality of amino acid 5 rather than 
for the side chain. 






can be replaced by a 
neutral amino acid when the chirality is retained. Indeed, peptide 17 (D-Ala 
derivative of peptide 2) showed the highest GRK2 inhibition potency of the 
series. These peptides retain specificity for the GRK2 since they were equally 
effective on GRK2 using two different substrates. Also, they keep selectivity 
since they are ineffective in inhibition GRK5 activity on the same substrates. 
Peptide 1, 2, 17 ability to increment basal and βAR stimulated cAMP 
production in HEK-293 cells is consistent with their effective inhibition of 
GRK2 (Figure 6). However, the low entity of those increments is likely due to 
the difficulty of the peptides to cross the cell membrane. The slight higher 




Figure 6. cAMP production in HEK-293 cells treated with 1, 2 and 17 as 
determines by enzyme immunoassay. ISO: Isoproterenol. Each data point represents 
the mean±SEM of 3 independent experiments; * = p<0.0001 vs Ctr; # = p<0.01 vs 
Iso. 89x57mm (600 x 600 DPI). 
 
Differently, slight higher activity of peptide 2 compared to 17 would 




is dispensable for GRK2 interaction (Table 2), it 
can improve the permeating properties of the peptide. 
NMR analysis of peptides 1, 2, 16, and 17 was performed in water and 
DPC micelle solutions. The last is a membrane mimetic medium and was 
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chosen since GRK2 phosphorylation of GPCRs occurs close to the plasma 
membrane. Peptides conformational preferences are similar since they have 
similar diagnostic NMR parameters. Peptides structures in DPC micelles are 










D-Arg), followed by a short extended region encompassing residues 6 and 7 
(Figure 7). The NMR structures of the peptides in DPC are very similar to the 
X-ray structure of the fragment encompassing the HJ loop of the GRK2 (pdb 
entry 3CIK)
53
 which, indeed, was the starting point for the design of the 
peptides 1 and 2. Figure 7 shows the superposition of the NMR structure of 17 
with that of the fragment 383-390 of the GRK2. Equivalent backbone atoms of 
17 and GRK2 superimpose to an RMSD of 0.17 Å. It can be also observed the 
good overlapping of the unchanged side chains which occupies similar space 
regions. Therefore, the isolated peptide keeps the 3D structure of the protein 




Figure 7. Stereoview of the 10 lowest energy conformers of 17. Structures were 
superimposed using the backbone heavy atoms. Heavy atoms are shown with 
different colours (carbon, green; nitrogen, blue; oxygen, red). Hydrogen atoms are not 
shown for clarity. 150x91mm (300 x 300 DPI). 
 
This result could explain the selectivity observed for these peptides  
towards GRK2 compared  to GRK5.  In  fact, GRK5  HJ  loop corresponding 
sequence  is  MIEGQS  (CLUSTAL Omega alignment; 
www.ebi.ac.uk/Tools/msa/clustalo) which  compared  to  the GRK2  sequence 
LLRGHS has,  inter alia, a very different charge content (-1 vs +1/+2). 
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4.2 Inhibitory activity of cyclic peptides (peptides 19-24) 
 
Once we demonstrated that peptides 1 and 2, selectively inhibit GRK2 in 
vitro we decided to focused on these compounds to identify more potent and 
selective inhibitors of GRK2.
34
 
Peptides 1 and 2 are the not acylated derivatives of compounds KRX-683107 
and KRX-683124, respectively (Table 1), in turn derived from the fragment 





Conformational similarity of these peptides to the protein fragment within 
the crystal structure of GRK2,
53
 prompted us to design novel analogues of 
peptides 1 and 2 based on head-to-tail and side chain-to-side chain cyclization, 
according to the HJ loop structure (Figure 2). Hence, the lactam were 
introduced as a conformational constraint to stabilize the putative 3D active 
conformation. The utility of backbone or side chain cyclization has been well 
established in peptides, and it has been demonstrated to increase biological 
activity and selectivity since they are usually more stable in metabolism than 
the parent linear molecules.
54
 In this context, lactam bridges are preferable 
over disulfide ones due to their chemical stability.
55
 
All cyclic peptides retain the ability to inhibit GRK2 (Table 3) 
demonstrating the validity of the design strategy. Potency fluctuations were 
observed upon the insertion of 
8
Ile in cyclic analogues. 
Probably, conformational restraints imposed by the cyclization also affect 
exocyclic Ile residue spatial orientation which, in turn, influences the 
inhibitory activity. Cyclic peptide 22 is the most active in the GRK2 inhibition 
overcoming of about 10% its precursor (peptide 2). Interestingly, peptides also 
retain selectivity towards GRK2 since they don’t affect GRK5 kinase activity 
on rhodopsin levels. To bring our observation to a biological setup, we tested 
the effects of GRK2 inhibitors in cells on the beta adrenergic receptors 
density. Indeed, it is known that GRK2 inhibition can change the affinity state 
of the beta adrenergic receptor by preventing desensitization,
56
 furthermore 
recent evidences suggest that also the total number of adrenergic receptors is 
under the control of GRK2 activity,
57
 thus indicating that the kinase also 
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control down regulation, the major and most effective mechanism of 
regulation of AR signaling. 
Interestingly, peptide 22 results to be more effective than the lead 
compound 2 to increase 2AR density (Figure 8A). Similar results are 
obtained in cAMP production studies. In fact, 22 increases both basal and 
2AR stimulated cAMP production in cells (Figure 8B). 
 
 
Figure 8. (A) 2-adrenergic receptors density in HEK-293 cells treated with 
peptides 2 and 22 (1 mM for 1 h). Each data point represents the mean " SEM of 3 
independent experiments; * p-value % 0.05. (B) cAMP production in HEK-293 cells 
treated with 2 and 22 as determined by cAMP immunoassay. ISO: Isoproterenol, 0.1 
mM. Each data point represents the mean " SEM of 3 independent experiments; **p < 
0.0001 vs Ctr; #p < 0.01 vs ISO. 
 
These results are particularly important since they indicated these peptides 
are able to penetrate the cell membrane by itself without the need of acylation 
(as for KRX-683124), conjugation with cell penetrating peptides, etc. To 
confirm this important suggestion, we measured the internalization of both 
fluorescently labeled peptides (Fl-2 and Fl-22, respectively). 
As observed in Figure 9A and B, both peptides are able to cross cell 
membrane with the linear compound Fl-2 incorporated to cells more 
effectively than compound Fl-22. 
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Figure 9. (A) Incorporation of fluorescently labeled peptides into 2HEK-293 
cells. The cells were incubated with 1 mM Fl-2 (upper panel) and Fl-22 (lower panel) 
for 1 h. Images were obtained by confocal microscopy. (B) Quantification of 3 
experiments measuring fluorescence incorporation of the cells incubated with either 
Fl-2 or Fl-22, at either 10 mM or 1 Mm p < 0.01 vs Control (Ctr). 
 
Probably, peptide 22 highest potency in the inhibition of GRK2 kinase 
activity is the predominant factor determining the observed significant 
increase of 2 adrenergic receptor density and cAMP production. 
Promising compound 22 was also investigated for its conformational 
preferences. NMR analysis of peptide 22 was performed in water and DPC 
micelle solutions. It is well-known that water is the best medium to be used for 
the structural study of peptides. Unfortunately it favors the prevailing of 
disordered and flexible conformations so that the building of a 3D model is 
often precluded. 
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Mixtures made up of water and organic solvents are the most used media to 
produce environmental constraints. In particular, alcohols and fluoro alcohols 
are known to stabilize peptide secondary structures.
58
 Micelle solutions are 
membrane mimetic environments and are largely used for conformational 
studies of peptide hormones and antimicrobial peptides.
59
 In this case, a 
micellar solution of DPC was chosen since GRK2 phosphorylation of GPCRs 
occurs close to the plasma membrane. Peptide 22 structure in DPC micelles is 











followed by a short extended region encompassing residues 6 and 7 (Figure 
10). Compared to the linear parent peptides, compound 22 shows a lower 
conformational flexibility (in fact, the backbone heavy atoms RMSD 
decreases from 0.31 to 0.20 Å, compared to the linear analogue).
34
 
More interestingly, the NMR structures of peptide 22 are very similar to the 
crystal structure of the fragment encompassing the HJ loop of the GRK2 (pdb 
entry 3CIK).
53
 Figure 9 shows the superposition of the NMR structure of 22 
with that of the fragment 383-390 of the GRK2. Equivalent backbone atoms of 
22 and GRK2 superimpose to an RMSD of 0.17 Å. It can be also observed the 
good overlapping of the unchanged side chains which occupies similar space 
regions. Also, 
8
Ile side chain is well overlapped with that of Pro390, 
supporting the positive contribution of this residue on peptide activity. 
Therefore, the isolated peptide keeps the 3D structure of the protein segment 





Figure 10. Stereoview of 22 lowest energy conformer (green) and fragment 383-
390 of GRK2 (1, yellow, pdb entry 3CIK). The structures are superimposed using the 
backbone heavy atoms.  
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4.3 Inhibitory activity of peptides 25-28 
 
The effectiveness of these peptides to inhibit GRK2 kinase activity was 
assessed by in vitro assay using GRK2 purified protein and the G protein–
coupled receptor rod outer segments (ROS) as a substrate (Figure 10) in 
presence of [γ-
32
P]- adenosine triphosphate (ATP). 
Peptide 26 was compared with peptide lead 1, with the same peptide 
synthetized with CPP (Cell Penetrating Peptide), two lactam cyclic peptides 
(21 and 23), another tetrapeptide (compound 25) and a tripeptide 27. 








DArg, inhibits GRK2 activity 
more than lead compound 1 (50.5% versus 47.6%) (Figure 11). 
Next, to verify whether these peptides selectively inhibit GRK2, we 
repeated the activity assay substituting GRK5 to GRK2 purified protein. 
GRK2 selective inhibition is suggested by the evidence that all peptides don’t 
affect GRK5 kinase activity on rhodopsin phosphorylation levels. 
Starting from these interesting data, we designed a peptidomimetic derived 




Figure 11.  Inhibitory GRK2 kinase activity for peptides 21, 23, 25, 26 and 27 in 
vitro assay using GRK2 purified protein and the G protein–coupled receptor rod outer 
segments (ROS) as a substrate in presence of [γ-
32
P]- adenosine triphosphate (ATP). 
 
Focused on peptide 2, we compared the lead compound, two lactam cyclic 








Ile, obtained from N- and C-terminal deletions of peptide 2. 
This compound inhibits GRK2 of 35.4% instead of 47.6% for peptide lead 
(Figure 12). 
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In conclusion, starting from peptides lead, 1 and 2, to design more stable 
and active peptides some improvement are required. Both deletions and/or 
cyclization lead to a more active peptides than peptide lead. 
The advantage in case of deletion is in a fast and economic synthesis and 
then we have the possibility to design peptidomimetics and small molecules 
starting from three-four amino acids. 
 
 
Figure 12. Inhibitory GRK2 kinase activity for peptides 20, 22, 24 and 28 in vitro 
assay using GRK2 purified protein and the G protein–coupled receptor rod outer 
segments (ROS) as a substrate in presence of [γ-
32
P]- adenosine triphosphate (ATP). 
 
4.4 Effects of  GRK2 inhibition on AR density: a comparison between 
peptides 22 and 26 
 
To confirm the effectiveness of GRK2 inhibition in a cellular setup, we 
tested the effects of GRK2 inhibitors in cells on beta adrenergic receptors 
density in HEK-293 cells stably overexpressing the 2 adrenergic receptor 
(2AR).
11
 In HEK-293 cells, incubation with compound 2, the cyclic peptide 
22 (1 mM) and the tetrapeptide 26 results in the increase in 2AR density, 
consistent with an effective inhibition of GRK2 (Figure 13). Interestingly, 
peptide 22 results to be more effective than the others. Peptide 26 and 2 
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Figure 13. (A) 2-adrenergic receptors density in HEK-293 cells treated with 
peptides 2, 22, 26 (1 mM for 1 h). Each data point represents the mean " SEM of 3 
independent experiments; * p-value %0.05. 
 





GRK2 is involved in the regulation of many pivotal cell functions, and is 
therefore a key player in human health and disease, such as in several relevant 
cardiovascular, inflammatory or cancer pathologies. Hence, modulation of its 
activity could be exploited with therapeutic purposes.  
The present study describes the design, synthesis, and biological evaluation 
of a series of linear and cyclic peptides which are able to selectively inhibit 
GRK2. 
Starting from peptides 1 and 2, this study: i) found the (in)dispensable 
residues which can be replaced in an attempt to improve peptide properties 
(GRK2 interaction, membrane permeation); ii) determined their 
conformational preferences which can help the design of novel peptides and 
peptidomimetics with enhanced conformational stability; iii) found that a 
restricted conformation increases inhibitory activity and lead to a more stable 
compound.  
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In particular, cyclic peptide 22 demonstrated to increase the inhibitory 
potency of the linear parent 2. Our results showed that 22 also increased, more 
effectively than 2, the density of  adrenergic receptors and the AR 
stimulated cAMP production in cardiac cells, further confirming the GRK2 
control on regulation of AR signaling. These findings confirm that 
conformational-based chemical modification of the linear fragment 
encompassing the HJ loop of the GRK2 is an effective approach to identify 
structures able to modulate GRK2 activity through inhibition.  
 
6. Experimental section 
 
6.1 Synthesis of linear derivatives (peptides 1-18, 25-30) 
 
The synthesis of GRK2 analogues was performed according to the solid 





-Fmoc-protected amino acids, Rink amide-resin, N-hydroxy-
benzotriazole (HOBt), 2-(1H-benzotriazole-1-yl)-1,1,3,3- tetramethyluronium 
hexafluoro-phosphate (HBTU), N,N-diisopropylethyl-amine (DIPEA), 
Piperidine and Trifluoroacetic acid were purchased from Iris Biotech 
(Germany). Peptide synthesis solvents, reagents, as well as CH3CN for high 
performance liquid chromatography (HPLC) were reagent grade and were 
acquired from commercial sources and used without further purification unless 
otherwise noted. The first amino acid, N
α
Fmoc-Xaa-OH (Xaa = Ile, Ser(tBu), 
Ala, DArg(Pbf), His(Trt)) was linked on to the Rink resin (100–200 mesh, 1% 
DVB, 0.75 mmol/g) previously deprotected by a 25% piperidine solution in 
N,N-dimethylformamide (DMF) for 30 min. 




















Fmoc-Ser(tBu)-OH. Each coupling reaction was accomplished using a 3-fold 
excess of amino acid with HBTU and HOBt in the presence of DIPEA (6 eq.). 
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-Fmoc protecting groups was removed by treating the protected peptide 
resin with a 25% solution of piperidine in DMF (1x 5 min and 1x 25 min). 
The peptide resin was washed three times with DMF, and the next coupling 
step was initiated in a stepwise manner. The peptide resin was washed with 
dichloromethane (DCM) (3×), DMF (3×), and DCM (3×), and the 
deprotection protocol was repeated after each coupling step. 
In addition, after each step of deprotection and after each coupling step, 
Kaiser test was performed to confirm the complete removal of the Fmoc 
protecting group, respectively, and to verify that complete coupling has 
occurred on all the free amines on the resin. 
The N-terminal Fmoc group was removed as described above, and the 
peptide was released from the resin with trifluoroacetic acid (TFA)/ 
triisopropylsilane (iPr3SiH)/H2O (90:5:5) for 3 h. The resin was removed by 
filtration, and the crude peptide was recovered by precipitation with cold 
anhydrous ethyl ether to give a white powder and then lyophilized.  
 
6.2 Synthesis of head-to-tail cyclic peptides (peptides 19-20, 31) 
 
The title peptides were synthetized using a 2-chlorotrityl chloride resin. The 
first N
α
Fmoc-Xaa-OH (Xaa = Ile, Ser(tBu), DArg(Pbf), (0.6-1.2 equiv relative 
to the resin for 2-chlorotrityl resin) and DIPEA (4 equiv relative to amino 
acid) were dissolved in dry dichloromethane (DCM) (approx. 10 mL per gram 
of resin) containing, if necessary, a small amount of dry DMF (enough to 
facilitate dissolution of the acid). This was added to the resin and stirred for 
30-120 min. After stirring, the resin was washed with 3×DCM/MeOH/DIPEA 
(17:2:1), 3×DCM, 2×DMF and 2×DCM. Other N

-Fmoc amino acids (4 
equiv) were sequentially coupled as previously described. The final cleavage 




6.2.1 General procedure for cyclization 
 
A solution of the linear protected peptide (0.03 mmol) in DMF (6.5 mL) 
was added at room temperature to a reaction flask containing a solution of N-
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hydroxybenzotriazole (HOBt) (3 equiv, 12 mg, 0.09 mmol), HBTU (3 equiv, 
34 mg, 0.09 mmol) and DIPEA (5 equiv, 0.26 mL, 1.5 mmol) in DMF (1 mL). 
The mixture was stirred for 24 h at room temperature and monitored by TLC. 
The mixture was concentrated under reduced pressure, and the residue was 
dissolved in ethyl acetate (AcOEt). The organic phase was washed twice with 
5% aqueous sodium bicarbonate (NaHCO3), dried over sodium sulfate 
(Na2SO4), and filtered. The solvent was removed by reduced pressure to give 
the final crude protected peptide. 
 
6.3 Synthesis of lactam analogues (peptides 21-24, 32-40) 
 
The corresponding linear peptides were synthetized as described above and 














-Fmoc-Dab(Alloc)-OH were used as lactam precursors. After linear 
assembly, the N-Alloc and the Allyl groups were removed according to the 
following procedure: 200 mg of peptide resin was washed with 
dichloromethane (DCM) under Ar and a solution of PhSiH3 (24 equiv) in 2 
mL of DCM was added. Subsequently a solution of Pd(PPh3)4 (0.25 equiv) in 
6 mL of DCM was added and the reaction was allowed to proceed under Ar 
for 30 min. The peptide resin was washed with DCM (3x), DMF (3x) and 
DCM (4x), and the deprotection protocol was repeated (3x). The macrocyclic 
lactam ring formation was mediated by addition of HBTU (6 equiv), HOBt (6 
equiv) and DIPEA (12 equiv) for 2 h.
36,46
 The process was repeated if 
necessary (Kaiser test used to monitor completion). The N-terminal Fmoc 
group was removed and the peptide was released from the resin as described 
above. 
 
6.3.1 Side-chain deprotection  
 
The protected cyclopeptide (0.02 mmol) was treated with 10 mL of a 
solution of TFA/triisopropylsilane (TIS)/H2O 95: 2.5: 2.5 at room temperature. 
After 24 h, the reaction mixture was evaporated in vacuo, and the residue was 
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washed with diethyl ether (Et2O) and concentrated in vacuo, yielding the side 
chain-deprotected cyclopeptide as a trifluoroacetate salt (quant.). 
 
6.4 Synthesis of peptoid 41 
 
For on-resin assembling of N
κ
-protected N-aminoalkylglycine residue, a 1 
M solution of bromoacetic acid in DMF (10 equiv) and DIC (10 equiv) was 
added to the N

-deprotected peptide resin. After the mixture was stirred for 45 
min, the resin was washed with DMF (6 times) and a solution of the selected 
diamine (1,3-diaminopropane and butyl-amine, 30 eq)  in DMF was added. 
After 2 h of reaction, the resin was collected by filtration and washed with 
DMF. The primary amino group on the resulting peptoid residue was protected 
by reaction with a 0.5 M solution of Dde-OH (10 equiv, 90 min) in DMF, and 
the assembling of the peptide chain was resumed. The last N-alkylglycine 
residue was Boc protected with Boc anhydride. Different from the Fmoc 
group, the Boc is stable to the basic conditions required to remove the Dde 
group. 
For on-resin guanidinylation of peptoid-peptide hybrids, the peptoid-
peptide hybrid, still attached to the solid support, was repetitively treated with 
2% hydrazine in DMF (3 times for 3 min) to remove the Dde group from the 
peptoid side chain. 
After the usual washing cycles, the resulting N-aminoalkylglycine residue 
was guanidinylated by reaction with 2 equiv of N,N’-bis-Boc-1-
guanylpyrazole (0.03 M in DMF); the reaction was performed at 35 °C and 
was complete in less than 2 h.
48
 
Cleavage of peptides from the resin and removal of the acid labile 
protecting groups were simultaneously achieved by treatment of the final 
peptide-peptoid hybrid resin with a TFA-H2O-triisopropylsilane (TIS) mixture 
(95:2.5:2.5 by volume) for 90-120 min at room temperature. Peptides were 
precipitated by addition of cold diethyl ether and dried overnight under 
vacuum. Crude peptides were obtained in 70-80% yield. 
 
 
Chapter 3           SAR studies and conformational analysis of a series of novel 
peptides G protein–coupled receptor kinase 2 (GRK2) inhibitors 
 
- 116 - 
 
6.5 Synthesis of labeled peptides (Fl-2, Fl-22) 
 
The starting peptides 2 and 22 were synthetized as described above. Then 
Fmoc-deprotected, resin-bound peptides, were reacted with 3 equiv of        
5(6)-carboxyfluorescein, N,N’-diisopropyl carbodiimide, and 1-
hydroxybenzotriazol, each in DMF for 16 h in 10-mL syringes on a shaker at 
RT. Reactions were stopped by washing the resins three times each with DMF, 
methanol, dichloromethane, and diethyl ether. Completeness of N-terminal 
acylation was confirmed using the Kaiser test. 
 
6.6 Purification and characterization 
 
All crude peptides were purified by RP-HPLC on a preparative C18-bonded 
silica column (Phenomenex, Jupiter Proteo 90Å, 100 mm × 21.2 mm, 10m) 
using a Shimadzu SPD 10A UV/VIS detector, with detection at 210 and 254 
nm. The column was perfused at a flow rate of 15 mL/min with solvent A 
(10%, v/v, water in 0.1% aqueous TFA), and a linear gradient from 10 to 90% 
of solvent B (80%, v/v, acetonitrile in 0.1% aqueous TFA) over 15 min was 
adopted for peptide elution. Analytical purity and retention time (tR, Tables 2-
5) of each peptide were determined using HPLC conditions in the above 
solvent system (solvents A and B) programmed at a flow rate of 1 mL/min 
using a linear gradient from 10 to 90% B over 15 min, fitted with 
Phenomenex, Aeris XB-C18 column (150 mm × 4.60 mm, 3.6 μm).  
All analogues showed >97% purity when monitored at 215 nm. 
Homogeneous fractions, as established using analytical HPLC, were pooled 
and lyophilized. 
At the same time, LC-MS was performed in a LC-MS 2010 instrument 
(Shimadzu) fitted with a C-18 column (Phenomenex, Aeris XB-C18 column 
(150 mm × 4.60 mm, 3.6 μm) eluted with a 10-90% linear gradient of B into A 
for all compounds. 
To check and to have a confirmation of peptides molecular were used ESI 
mass spectrometry. ESI-MS analysis in positive ion mode, were made using a 
Finnigan LCQ ion trap instrument, manufactured by Thermo Finnigan (San 
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Jose, CA, USA), equipped with the Excalibur software for processing the data 
acquired. The sample was dissolved in a mixture of water and methanol 
(50/50) and injected directly into the electrospray source, using a syringe 
pump, which maintains constant flow at 5 mL/min. The temperature of the 
capillary was set at 220 °C. 
 
6.7 NMR Spectroscopy  
 
The samples for NMR spectroscopy were prepared by dissolving the 
appropriate amount of peptide to obtain a concentration 1-2 mM in 0.55 mL of 
1
H2O (pH 5.5), 0.05 ml of 
2
H2O for water samples, 200 mM DPC-d38 for 
micelle samples.
34
 NMR spectra were recorded on a Varian INOVA 700 MHz 
spectrometer equipped with a z-gradient 5 mm triple-resonance probe head. 
All the spectra were recorded at a temperature of 25°C. The spectra were 
calibrated relative to 3 (trimethylsilanyl)propionic acid (TSP, 0.00 ppm) as 
internal standard. One-dimensional (1D) NMR spectra were recorded in the 
Fourier mode with quadrature detection. Water suppression was achieved by 
using the double-pulsed field gradient spin-echo (DPFGSE) scheme.
60
 2D 







 spectra were recorded in the phase-sensitive mode using the 
method of States.
64
 Data block sizes were 2048 addresses in t2 and 512 
equidistant t1 values. Before Fourier transformation, the time domain data 
matrices were multiplied by shifted sin
2
 functions in both dimensions. A 
mixing time of 70 ms was used for the TOCSY experiments. NOESY 
experiments were run with mixing times in the range of 100-200 ms. The 
qualitative and quantitative analyses of DQF-COSY, TOCSY, and NOESY 





Hα coupling constants were obtained from 1D 
1
H NMR and 2D DQF-COSY 
spectra. Many 
3
JHN-Hα coupling constants were difficult to measure in DPC 
solution probably because of a combination of small coupling constants and 
broad lines. The temperature coefficients of the amide proton chemical shifts 
were calculated from 1D 
1
H NMR and 2D TOCSY experiments performed at 
different temperatures by means of linear regression. 
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6.7.1 Structural Determinations 
 
The NOE-based distance restraints were obtained from NOESY spectra 
collected with a mixing time of 200 ms. The NOE cross peaks were integrated 
with the XEASY program and were converted into upper distance bounds 
using the CALIBA program incorporated into the program package 
VDYANA. Cross peaks which overlapped more than 50% were treated as 
weak restraints in the DYANA calculation. For each examined peptide, an 
ensemble of 100 structures was generated with the simulated annealing of the 
program DYANA. An error-tolerant target function (tf-type=3) was used to 
account for the peptide intrinsic flexibility of the peptide. The annealing 
procedure produced 100 conformations from which 20 structures were chosen, 
whose interprotonic distances best fitted NOE derived distances, and then 
refined through successive steps of restrained and unrestrained EM 
calculations using the Discover algorithm (Accelrys, San Diego, CA) and the 
consistent valence force field (CVFF)
66
 as previously described. Graphical 
representation were carried out with the the UCSF Chimera package.
67
 RMS 





6.8 In Vitro Methods 
 
6.8.1 GRK Activity in Rhodopsin Phosphorylation Assays 
 
To evaluate the effect of all synthetized peptides on GRK2 activity we 
assessed GRK2 or GRK5 purified proteins by light-dependent phosphorylation 





 Briefly, 50 ng of active GRK2 or GRK5 were 
incubated with ROS membranes in presence or absence of inhibitor peptides in 
reaction buffer (25 mL) containing 10 Mm MgCl2, 20 mM Tris-Cl, 2 mM 
ethylenediaminetetraacetic acid (EDTA), 5 mM ethylene glycol tetraacetic 
acid (EGTA), and 0.1 mM ATP and 10 Ci of [γ-
32
P]-ATP. After incubation 
with white light for 15 minutes at room temperature, the reaction was 
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quenched with ice-cold lysis buffer and centrifuged for 15 minutes at 13000g. 
The pelleted material was resuspended in 35 μL protein gel loading dye, 
electrophorosed and resolved on SDSPAGE 4‐12% gradient (Invitrogen), 
stained with Coomassie blue, destained, vacuum dried, and exposed for 
autoradiography. Phosphorylated rhodopsin was visualized by 
autoradiography of dried gels and quantified using a PhosphorImager 
(Molecular Dynamics). Alternatively, the pellet was resuspended in 100 μL of 
ice-cold lysis buffer and the level of [γ-
32
P]-ATP incorporation into ROS was 
determined by liquid scintillation counter. 
 
6.8.2 MBP Kinase assay  
 
50 ng of active GRK2 or GRK5 were assayed on 100 ng of purified MBP 
in presence or absence of peptides 1-30. Phosphorylation reactions were 
initiated by adding 20 mM ATP, 1 mM CaCl2, 20 mM MgCl2, 4 mM Tris, pH 
7.5, and 10 Ci of [γ-
32
P]-ATP (specific activity 3000 Ci/mmol) and prolonged 
for 30 min at 37°C. Laemmli buffer was added to stop the reaction. 




6.8.3 cAMP synthesis 
 
 HEK 293 overexpressing β2AR were plated in 96-well plates (10,000 
cells/well) and serum starved overnight. Cells were incubated in a fresh 
medium in the presence 2 and 22 peptides 1 μM for one hour and then 
stimulated with non selective β adrenergic receptor agonist Isoproterenol 10 
μM for 15 min. The cAMP quantification was evaluated by enzyme 
immunoassay, using an EIA commercial kit (RPN 2255 GE Healthcare Bio-
Sciences AB, Uppsala, Sweden). The cAMP content present in HEK- 293 cell 
was expressed in fmoles per well. All values are presented as mean ±SEM of 
three independent experiments. One-way ANOVA was performed to compare 
the different groups. A significance level of P<0.05 was assumed for all 
statistical evaluations. 
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Statistics were computed with GraphPad Prism Software (GraphPad 
Software Inc., version 4, San Diego, CA, USA). 
 
6.9 -Adrenoreceptor radioligand binding  
 
Cultured Hembriogenic Kidney cells overexpressing 2 adrenergic receptor 
(2HEK-293) were treated with peptides 2 and 22 1 mM for one hour. 
Membrane fraction was prepared by homogenization of whole cell in ice-cold 
buffer (25 mM Tris-HCl (pH 7.5), 5 mM EDTA, 5 mM EGTA, 1 mM 




Total AR density was determined by incubating 60 mg of sarcolemmal 
membranes with a saturating concentration of [
125
I]cyanopindolol and 20 
mmol/L alprenolol to define nonspecific binding. 
Assays were conducted at 37 °C for 60 min and then filtered over GF/C 
glass fiber filters (Whatman) that were washed and counted in a gamma 
counter.
56
 All values are presented as mean ± SEM of three independent 
experiments. One-way ANOVA was performed to compare the different 
groups. A significance level of P <0.05 was assumed for all statistical 
evaluations. Statistics were computed with GraphPad Prism Software 
(GraphPad Software Inc., version 4, San Diego, CA, USA). 
 
6.10 Internalization studies 
 
2HEK-293 overexpressing human 2AR cells were plated in 4-well ibidi 
plate (10,000 cells/well) and serum starved overnight. 
The cells were then incubated with fluorescently labeled peptides (Fl-2 and 
Fl-22) 1 mM for 60 min at 37°C. After washing twice with PBS cell images 
were taken by using an Eclipse E1000 Fluorescence Microscope (Nikon) and 
acquired by using Sigma Scan Pro software (Jandel). Images were optimized 
for contrast in Adobe Photoshop, but no further manipulations were made. 
Alternatively HEK-293 cells were plated in 24-well plates (20,000 
cells/well) and serum starved overnight The cells were then incubated with 
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fluorescently labeled peptides (Fl-2 and Fl-22) at the concentration of 10 and 1 
mM for 60 min at 37°C. The fluorescence incorporation was quantified on a 
Tecan Genios plate reader with a 485 nm excitation filter and a 510 nm 
emission filter using a gain setting of 1.0. The background signal from cells 
untracted was subtracted. All values are presented as mean ± SEM of three 
independent experiments. One-way ANOVA was performed to compare the 
different groups. A significance level of P <0.05 was assumed for all statistical 
evaluations. Statistics were computed with GraphPad Prism Software 
(GraphPad Software Inc., version 4, San Diego, CA, USA). 
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Abstract Analogues of potent CaMKinase II inhibitor, CaM-KNtide, were 
prepared to explore new structural requirements for the inhibitory activity. The 
full potency of CaMKII inhibition by CaM-KIIN is contained within a 
minimal region of 17 amino acids (peptide 5, KRPPKLGQIGRAKRVVI). 
Fusion with the tat sequence generated the cell-penetrating inhibitor version 
tat-5. This tat-5 fusion peptide maintained selectivity for CaMKII over CaMKI 
and CaMKIV, and appeared to slightly further enhance potency (IC50 ~30 
nM). Within a breast cancer cell line and in primary human fibroblasts, tat-5 
inhibited the Erk signaling pathway and proliferation without any measurable 
cytotoxicity. 
 
Keywords Protein kinase Ca
2+
/calmodulin-dependent protein kinase, 




/calmodulin-dependent protein kinase; CaM-
KNtide, CaMKinase II inhibitor; CaM, calmodulin; ATP, adenosine 
triphosphate; PKA, phosphokinase A; PKC, phosphokinase C; RP-HPLC, 
reversed-phase high performance liquid chromatography; Ant, 16-amino-acid 
sequence from the Drosophila Antennapedia; Tat, 35-amino-acid sequence 
from the HIV Tat protein; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; DAPI, 4,6-diamidino-2- phenylindole; CD, 
circular dichroism; HFA, hydrofluoroalkane; RMSD, root-meansquare 
deviation; Fmoc, 9-fluorenyl-methoxycarbonyl; DCM, dichloromethane; 
DIEA, N,N-diisopropylethylamine; DMF, N,N-dimethylformamide; TIS, 
triisopropylsilane; CH3CN, acetonitrile; HOBt, N-hydroxy-benzotriazole; 
HBTU, 2-(1H-benzotriazole- 1-yl)-1,1,3,3-tetramethyluronium hexafluoro 
phosphate; ESI-MS, electrospray ionization mass spectrometry; DMEM, 
Dulbecco’s modified eagle medium; EDTA, ethylenediaminetetraacetic acid; 
EGTA, ethylene glycol tetraacetic acid; SDS, sodium dodecyl sulfate; CaCl2, 
calcium chloride; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid; BSA, bovine serum albumin; NaOH, sodium hydroxide; PBS, phosphate 
buffered saline. * Abbreviations used for amino acids follow the rules of the 
IUPAC-IUB Commission of Biochemical Nomenclature in J Biol Chem 1972, 
247, 977-983. Amino acid symbols denote L-configuration. 
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1. Introduction 
Calmodulin (CaM) kinases are a large family of Ser/Thr protein kinases 
that include kinases with broad substrate spectrum and with high substrate 
selectivity.
1
 As the name implies, CaM kinases (CamKs) are generally 
activated by binding of Ca
2+
/CaM to their regulatory region. Among CaMKs, 
CaMKII transduces elevated Ca
2+
 signals in cells to a number of target 








/Calmodulin-dependent protein kinase II (CaMKII) constitutes a family 
of closely related multifunctional serine/threonine kinases that transduces 
elevated Ca
2+
 signals in cells to a number of target proteins ranging from ion 
channels to transcriptional activators.
1,2
 The enzyme consists of 8-12 subunits 
in a combination of various isoforms  and ). The  and  isoforms are 
predominantly expressed in the nervous system, whereas the  and  isoforms 
are ubiquitous.
3
 Local changes in Ca
2+
 concentration induce activation of 
CaMKII by binding to calmodulin (CaM).
4
 Binding of the Ca
2+
/CaM complex 
to an autoregulatory region of the enzyme disrupts auto-inhibitory interactions, 
allowing substrates and ATP to gain access to the catalytic domain.  
Simultaneous Ca
2+
/CaM binding to adjacent subunits within the same 
holoenzyme, stimulates autophosphorylation at Thr286. This CaMKII 
autophosphorylation markedly enhances the avidity of CaMKII for Ca
2+
/CaM 
(from nanomolar to picomolar affinity), but confers significant “autonomous” 





independent activity). In the absence of Ca
2+
/CaM, CaMKII undergoes 
autophosphorylation at Thr305/306 and Ser314, which blocks Ca
2+
/CaM 
binding, thereby inactivating the enzyme.
5
 Likewise other signaling enzymes, 
CaMKII has important regulatory consequences in many physiological 
processes. Among processes regulated by CaMKII are neuronal growth and 




 as well as the 







proper function of the immune system,
11
 and the central control of energy 
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 CaMKII also regulates diverse cellular functions that are important 









 and gene transcription.
16
 On the other hand, 
different studies demonstrated that the misregulation or dysfunction of this 









 and cardiovascular diseases 





 Current knowledge about CaMKII control on 
physiological or pathological functions is largely based on experiments with 
pharmacological inhibitors.
26,27
 This prompted an intensive research in this 
area. Over the past two decades, a number of relatively potent and selective 
CaMKII inhibitors have been reported. 
 
2. Aim of work 
 




 and peptides derived from the 




 are useful tools 
for examining the functional significance of Ca
2+
/CaMKII in the periphery and 
in the CNS system. Nevertheless, these compounds showed low potency and 
absence of highly specific inhibition. Thus, auto inhibitory region-derived 
peptides also inhibit other CaM-kinases and PKC,
32
 while KN62/KN93 cannot 







 A natural inhibitor of CaMKII, protein CaM-KIIN, 
provides a promising alternative in the research of selective inhibition.
35
 Two 
different isoforms of CaM-KIIN, named CaM-KIIN and CaMKIIN, are 
found in the brain. These proteins show 80% similarity with 70% identity into 
their amino acid sequences and are 95% identical in their inhibitory domain, 
differing by only one residue (S12 in CaM-KIINversus A12 in CaM-
KIIN).
35
 The inhibitory protein CaM-KIIN is highly selective for inhibition 
of CaMKII with little effect on CaMKI, CaMKIV, CaMKK, PKA, or PKC. A 
27-residue peptide derived from it, (CaM-KNtide 
KRPPKLGQIGRSKRVVIEDDRIDDVLK), retains the same selectivity and 
has a similar IC50 of 50 nM for both the total and the Ca
2+
-independent 
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activities of CaMKII. Recently, Vest et al. has identified a new peptide with an 
active sequence of 21 residues named CN21 
(KRPPKLGQIGRSKRVVIEDDR).
33
 Recently, Coultrap and Bayer reported 
that the compound named CN19 (KRPPKLGQIGRSKRVVIED) represents 
the minimal region of CaMKIIN that retains full potency and specificity for 
CaMKII inhibition.
36,37
 As part of our current interest in the study of CaMKII-
dependent cell signaling,
38
 we directed our efforts toward the identification of 




2.1 Selective CaMKII peptide inhibitors 
 
Focused on the inhibitory region of CaM-KIINwe designed different 
CaM-KNtide analogues and evaluated the inhibitory activity and specificity. 
The starting
40
 69 fragment of CaM-KIIN (CaMKNtide) and CaM-KNtide 
differs by only one amino acid (A12 to S12). This modification could prevent 
the S12 phosphorylation of substrate reducing interferences with CaMKII 
inhibition, analogously to what happens with the natural peptides and in 
agreement with Coultrap and Bayer hypothesis. 
Moreover, we describe the selectivity data for the more potent derivative 
characterized (peptide 17), as well as the structural results obtained using CD 
and NMR techniques. Finally, the biological effects of this fragment, 
conveniently conjugated to cell-permeating peptide tat, on the tumor cells 
growth inhibition, cytotoxic data and the activation of cell proliferation 
signaling pathway were also discussed. 
 
2.2 The first series of inhibitors (peptides scramble and 1-7) 
 
As first series, we synthetized a scramble analogue of the CaM-KNtide 
sequence and seven peptides that cover the entire CaM-KNtide sequence. 
Each short peptide had the sequence shifted of five residues, both from N- and 
C-terminal side (compounds 1-7, Table 1). 
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Inhib. HPLC ESI MS 




KRPPKLGQIGRAKRVVIEDDRIDDVLK 94.8± 5.0 3.27 3115.30 3115.70 
 Scramble IDGVIAQGDLPVDKEPKRLRKDIRKRV 13.3±6.2 3.27 3115.82 3115.70 
6-27 1 LGQIGRAKRVVIEDDRIDDVLK < 5 2.69 2509.22 2508.90 
11-27 2 RSKRVVIEDDRIDDVLK < 5 2.49 2057.23 2056.30 
17-27 3 VIEDDRIDDVLK 13.0±9.1 2.52 1429.70 1429.50 
1-22 4 KRPPKLGQIGRAKRVVIEDDRI 56.0±14.0 2.78 2544.62 2544.04 
1-17 5 KRPPKLGQIGRAKRVVI 76.0±4.1 3.12 1916.64 1915.40 
1-12 6 KRPPKLGQIGRA < 5 2.75 1321.04 1320.60 
1-7 7 KRPPKLG < 5 2.08 796.21 795.01 
 k’=[(peptide retention time-solvent retention time)/solvent retention time]. 
Peptide concentrantion 5 M.  
 
The shortest peptide that retained good inhibition of CaMKII (>75%) was 
the fragment containing amino acids 1-17 (peptide 5, named now CN17). All 
further truncations at the C-terminus by 4 amino acids or more (peptides 6 and 
7) and any truncation at the N-terminus by 5 amino acids or more (peptides 1-
3) showed minimal or no inhibition. 
CN17 seems to be slightly more potent than the corresponding analogue 
S12 (KRPPKLGQIGRSKRVVI, termed CN17), described by Vest et al., 
which inhibit <70% CaMKII activity at 5 M. These results confirmed that 
CaM-KNtide sequence containing an Ala residue at position 12 was an 
effective starting point to develop novel agents with CaMKII inhibitor activity. 
 
2.3 A truncation study at both the N- and C-terminals of the fragment 
1-17 (peptides 8-16) 
 
Subsequently, a truncation study at both the N- and C-terminals of the 
fragment 1-17 was performed in order to obtain additional information on the 
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minimum active sequence. Also, CN19 was synthetized and tested for 
comparative purpose.
36
 In our experimental conditions, CN19 lost about 40% 
of the CaM-KNtide activity (Tables 1 and 2) while Coultrap and Bayer found 
that it retained full potency and specificity for CaMKII inhibition.
36,37
 The 
discrepancy between our results and those obtained by Coultrap and Bayer on 
CN19 inhibition potency could be explained considering that the experimental 
conditions used in CaMKII activity assays are not exactly matching. 
 








Inhib. HPLC ESI MS 
(%±SD) k’ Found Calculated 
1-19 CN19  KRPPKLGQIGRSKRVVIED 54.0±1.0 3.17 2176.23 2175.28 
1-17 5  KRPPKLGQIGRAKRVVI 76.0±4.1 3.12 1916.64 1915.40 
2-17 8    RPPKLGQIGRAKRVVI < 5 3.01 1788.40 1788.23 
3-17 9       PPKLGQIGRAKRVVI < 5 3.08 1632.72 1632.04 
4-17 10         PKLGQIGRAKRVVI < 5 2.57 1535.03 1534.93 
5-17 11           KLGQIGRAKRVVI < 5 2.54 1437.98 1437.81 
6-17 12               LGQIGRAKRVVI < 5 2.58 1309.72 1309.60 
1-16 13 KRPPKLGQIGRAKRVV 10.2±2.0 2.61 1803.77 1803.25 
1-15 14 KRPPKLGQIGRAKRV 18.0±9.0 2.60 1704.30 1704.13 
1-14 15 KRPPKLGQIGRAKR < 5 2.09 1605.11 1604.98 
1-13 16 KRPPKLGQIGRAK < 5 2.34 1449.99 1448.79 
k’=[(peptide retention time-solvent retention time)/solvent retention time]. Peptide 
concentrantion 5 M.  
 
 
2.4 Alanine scanning approach of fragment 1-17 (peptides 17-32) 
 
Further truncation of compound CN17 significantly reduced CaMKII 
inhibition (compounds 8-16, Table 2), suggesting a bioactive role for both the 
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N- and C-terminal sequences. These results demonstrate that a satisfactory 
inhibitory activity is contained in 1-17 fragment of the CaM-KNtide.  
For this reason, we decided to check the contribution of the various amino 
acid residues to the inhibitory activity of CN17 through an L-Ala scanning 
analysis (peptides 17-32, Table 3). 
 
Table 3. Structure and inhibitory activity of compounds CaM-KNtide, and 
peptides 17-32. 
k’=[(peptide retention time-solvent retention time)/solvent retention time]. Peptide 
concentrantion 5 M.  
 
Data indicate a different sensitivity of our CN17 to Ala substitutions, 
compared to results obtained by Coultrap and Bayer with the same mutation in 
the peptide CN19.
36,37
 Only one mutant enhanced the potency of CN17 
versus the three mutants 19, 28, and 29, which increased significantly the 
 Inhib. HPLC ESI MS 
Pep. Sequence (%±SD)    k’ Found Calculated 
5     KRPPKLGQIGRAKRVVI 76.0±4 4 3.15 1916.64   1915.40 
17 AARPPKLGQIGRAKRVVI 13.5±2  3.20 1859.32 1858.30 
18 KKAPPKLGQIGRAKRVVI < 5 3.17 1832.72 1830.29 
19 KKRAPKLGQIGRAKRVVI 78.4±4 3.13 1890.09 1889.36 
20 KKRPAKLGQIGRAKRVVI 13.2±2 3.13 1890.75 1889.36 
21 KKRPPALGQIGRAKRVVI 7.0±2 4.71 1859.96 1858.30 
22 KKRPPKAGQIGRAKRVVI < 5 3.35 1876.40 1874.33 
23 KKRPPKLAQIGRAKRVVI 26.1±4 3.18 1931.16 1929.43 
24 KKRPPKLGAIGRAKRVVI 34.4±3 3.16 1860.22 1858.35 
25 KKRPPKLGQAGRAKRVVI < 5 3.15 1874.58 1873.32 
26 KKRPPKLGQIARAKRVVI 21.6±2 3.15 1931.22 1929.43 
27 KKRPPKLGQIGAAKRVVI 13.0±2 3.19 1831.12 1830.29 
28 KKRPPKLGQIGRAARVVI 33.7±1 3.17 1860.14 1859.31 
29 KKRPPKLGQIGRAKAVVI 69.0±2 3.16 1830.95 1831.30 
30 KKRPPKLGQIGRAKRAVI 24.2±2 3.16 1889.21 1888.35 
31 KKRPPKLGQIGRAKRVAI 74.2±1 3.14 1888.16 1888.30 
32 KKRPPKLGQIGRAKRVVA 48.7±3 4.71 1875.52 1874.32 
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 In our case, compound 19 increased slightly the inhibitor 
activity of CN17 while peptide 28 reduced its potency of more than 2.5 fold, 
indicating an important role for residue 
13
Lys in the CN17- CaMKII binding. 
Finally, mutant R14 maintained the inhibitor efficacy. 
 
2.5 Cell penetrating peptide (ant-CN17, tat-CN17) 
 
With the aim to improve the ability to penetrate cell, CN17was fused with 
two well known penetrating peptides (Ant: RQIKIWFQNRRMKWKKGGC 
and Tat: RKKRRQRRRPPQC) leading to peptides ant-CN17 and tat-CN17, 
respectively (Table 4). 
 










 CN17 KRPPKLGQIGRAKRVVI 3.12 1916.64 1915.40 
ant-CN17 ant- KRPPKLGQIGRAKRVVI 3.72 4362.35 4363.56 
tat-CN17 tat- KRPPKLGQIGRAKRVVI 3.75 3663.48 3664.23 
k’=[(peptide retention time-solvent retention time)/solvent retention time]. 
 
To test whether these fusion peptides were able to inhibit CaMKII activity, 




3.1 General procedure for synthesis 
 
Peptides were synthetized according to the solid-phase approach using 
standard Fmoc methodology in a manual reaction vessel.
41
 The first amino 
acid, N𝛼Fmoc-Xaa-OH, was linked onto the Wang resin (100–200 mesh, 1% 
DVB, 1.1 mmol/g) and was attached to Wang resin using HOBt/HBTU as an 
activating agent (3eq.) and a catalytic amount of DMAP. The following 
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protected amino acids were then added stepwise. The N𝛼-Fmoc protecting 
groups were removed by treating the protected peptide resin with a 25% 
solution of piperidine in DMF (1 × 5min and 1 × 25min) and the deprotection 
protocol was repeated after each coupling step. 
In addition, after each step of deprotection and after each coupling step, 
Kaiser test was performed to confirm the complete removal of the Fmoc 
protecting group, respectively, and to verify that complete coupling has 
occurred on all the free amines on the resin. Then Kaiser test was performed to 
confirm the acetylation reaction. 
The N-terminal Fmoc group was removed as described above, and the 
peptide was released from the resin with TFA/iPr3SiH/H2O (90 : 5 : 5) for 3 h.  
The resin was removed by filtration, and the crude peptide was recovered 
by precipitation with cold anhydrous ethyl ether to give a white powder and 
then lyophilized. 
 
3.2 Purification and Characterization 
 
All crude peptides were purified by RP-HPLC on a preparative C18-bonded 
silica column using a Shimadzu SPD 10A UV/VIS detector, with detection at 
215 and 254 nm. All peptides were characterized with analytical RP-HPLC 
and peptides molecular weights were determined by ESI mass spectrometry 
and LC-MS in a LC-MS 2010 instrument (Shimadzu) fitted with a C-18 
column. All analogues showed >97% purity when monitored at 215 nm. 
Homogeneous fractions, as established using analytical HPLC, were pooled 
and lyophilized. 
 
4. Results and Discussion 
 
The first part of the work focused on a SAR study of entire CaM-KNtide 
sequence designed a scramble analogue of the CaM-KNtide sequence and 
seven peptides that cover the entire sequence.  Each short peptide had the 
sequence shifted of five residues, both from N- and C-terminal side 
(compounds 1-7, Table 1). 
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The shortest peptide that retained good inhibition of CaMKII (>75%) was 
the fragment containing amino acids 1-17 (peptide 5, named now CN17). 
Starting from these data, CN17 was considered the peptide lead. 
Two different approaches were used to identify more potent and selective 
compounds: i) a truncation study at both N- and C-terminals of the fragment 1-
17; ii) Alanine scanning approach. 
Interestingly, further truncation of compound CN17 significantly reduced 
CaMKII inhibition (compounds 8-16, Table 2), suggesting a bioactive role for 
both the N- and C-terminal sequences. In particular all peptides showed an 
inhibitory activity < 5% except compounds 13 and 14 that showed 10.2% and 
18.0% of inhibitory activity respectively. 
These results suggested that a satisfactory inhibitory activity is contained in 
1-17 fragment of the CaM-KNtide. For this reason we decided to apply the 
Alanine scanning approach to peptide lead. 
The involvement of the N-terminal, internal or C-terminal amino acids in 
the CN17 activity can be summarized as follows: (a) in the N-terminal 
fragment (KRPPK) 
2







are important and significantly contribute to the potency of CN17, while the 
substitution of 
3
Pro by Ala leads to the analogue 19 with a slightly increase 
potency; (b) the internal hexapeptide Leu-Gly-Glu-Ile-Gly-Arg sequence is 




Ile result to be critical for the 
inhibitory activity of CN17while the contribution of 
8
Glu is lower; (c) in the 











contribute to a lesser extent to the activity. 
 
4.1  Biological effects of cell permeating tat-CN17 
 
With the aim to improve the ability to penetrate cell, CN17 was fused with 
two well known penetrating peptides (Ant: RQIKIWFQNRRMKWKKGGC 
and Tat: RKKRRQRRRPPQC) leading to peptides ant-CN17 and tat-CN17, 
respectively. To test whether these fusion peptides were able to inhibit 
CaMKII activity, we performed an in vitro kinase assay. 
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The results of the concentration response curve for tat-CN17, ant-CN17, 




Figure 1. Dose-response curves for CaM-KNtide and peptides tat-CN17 and ant-
CN17. Data are indicated as percent of inhibition over untreated; error bars represent 
±standard deviation (SD).  
 
CaM-KNtideexhibited an apparent IC50 of 50 nM toward CaMKII, while 
tat-CN17 and ant-CN17 showed approximately IC50 of 30 and 40 nM, 
respectively. Indeed, for CaM-KNtide and tat-CN17 the inhibitory effect 
was maximal at 1 M (~95% inhibition) and didn’t change even at the highest 
concentration of 5 M. At this last concentration, ant-CN17 exhibited a 
minor percentage of inhibition (76.2%). Similarly to the results described by 
Vest et al.,
33a
 the fusion of CN17with tat led to an increment of both potency 
and selectivity of the resulting peptide, while after the fusion with ant, the 
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Figure 2. Inhibitory activity and selectivity of peptides ant-CN17, tat-CN17, 
and CN17 at 5 M. Data are indicated as fold decrease; error bars represent 
±standard deviation (SD); **p-value < 0.01. 
 
In fact, as shown, neither peptide ant-CN17 nor tat-CN17 inhibit CaMKI 
(6.1% or -) or CaMKIV (-). The antennapedia cell-penetrant motif used in this 
study has been previously shown to bind calmodulin and affect CaMKII 
activity indirectly.
33a
 Anyway, since the selective inhibitory activity for 
CaMKII was observed for both the conjugate peptides ant-CN17 and tat-
CN17, with the best results obtained with tat-CN17, this indicates that the 




As described above, CaMKII plays a pivotal role in the cell pathways 
regulating proliferation, and its inhibition can reduce cardiovascular 
hyperplasia
42
 and tumor cell growth.
43
 We investigated the possibility that cell 
permeating compound tat-CN17 inhibited the proliferation of both tumor and 
vascular cell lines. We determined the effect of our compound on a breast 
cancer MCF7 and a colon cancer HT29 cell lines, on primary rat vascular 
smooth muscle VSMC cells, and on primary human fibroblasts. 
DNA duplication was assessed by the uptake of tritiated thymidine (3HT).
44
 
In this assay we used also the selective CaMKII inhibitor ant-CaNtide (ant-
fused CaM-KNtide) as reference peptide. 
As observed in Figure 3A, both ant-CaNtide and tat-CN17 reduced 3HT 
uptake, but the percent of inhibition depends upon the cell line used. Tat-
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CN17 was more effective than ant-CaNtide. Antiproliferative effect is clearly 
correlated to the proliferation rate of the cell line, indeed immortalized tumor 
lines MCF7 and HT29 are more affected than primary normal cells. We also 
investigated whether the inhibition of cell proliferation was correlated to a 
cytotoxic effect of tat-CN17 in our cell models.
45
 Cell viability was measured 
using PrestoBlue
TM 
Cell Viability Reagent (Invitrogen Inc, San Diego, CA). 
As shown in Figure 3B, at the same concentration, none of the peptides in the 
study modified the cell viability in any of cell lines we tested. These seems 
results suggest that the mechanism underlying the inhibitory activity of our 
peptides involves the proliferation signaling without promoting cellular death 
process in the time assay. 
 
 
Figure 3. A) Antiproliferative and (B) cytotoxic activities of ant-CaNtide and tat-
CN17 at 5 M. Results are presented as total incorporated counts per minute (cpm). 
Average ± SD values from n = 4 experiments are shown. *p-value ≤ 0.05. **pvalue ≤ 
0.01. 
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4.1.2 Signal transduction 
 
CaMKII is involved in the activation of the most important signaling 
pathway regulating cell proliferation: the Ras/Raf/MEK/ERK signaling 
pathway. Illario et al. demonstrated the existence of a cross-talk between 
Ca
2+
/CaM/CaMKII and Ras/Raf/MEK/ERK pathways.
46
 Accordingly, ant-
CaNtide is able to significantly affect CaMKII-mediated cell proliferation, by 
down regulating ERK activation. As tat-CN17 affected cell proliferation, we 
investigated whether it is also able to interfere with ERK activation. With this 
aim, we evaluated the expression of Erk, phospho(p)Erk, CaMKII, and 
phospho(p)CaMKII in cardiomyoblast (H9C2) and colon cancer (HT-29) cell 
lines by western blot (Figure 4A and B). Cells were serum starved over night 
in 0.5% DMEM/BSA and treated for 30 min with 10% of FBS, with or 
without CaMKII inhibitor tat-CN17. As shown in Figure 4A and B, serum 
stimulation induced both CaMKII and ERK activation, which was altered by 
treatment with different concentrations of tat-CN17. Densitometry 
measurements of immunoblots analyzing the levels of depicting pCaMKII and 
pERK in H9C2 and HT29 cells were performed using Image J software (NIH) 
(Figure 4C, D). In H9C2 cells (Figure 4A, C), ERK phosphorylation was 
down-regulated in a dose-dependent manner, whereas in HT-29 cells tat-
CN17 at 100 nM induced the maximal down-regulation of ERK 
phosphorylation (Figure 4B, D). These results suggest that the peptide 
interferes with cell proliferation by regulating, at least, the Ras/Raf/MEK/ERK 
signaling pathway. 
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Figure 4. Immunoblots for Erk, phospho(p)Erk, CaMKII, and phospho(p)CaMKII 
in (A) H9C2 and (B) HT-29 cells stimulated with serum and treated with 0.1, 1, and 5 
M tat-CN17 for 30 min. The respective densitometry analysis (C) and (D) are 
shown. Signal densities of bands represent individual and average values ± SD from 3 
experiments. 
 
4.2 CaMKII activity in cells 
 
The ability of peptides ant-CN17 and tat-CN17 to permeate the 
membranes allowed us to measure CaMKII activity in cells. To this purpose, 
the cardiomyoblast-like, H9C2, cells were starved for 12 h, and then 
stimulated for 30 min with 10% FBS in absence or presence of 5 M of 
indicated peptides. Endogenous CaMKII was immunoprecipitated, and its 
activity was measured by kinase assay using AC2. The ant-CaNtide was also 
tested as reference peptide. 
As shown in Figure 5 all tested peptides significantly inhibited activation of 
endogenous CaMKII. Tat-CN17 and ant-CN17 inhibited the CaMKII 
activity of 58 and 52%, respectively, and they seem to be moderately more 
potent than ant-CaNtide, which inhibits 39% of the CaMKII activity. 
According to these results, and analogously to that described by Vest et al. 
about tat-CN21,
33a
 the shorter derivative tat-CN17 becomes a powerful, 
readily accessible, and easy to-use tool for studying cellular CaMKII 
functions. 
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Figure 5. Inhibition of endogenous CaMKII activation by ant-CaNtide, ant-
CN17, tat- CN17 peptides as determined by kinase assay. Results are presented as 
total incorporated counts per minute (cpm). Average ± SD values from n= 4 
experiments are shown. *p-value ≤0.05. 
 
4.3 Conformational studies 
 
To drive the next design steps, we also carried out a study on the 
conformational preferences of the CN17. A preliminary screening of the 
conformational preferences of CN17 as a function of the solvent system was 
performed by means of CD spectroscopy (data not shown). CD spectra were 




Quantitative analysis of CD curves was carried out using both SELCON3 
and ContinLL algorithm on DICHROWEB
49
 website.  
The most common conformation of CN17 in water is random coil (≈80% 
of the total conformer population). In water/HFA (50:50, v/v) mixture, turn 
helical structures (≈65%) and minor amounts of -strand and unordered 
conformations (respectively ≈15% and 20% of the total conformer population) 
are observable. 
NMR spectra were acquired in water/HFA (50:50, v/v) the same solvents 
used for the CD measurement. Chemical shift assignments of the proton 
spectra of CN17 in water/HFA mixture were achieved via the standard 




 and NOESY 
experiments,
52
 using the SPARKY software package
53
 according to the 
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 Analysis of sequential and medium range NOE 
connectivities reveals the presence of regular secondary structures. In 




Arg residues, whereas strong sequential -N(i,i + 1) connectivities are 





The structural calculations of CN17 in water/HFA solution (50:50 v/v) 
based on sequential and medium range NOE data were performed using 
DYANA and Amber 5.0 softwares.
55,56
 Figure 6 shows the superposition of 





backbone atoms.  
 
 
Figure 6. NMR structure bundle (20 low energy conformers) of CN17 




Gly backbone atoms (RMSD ≤0.54). NMR structures 
were calculated using DYANA software on the basis of NOESY spectra recorded at 
600 MHz (T = 300 K) in water/HFA solution (50:50 v/v). 
 
The bundle reveals a high structural similarity (backbone RMSD ≤ 0.54 Å) 
in the overlapped region, suggesting that NMR structures are defined with 
high precision in this region. Analysis of CN17 NMR structures using 
PDBSUM on-line server
57










The crystal structure of the 21-residue segment of CaM-KNtide, the parent 
peptide of compound 5, is characterized by -helical conformation in the 
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 The remaining residues assume extended conformation 
to interact with a large surface of CaMKII structure. According to previous 
crystallographic studies, CAMKII structure exhibits three docking sites-
docking site A, B and C e to interact with R1 portion of the regulatory 
segment.
40
 Analogously to R1, these docking sites are contacted by 













Val occupy docking site A. The comparison of our best NMR 
structure of CN17with the crystal structure of CaM-KNtide bound to the 
kinase domain of CaMKII (Figure 7), indicates that the two structures have 











residues, belonging to the-helix and involved in interaction with CAMKII, 
share a common orientation of the side chains. Other indispensable residues 






Val; Ala scan, see above) do 
not overlap well by comparing the two structures. Anyway, they belong to the 
terminal regions of the peptide which are highly flexible in water/HFA 













Val assume the 
appropriate binding conformation by induced fitting. The design of novel 
CaM-KNtide based inhibitors should point to restrict the conformational space 
of the indispensable but flexible residues to fit the active conformation of the 
peptide in the complex. 
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Figure 7. Structural comparison of the NMR-derived lowest energy conformation 
of CN17 (dark blue) in water/HFA solution (50:50 v/v) and 21-residue segment of 
CaMKNtide (CN21) crystal structure (red) complexed to CaMKII enzyme (pdb code 




Arg residues. (For interpretation of the references to color in this figure legend, 




CaMKII is involved in the regulation of many pivotal cell functions, such 
as proliferation, and is therefore a key player in pathological processes, like 
oncogenesis. Hence, modulation of its activity could be exploited with 
therapeutic purposes. The present study describes the finding of a small 
CN17, the 1-17 fragment of CaM-KNtide, that selectively inhibits CaMKII. 
The fusion of CN17 with penetrations led to the conjugate peptides, ant-
CN17 and tat-CN17, which maintained usable inhibitory potency and 
selectivity of action compared to the parent peptide. 
Tat-CN17demonstrated to retain inhibitory potency, and to be more 
active than full length ant-CaNtide, to inhibit the proliferation of different cell 
lines, in particular of a breast cancer cell line and of primary human fibroblasts 
even if its sequence was 16 residues shorter. Our results indicated that tat-
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CN17inhibits cell growth and interferes with the Ras/Raf/MEK/ERK 
signaling pathway, through the inhibition of endogenous CaMKII. 
Finally, conformational analysis of parent CN17 gave important 
information on the design of novel analogues. Our data outline a promising 
perspective: the availability of a small peptide as a tool to modulate complex 
signal transduction pathways, and interfere with their homeostasis in disease, 
as well as the generation of specific, more stable and cell targeted peptides. 
 
6. Experimental section 
 
6.1 Peptide synthesis 
 
The synthesis of CaM-KNtide analogues was performed according to the 





-Fmoc-protected amino acids, Wang resin, HOBt, HBTU, DIEA, 
DMAP, piperidine and trifluoroacetic acid were purchased from Iris Biotech 
(Germany). Peptide synthesis solvents, reagents, as well as CH3CN for HPLC 
were reagent grade and were acquired from commercial sources and used 

















Arg(Pbf)-OH) was linked on to the resin previously deprotected by a 25% 
piperidine solution in DMF for 30 min. The following protected amino acids 

































Each coupling reaction was accomplished using a 3-fold excess of amino 
acid with HBTU and HOBt in the presence of DIEA (6 eq.). The N

-Fmoc 
protecting groups were removed by treating the protected peptide resin with a 
25% solution of piperidine in DMF (1 × 5 min and 1 × 25 min). The peptide 
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resin was washed three times with DMF, and the next coupling step was 
initiated in a stepwise manner. 
The peptide resin was washed with DCM (3 × 25), DMF (3×), and DCM 
(3×), and the deprotection protocol was repeated after each coupling step. 
The N-terminal Fmoc group was removed as described above, and the 
peptide was released from the resin with TFA/TIS/H2O (90:5:5) for 3 h. The 
resin was removed by filtration, and the crude peptide was recovered by 
precipitation with cold anhydrous ethyl ether to give a white powder and then 
lyophilized. 
 
6.2 Purification and characterization of CaMKII inhibitors 
 
All crude peptides were purified by RP-HPLC on a preparative C18-bonded 
silica column (Phenomenex, Jupiter 300Å, 100 mm × 21.2 mm, 10m,) using 
a Shimadzu SPD 10A UV−Vis detector, with detection at 210 nm and 254 nm. 
The column was perfused at a flow rate of 15 mL/min with solvent A (10%, 
v/v, water in 0.1% aqueous TFA), and a linear gradient from 10% to 90% of 
solvent B (80%, v/v, acetonitrile in 0.1% aqueous TFA) over 15 min was 
adopted for peptide elution. Analytical purity and retention time (tR) of each 
peptide were determined using HPLC conditions in the above solvent system 
(solvents A and B) programmed at a flow rate of 1 mL/min using a linear 
gradient from 10% to 90% B over 15 min, fitted with C-18 column 
Phenomenex, Aeris XB-C18 column (150 mm × 4.60 mm, 3.6 μm). All 
analogues showed >97% purity when monitored at 215 nm. Homogeneous 
fractions, as established using analytical HPLC, were pooled and lyophilized. 
At the same time, analytical reversed-phase HPLC was performed on C-18 
Phenomenex column Aeris XB-C18 column (150 mm × 4.60 mm, 3.6 μm) in a 
model LC-2010 system (Shimadzu, Kyoto, Japan). 
Elution was done with linear 10−90% gradients of solvent B into A 
(Solvent A was 0.1% TFA in water; solvent B was 0.1% TFA in CH3CN) over 
15 min at 1 mL/min flow rate, with UV detection at 220 nm for all peptides.  
To check and to have a confirmation of peptides molecular weights were 
used ESI mass spectrometry. ESI-MS analysis in positive ion mode, were 
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made using a Finnigan LCQ ion trap instrument, manufactured by Thermo 
Finnigan (San Jose, CA, USA), equipped with the Excalibur software for 
processing the data acquired. The sample was dissolved in a mixture of water 
and methanol (50/50) and injected directly into the electrospray source, using 
a syringe pump, which maintains constant flow at 5 μL/min. The temperature 
of the capillary was set at 220 °C. 
 
6.3 Cell culture 
 
Cardiomyoblasts H9C2, human breast cancer MCF-7, human colon 
adenocarcinoma grade II HT29, primary cultures of VSMCs obtained from 
thoracic aortas of WKY rats, primary cultures of fibroblasts obtained from 
human gum were maintained in DMEM with 10% fetal bovine serum. All 
media were supplemented with 100 units/mL penicillin and 100 g/mL 
streptomycin. 
 
6.4 CaMKII activity assay 
 
In all CaMKII assays, purified or endogenous CaMKII was incubated with 
Ca
2+
/CaM; EGTA was used as a negative control. 
Active recombinant full-length alpha CaMKII (Signal Chem, La Jolla) was 
incubated for 30 min at 30 °C with 1 mmol/L CaCl2 and 1 mol/L CaM in 10 
l of a reaction mixture (50 mmol/L HEPES pH 7.5, 10 mmol/L MgCl2, 0.5 
mmol/L dithiothreitol (DTT), 100 nmol/L microcystin, 0.1 mmol/L non-
radiolabeled ATP).
58
 In a second reaction step, an aliquot from the first 
reaction was incubated with 200 M of Autocamtide-2 as a substrate for 
CaMKII and the different peptides at concentration of 5 M, in presence of 0.2 
Ci/mL of Easy Tides Adenosine 50-triphosphate [
32
P]-ATP (Perkin Elmer) 
for 30 min at 30 °C; EGTA was added to quantify CaMKII autonomous 
activity. 
32
P-incorporation was determined by spotting 20 l of the reaction to 
Whatman P-81 phosphocellulose paper, and subsequently washing in 75 mM 
phosphoric acid. 
Dried filters were counted on a Beckman LS 6000 scintillation counter. 
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6.5 CaMKI and CaMKIV activity assay 
 
CaMKI and CaMKIV phosphorylation assays were performed at 30 °C in a 
standard solution consisting of 50 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM 
CaCl2, 1 mM dithiothreitol, 0.1% Tween 80, 0.5 mg/mL bovine serum 
albumin, and 25 M of CaM, 50 ng of CaMKK2, ATP (~50 cpm/pmol), and 
activated CaMKI (ENZO life sciences) or CaMKIV (ENZO life sciences) in a 
final volume of 50 l.
59
 The reactions were initiated by the addition of enzyme 
to a final concentration of 1 nM and terminated after 5 or 10 min. In a second 
reaction step, an aliquot from the first reaction was incubated with 200 M of 
ADR1G as a substrate for CaMKI or 200 M of -peptide as a substrate for 
CaMKIV and 5 mM of peptides ant-CN17, tat-CN17 and CN17 in 
presence of 0.2 Ci/l of Easy Tides Adenosine 50-triphosphate [
32
P]-ATP 
(Perkin Elmer) for 30 min at 30 °C. Reactions were terminated by spotting 20 
l on Whatman P-81 phosphocellulose filters followed by extensive washing 
in 75 mM phosphoric acid. The dried filters were counted on a Beckman LS 






To determine DNA synthesis, cells (MCF-7, HT29, VSMC, primary 
fibroblasts) were placed in a 24-well plate and serum-starved for 12 h in 
DMEM, 0.5% BSA. To test the effects of CaMKII’s inhibitors on cell 
proliferation 5 M of ant-CaNtide and tat-CN17 were added to wells. A total 
of 0.5 Ci [

H]thymidine was then added to the plates. After 24 h, the plates 
were gently washed with PBS and then with 10% trichloroacetic acid (TCA), 
and incubated 10 min with 20% TCA at 4 °C. The plates were washed with 
5% TCA, and cells were lysed with 0.2% SDS, 0.5 N NaOH for 15 min at 4 
°C. The lysates were then resuspended in 5 mL scintillation fluid and counted 
in a -counter (Becton Dickinson, Franklin Lakes, NJ, USA). 
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6.7 Cell viability assay 
 
This assay was performed using PrestoBlue
TM 
Cell Viability Reagent 
(Invitrogen Inc, San Diego, CA). PrestoBlue
TM
 reagent is a resazurin-based 
solution that functions as a cell viability indicator by using the reducing power 
of living cells to quantitatively measure the proliferation of cells. The 
PrestoBlue
TM
 reagent contains a cell-permeant compound that is blue in color 
and virtually not fluorescent. When added to cells, the PrestoBlue
TM
 reagent is 
modified by the reducing environment of the viable cell, turns red in color and 
becomes highly fluorescent. This change in fluorescence is detected as 
measurement of absorbance, referred to the two controls (medium alone, and 
untreated cells). This reagent was used to evaluate cell viability in presence or 
absence of CaMKII inhibitors. Briefly, MCF7, HT29, VSMC, primary 
fibroblasts cells were plated into 96 multi-well at a density of 2000 cells/well 
in quadruplicate. CaMKII inhibitor, ant-CaNtide and tat-CN17, were added 
to each well at a concentration of 5 M for 24 h. Then 10 l of reagent were 
added to each well, and the plates were returned to cell culture incubator for 2 
h at dark. The absorbance in each well was measured at 570 nm in a 
microplate plate reader, and was referred to the absorbance of the two 
controls, that were used to calibrate the plate reader. 
 
6.8 Western blot analysis 
 
H9C2 and HT-29 were serum starved over night with DMEM/0.5% BSA. 
Cells were stimulated with 10% of FBS for 30 min and treated with different 
concentration of tat-CN17 for 30 min. At the end of the stimulation, cells 
were lysed in ice-cold RIPA/SDS buffer [50 mmol/L TriseHCl (pH 7.5), 150 
mmol/L NaCl, 0.01 g/L NP-40, 0.0025 g/L deoxycholate, 2 mmol/L Na3VO4, 
0.2 g/L sodium dodecylsulfate]. 
Protein concentration was determined using BCA assay kit (Pierce). Equal 
amounts of total cellular extracts or immunocomplexes were electrophoresed 
on 4-12% SDS-PAGE gel (NOVEX) and transferred to a nitrocellulose filter 
(Immobilon P; Millipore Corporation, Bedford, MA). The membranes were 
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blocked in Tris buffered saline containing 0.002 g/L Tween 20 (TBST) and 
0.05 g/L nonfat dry milk. After blocking, the membranes were washed three 
times in TBST and then incubated overnight at 4° C in TBST containing 5% 
BSA with primary specific antibody: total CaMKII and ERK 1/2 (1:1000, 
Santa Cruz, CA), phospho-tyrosine p44/p42 ERK (1:1000 Santa Cruz, CA) 
and phospho-CaMKII antibody (pT286) (Invitrogen). The blots were washed 
three times in TBST incubated in appropriate HRP-conjugated secondary 
antibodies (1:2000, Santa Cruz, CA) diluted in TBST containing 5% nonfat 
dry milk and incubated for 1 h at room temperature. After 3 additional washes 
with TBST, immunoreactive bands were visualized by enhanced 
chemiluminescence using the ECL-plus detection kit (Amersham Biosciences) 
and quantified by using ImageQuant software (Amersham Biosciences). 
 
6.9 Sample preparation for CD and NMR analysis 
 
To record CD and NMR experiments in water/HFA solution (50:50 v/v) 
CN17was added to an aqueous solution (pH 5.4, phosphate buffer 25 mM). 
This yielded final concentrations of 0.15 mM for CD experiments. For NMR 
samples, a H2O/D2O (90:10 v/v) mixture was used. To exclude potential 
aggregation, we recorded the 1D proton spectra of CN17 at a concentration 
range spanning 1.0-0.1 mM. At a peptide concentration of 1.0 mM there were 
not any noticeable effects of aggregation. Therefore, our NMR analyses were 
carried at sample concentrations of 1 mM. 
 
6.10 CD analysis 
 
All CD spectra were recorded using a JASCO J810 spectropolarimeter at 
room temperature and with a cell path length of 1 mm. CD spectra were 
performed at 25 °C using a measurement range from 260 to 190 nm, 1-nm 
bandwidth, 4 accumulations and a 10 nm/min scanning speed. Spectra were 
corrected for solvent contribution. For an estimation of secondary structure 
content, CD spectra were analyzed using both the ContinLL and SELCON3 
algorithms from the DICHROWEB website.
49
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6.11 NMR analysis 
 
NMR spectra were collected using a Bruker DRX-600 spectrometer at 300 
K. 1D NMR spectra were recorded in the Fourier mode with quadrature 
detection. The water signal was suppressed by low-power selective irradiation 
in the homo-gated mode. DQFCOSY, TOCSY, and NOESY
45,47
 experiments 
were run in the phase-sensitive mode using quadrature detection in 1 via 
time-proportional phase increases of the initial pulse. Data block sizes were 
2048 addresses in t2 and 512 equidistant t1 values. Prior to Fourier 
transformation, the time domain data matrices were multiplied by shifted sin 2 
functions in both dimensions. A mixing time of 70 ms was used for the 
TOCSY experiments. NOESY experiments were run with mixing times in the 
range of 100-300 ms. Qualitative and quantitative analyses of DQF-COSY, 




6.12 NMR structure calculations 
 
Peak volumes were translated into upper distance bounds with the CALIBA 
routine from the DYANA software package.
55
 The requisite pseudoatom 
corrections were applied for non-stereospecifically assigned protons at 
prochiral centers and for the methyl group. After discarding redundant and 
duplicated constraints, the final list of experimental constraints was used to 
generate an ensemble of 100 structures by the standard DYANA protocol of 
simulated annealing in torsion angle space implemented (using 6000 steps). 
No dihedral angle or hydrogen bond restraints were applied. The best 20 
structures that had low target function values (0.83-1.19) and small residual 
violations (maximum violation = 0.38 Å) were refined by in vacuo 
minimization in the AMBER 1991 force field using the SANDER program of 
the AMBER 5.0 suite.
56
 To mimic the effect of solvent screening, all net 
charges were reduced to 20% of their real values. Moreover, a distance-
dependent dielectric constant (ε = r) was used. The cut-off for non-bonded 
interactions was 12 Å. NMR-derived upper bounds were imposed as semi-
parabolic penalty functions, with force constants of 16 kcal/mol Å
2
. The 
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function was shifted to be linear when the violation exceeded 0.5 Å. The best 
10 structures after minimization had AMBER energies ranging from -441.4 to 
-391.1 kcal/mol. 
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Appendix A- Automated peptide synthesizers 
 
Solid-phase peptide synthesis (SPPS) is still often faced with challenges in 
the assembly of long and ‘difficult’ sequences, e.g. due to aggregation and 
steric hindrance giving rise to incomplete reactions. 
These problems have only partly been solved by new coupling reagents and 
solid supports. Precise microwave heating has emerged as one new parameter 
for SPPS, in addition to coupling reagents, resins, solvents etc.
1
 
Fast and precise heating by microwave irradiation during solid-phase 
peptide synthesis (SPPS) can reduce reaction times as well as provide better 
purities and greater yields for the synthesis of difficult peptides. 
Microwave- assisted SPPS has proven to be a useful and reliable tool for 
the synthesis of peptides as well as small proteins. It is particularly well suited 
for sequences with a high propensity to form -sheet-type structures and for 
sterically difficult coupling. 
Several chemical methods to suppress intramolecular aggregation have 








Heating is likely to reduce both the inter- and intramolecular-derived self-
assemblies and thereby decrease the reaction time and improve the coupling 
efficiency of bulky and -branched amino acids. 
Microwave irradiation is a promising tool in peptide chemistry because of 
the rapid and precise elevation of the temperature and the efficient temperature 
control during the synthesis.  
 
A.1 Automated Peptide Synthesizers 
 
Following Merrifield’s pioneering invention of solid-phase peptide 
synthesis, his group also developed the concept of automated solid-phase 
peptide synthesis
5,6
 and constructed the first synthesizers in the mid-1960s.
7,8
 
Using one of the first synthesizers, Gutte and Merrifield synthesized 
Ribonuclease A, a 124 amino acid protein, using an astonishing 369 chemical 
reactions and 11,391 steps on the automated peptide synthesizer, relying on 
the synthetic chemistry and analytical methods available at that time.
9,10
 Later 
other laboratories and companies developed a diverse range of laboratory 
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 The introduction of Fmoc based SPPS
13
 and more 
sophisticated hardware as well as software allowed for simpler designs of 
automated peptide synthesizers. The simplified synthesizers have over the 
years led to comparably robust and reliable synthesizers, which have resulted 




In the last year of my PhD, my research group started to approach to 
automated synthesizer, in particular to SyroWave
TM
 (Biotage) (Figure 1) 
which has shown to be a very flexible instrument for SPPS due to its ability to 
perform either single microwave reactions or conventional parallel synthesis at 
RT.  
 




This instrument is built around a valve-free robot originally developed for 
parallel peptide synthesis, where the robotic arm trasports reagents instead of 
pumping via valves. Additionally, the reaction vessel is vortexed in the 
microwave cavity.  
This is the first example of an “X-Y” robotic microwave-assisted 
synthesizer developed for the assembly of long peptides. Several group have 
shown that mixing is extremely important during microwave-assisted 
SPPS.
14,15
 Overall the use of microwave heating during SPPS will often aid the 
synthesis of difficult peptides and small proteins, provided that commonly 
occurring side reactions can be avoided. 
For the synthesis of difficult sequence the introduction of state of-the-art 
resins and coupling reagents has solved previous problems associated with its 
synthesis. 
Microwave irradiation in combination with the optimal coupling reagent 
showed to solve most of challenges with the assembly of peptide. 
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A.2.1 Optimization of automated peptide synthesizers  
 
The possibility of a so-called microwave effect
16
 has been discussed but 
studies have indicated that the observed enhancement was purely of a thermal 
nature, as similar results were obtained with conventional heating.
17
 
Another significant question is how to prevent the occurrence of 
epimerization. Studies on the risk of epimerization in peptides containing Cys 
and His residues during microwave-assisted SPPS indicated that His and Cys 
should be coupled at 50°C or maybe even at room temperature. 
The aim of this study was to develop a general protocol for microwave 
accelerated solid-phase synthesis of carboxyl sequence.  
Microwave irradiation in combination with the optimal coupling reagent 
showed to solve most of challenges with the assembly of peptide. 
The synthesis of PTPRJ agonist, peptide 6 [CHHALTHAC] (see Chapter 2) 
was used to investigate optimal coupling conditions, especially temperature, 
time, solid supports and coupling reagents on the automated microwave-





A first attempt to prepare peptide 6 by a standard Fmoc procedure using 
Wang resin not functionalized and the same protocol used for manual 
synthesis (HBTU/HOBt as coupling reagents and DMF as solvent of choice) 
showed a yield rather low (Figure 2). 
LC-MS analysis of the crude product showed the expected peptide without 
Alanine-Cysteine in C-terminal (m/z 818) as the main peak but the overall 
quality of the material was rather low (Figure 2). 
Different synthesis were planned using i) Fmoc-Cys(trt)-Wang resin 
avoiding the use of a catalytic amount of DMAP; ii) 2-Cl trityl resin; iii) 
Fmoc-Cys-(trt)-Wang resin and HOAt instead HOBt like coupling reagent. 
i)The use of functionalized Wang resin allowed us to reduce the side reactions 
at least in part, but the yield was still low. It was necessary to optimize the 
synthesis protocol changing resin and/or coupling reagents. 
ii)We investigated the impact of heating on 2-Cl trityl resin during the 
synthesis of C-terminal carboxylic acid peptides. The first N

-Fmoc amino 
acid were dissolved in dry dichloromethane (DCM) and with this solvent it is 
not possible to use MW irradiation leading to a long reaction time. 
We understand also that the use of microwave during couplings lead to a 
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iii)The purity was further optimized by substituting HBTU with other coupling 
reagents. Interestingly, for this particular peptide, the results for HOAt gave a 
superior outcome compared to other coupling reagents. 
 
Figure 2. HPLC crude profile of peptide 6 and ESI-MS spectrum of peptide 6: 
[M+2H]
2+










Summarizing, two possible synthetic approaches could be used to obtain 
satisfactory results: 1) manual synthesis with 2-Cl trytil resin. The steric size 
of 2Cl-Trt group not allow the formation of diketopiperazide (see Chapter 2); 
2) automated microwave synthesis with Fmoc-Cys(trt)-Wang resin which 
allowed to use high temperature reducing time of synthesis and side reactions. 
The protocol was optimize using HOAt as coupling reagent instead HOBt 
that leads to several side reactions. Moreover the preferred solvent with 
microwave is NMP, N-methyl pyrrolidone instead DMF, Dimethylformamide. 
To ensure the completed coupling or deprotection we used all double 
coupling and/or double deprotection protocol which allow to repeat the 
reaction in the same condition twice (Table 1). 
The optimal coupling condition for Histidine and Cysteine couplings 
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Appendix B- An Optimized Fmoc Synthesis of  
Human Defensin 5 
 
Current methods for solid-phase peptide synthesis (SPPS) can reliably 
generate a very wide range of peptides. However, peptide synthesis can be a 
rather time-consuming process and accelerating reactions using elevated 
temperatures to enhance coupling rates has been explored.
1
 Furthermore, 
despite the many advances in the chemistry of peptide synthesis, assembly of 
“difficult sequences” often remains a problem, due to aggregation and steric 
hindrance giving rise to incomplete reactions.  
These problems have only partly been solved by new coupling reagents and 
solid supports. 
To understand how different resins and different protocols influence the 
efficiency of the synthesis, I focused the attention on a difficult synthesis, 
Human -defensin 5 (DEF5). In particular I performed a research project in 
Barcelona, to Pompeu Fabra University, with the scientific support of Prof. 
David Andreu and Dr. Beatriz G. de la Torre.
2
 
I used different protocols to optimize solid-phase synthesis of DEF5 using 
the Fmoc strategy. 
 
B.1 Human defensin 5 (DEF5) 
 
Human defensin 5 (DEF5) is a 32-residue cysteine-rich host-defense 
peptide that exhibits three disulfide bonds in the oxidized form (DEF5ox) 
(Figure 1). 
DEF5 belongs to Defensins, antimicrobial peptides (AMPs)
 3,4
 that play an 
important role in host defense as components of the innate immune system.
5,6
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Figure 1. a) Three-dimensional structure of DEF5 showing the triple-strand -
sheet and the disulfide bridges;
12
 (b) Amino acid sequence and disulfide connectivity 
of DEF5. Residues in red refer to points at which peptide-resin samples were taken 
and a mini-cleavage (arrow) performed; see text for more details. 
 
It is stored in Paneth cell secretory vesicles as a 75-amino acid propeptide 
which, in response to microbial invasion, is converted into a 43-aa propeptide 
by the metalloproteinase matrilysin,
7
 then by trypsin proteolysis into the 32-
residue mature form that is released into the intestinal lumen.
8
 DEF5 has been 
reported to play an important role in Crohn’s disease, where loss of 
endogenous DEF5 is observed in the small intestinal while other Paneth cell 
products remain unchanged;
9
 also, a single R13H point mutation in DEF5 has 
been observed in patients with inflammatory bowel disease.
10
 
A growing interest on defensin structural and functional studies has placed 
increasing pressure on the sources of these peptides. Most studies to date have 
used defensins directly purified from cell extracts and tissues, but low yield 
makes studies costly and highly time-consuming. The alternative of 
overexpressing DEF5-coding genes was for long complicated by the toxicity 
of the peptide toward host cells, its susceptibility to proteolytic degradation 
and its small size; only recently have these difficulties been partly avoided and 
expression of mature DEF5 achieved in moderate efficiencies in P. pastoris
11
 
or E. coli expression systems.
12,13
 Even so, a peptide of DEF5’s size and 
complexity would ideally appear to be well within the scope of chemical 
synthesis methods, with their inherent expediency and flexibility. Surprisingly, 
however, while various synthetic accounts of “defensin like” peptides -i.e., 
Appendix B                              An Optimized Fmoc Synthesis of Human Defensin 5 
 
- 169 - 
 
around 30-residue long and with three disulfide bridges– came up in a 
thorough revision of the literature, only one synthesis of DEF5
14
 has been 
hitherto reported, and that by a synthetic (Boc-based) methodology that is 
unfeasible at many labs due to hazard restrictions to the use of anhydrous HF. 
It seemed worthwhile, therefore, to explore whether DEF5 could be efficiently 
made by the more convenient Fmoc methodology that we have successfully 
applied to other peptides of similar size and complexity.
15,16
 Indeed, the goal 
proved considerably more challenging than originally expected: a trial DEF5 
synthesis run using standard Fmoc methods turned up a very unpromising 
product in very low yields. What follows is an account of the various synthetic 
improvements that have finally enabled a reasonably efficient Fmoc synthesis 
of DEF5. This has involved identifying problematic stretches during the 
sequence assembly process and introducing corrective modifications, 
particularly regarding the solid support and the use of Pro dipeptide units at 
identified trouble spots. These improvements can be combined to produce an 
hexathiol DEF5 precursor clean enough to be oxidized as a crude product, 
with no need of purifying the intermediate, thus increasing the efficiency of 
the synthetic approach. 
 
B.2 Results and discussion  
 
The goal of this research was to find a strategy for producing DEF5, and 
eventually analogues thereof, by an efficient solid phase synthesis method 
using Fmoc chemistry. The only reports of DEF5 and DEF5 analogue 
synthesis published so far
14,17
 rely on Boc chemistry for chain assembly and 
anhydrous HF for final cleavage and deprotection, the last step being 
impractical for many laboratories given the safety hazards and consequent 
restrictions on HF use. In the search for a robust Fmoc-based synthetic route to 
DEF5 we have encountered a variety of hurdles that have been overcome, with 
reasonable success, as summarized in the workflow diagram shown in Figure 
2.  
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Figure 2. Workflow in the optimization of DEF5 synthesis. Asterisks in runs #2 to 
#6 refer to DEF5
a
 instead of DEF5 being used as synthetic target, for expediency 
reasons.   
 
A first attempt to prepare DEF5 by a standard Fmoc procedure using Fmoc-
L-Arg(Pbf)-Wang resin as starting material clearly showed that optimization 
would be required. UV monitoring of the sequence assembly process indicated 
several non-quantitative couplings and, accordingly, while LC-MS analysis of 
the crude product showed the expected hexathiol (MW 3588) as the main peak 
(Figure 3a), the overall quality of the material was rather low. In view of this, 
in a second trial ChemMatrix
®
 resin, a PEG-based support known to minimize 
the aggregation phenomena
18
 suspected largely responsible for the poor results 
of the first synthesis, was used instead of polystyrene-based Wang resin. 
Assuming also that the synthetic problems were unrelated to the (carboxyl or 
amide) nature of the C-terminus, a Rink amide-functionalized ChemMatrix
®
 
resin, eventually furnishing DEF5 amide (DEF5
a
), was chosen in order to 
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simplify the C-terminal attachment step. In addition, the chain elongation 
process was monitored by mini-cleavage of peptide resin aliquots (N-
deprotected beforehand) and LC-MS analysis of the product at three pre-
selected positions: (1) 
27
Tyr, early in the synthetic process, to ensure that chain 
assembly was proceeding adequately or, if not, try to solve the problem by 
decreasing resin loading; (2) 
22
Ile and (3) 
14
Glu, two positions preceded each 
by a Ser residue, hence amenable to pseudoproline (Pro) dipeptide 
replacement, a tactic to deliberately disrupt -sheet structures causing 
interchain aggregation and sluggish chain growth.
19,20
 MS confirmed that 
synthesis was proceeding smoothly at steps (1) and (2); in both cases, the 
mini-cleavage afforded a highly homogeneous product with the mass expected 
at that stage. Mini-cleavage at (3), however, showed the (14-32) sequence to 
be present only in minor amounts and accompanied by various deletion 
peptides indicating low coupling efficiencies in the 14-23 (ESLSGVCEIS) 
stretch. Elongation up to the N-terminus, deprotection and cleavage gave a 
crude (Figure 3b) of very similar complexity to that of the mini-cleavage, only 
marginally cleaner than the first synthesis (Figure 3a). In view of this, two new 
syntheses of DEF5 amide were planned, again on ChemMatrix
®
 resin, and 
with Pro replacements at the above-mentioned positions. The synthesis 
with the Ile-Ser(
Me,Me
pro)-OH dipeptide replacement at positions 22-23 
brought no improvement over previous runs; indeed, the main peak of the 
extremely poor crude (Figure 3c) could not be matched by LC-MS to the 
target 3587 Da mass. In contrast, replacement at positions 14-15 with 
Glu(OtBu)-Ser(
Me,Me
pro)-OH dipeptide resulted in a product with and HPLC 
profile (Figure 3d) significantly cleaner than any of the earlier attempts, and 
with the expected mass of 3587 Da for the main peak. Purification of this 
crude product by preparative HPLC, however, afforded a disappointingly low 
recovery of DEF5
a
 hexathiol precursor. Suspecting that the standard workup of 
the TFA cleavage solution, i.e., adding cold diethyl ether and centrifuging, 
was in this case inefficient, hence the peptide remained stuck to the resin, we 
resorted to a more thorough peptide isolation procedure, namely filtering-off 
the resin first (see Experimental section) and then treating the filtrate with 
chilled ether to induce peptide precipitation in the absence of resin. After 
centrifugation and drying, the amount of solid crude product was ca. 5 times 
higher than with the standard procedure. This improved isolation protocol was 
applied systematically henceforth (Figure 2). At this point it was clear that 
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Ser dipeptide combined with ChemMatrix
®
 
resin usage had meant a significant difference in DEF5
a
 synthesis. To 
elucidate the specific contribution of the resin to the improved result, another 
DEF5
a
 synthetic run was done, this time using Rink-amide-MBHA resin, the 
Glu(OtBu)-Ser(
Me,Me
pro)-OH dipeptide at positions 14-15, and the optimized 
peptide isolation protocol described above. The crude product (Figure 3e) was 
slightly cleaner than in the first -also polystyrene-based- synthesis (Figure 3a), 
hence confirming the favorable effect of the Pro replacement, but 
nonetheless of poorer quality than when Pro and ChemMatrix
®
 resin were 
simultaneously used, proving that only by combined usage of both 
modifications a substantial improvement was achieved. These advantages 
were again verified in the synthesis of the carboxyl (natural) sequence of 
DEF5, for which an aminomethyl ChemMatrix
®
 resin was functionalized with 
the HMPP linker, loaded in manual mode with Fmoc-Arg(Pbf)-OH, then 
elongated as above in the synthesizer. The resulting crude (Figure 3f) was of 
comparable quality to the previous DEF5
a
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Figure 3. Optimization of DEF 5 synthesis; see workflow chart in Figure 2 for 
details. HPLC profiles of crude products (a) and (f) correspond to DEF5 syntheses; 
(b) to (e) to DEF5
a
 syntheses. In all instances, the asterisk-marked peak eluting at ca. 
5.3 min corresponds to the hexathiol precursor of DEF5 or DEF5
a
. Elution was with a 
linear 20 to 50% gradient of B into A over 15 min, at 1 mL/min flow rate; solvents A 
and B as described in the experimental.  
 
For the final, oxidative folding step of DEF5 synthesis, an HPLC-purified 
hexathiol precursor was initially used. Disulfide formation in 0.1 M NH4OAc 
buffer containing both reduced (GSH) and oxidized (GSSG) glutathione under 
N2 atmosphere was complete after overnight reaction and led to a single folded 
product with the expected 3582 Da mass. Also, taking cue from the good 
results obtained by Wu et al. (2004) in the oxidation of the hexathiol precursor 
in unpurified form, we proceeded accordingly and confirmed that unpurified 
crude (Figure 4a) could be similarly converted to the oxidized/folded form 
using the above anaerobic conditions (Figure 4b). In this way, a typical 
synthesis run (0.1 mmol) required only a single HPLC purification step and 
led to highly homogeneous (>95%) folded product in amounts of ca. 15 mg. 












Cys) of our synthetic material 
was verified by comparison with an authentic (commercial) DEF5 sample by 
analytical HPLC, with both peptides found to coelute (Figure 4c). 
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Figure 4. (a) Hexathiol precursor (run #7, Figure 2) is efficiently converted to 
native-folded DEF5 (b); for conditions see text. (c) HPLC-purified DEF5 (full line) 
coelutes with an authentic sample (broken line); inset: ESI-MS spectrum of DEF5: 
[M+6H]
6+
 (m/z 598.05), [M+5H]
5+
 (m/z 717.60) and [M+4H]
4+
 (m/z 896.70) peaks 
are shown. In all cases, HPLC elution was with a linear 5 to 40% gradient of B into A 
over 15 min, at 1 mL/min flow rate; solvents A and B as described in the 
experimental. 
B.2.1 Proteolytic Stability of both DEF5ox and DEF5red. Trypsin is a 
serine protease that preferentially cuts after cationic residues including Arg 
and Lys, and it is the processing enzyme for the DEF5 propeptide.
21
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It is accepted that the defensin disulfide array confers protease resistance, 
and DEF5ox (defensin 5 oxidated) is a very poor substrate for trypsin.
22
 
In contrast, treatment of DEF5red (defensin 5 reduced) with proteases such 
as trypsin results in rapid proteolytic cleavage.
23
 
Anyway to check this, the time course of trypsin digests of reduced and 
oxidized peptide was monitored by LC-MS. As expected, the DEF5red was 
totally degraded after 5 min digestion (data not shown). Instead, longer 
incubation times are required for complete proteolytic breakdown of the DEF 
5ox. In fact as expected the DEF5ox is quite impervious to proteolysis, with an 
appreciable decay only after six hours of incubation (80% degraded) and a 
totally digestion only after 18 hours . 
In conclusion, the presence of three disulfide bonds decreases the 
accessibility of trypsin cleavage sites.  Therefore, the complete disulfide array 
of native DEF5ox is essential for protease resistance. 
 
 
Figure 5. Stability of DEF5ox. The amount of peptide remaining after incubation 




Results presented in this study illustrate how concomitant use of 
ChemMatrix
®




Ser position transform the initially impractical production of DEF5 into 
a satisfactory stepwise Fmoc synthesis method. The two critical improvements 
in the sequence assembly process, complemented by optimized work-up after 
cleavage, enabled oxidative folding directly on the synthetic crude, avoiding 
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one intermediate purification step and thus making the global process quite 
efficient. This optimized synthesis paves the way to obtaining DEF5 and its 
analogues in sufficient quantities for structural and biological studies. 
 




Fmoc-protected amino acids, HBTU and Fmoc-L-Arg(Pbf)-Wang resin 
were from Iris Biotech (Marktredwitz, Germany). Fmoc-Rink-amide 
ChemMatrix resin was from PCAS BioMatrix, Inc. (Saint-Jean-sur-Richelieu, 





pro)-OH were from 
Novabiochem (Laüfelfingen, Switzerland). An authentic sample of DEF5 was 
purchased from Innovagen (Sweden). HPLC-grade CH3CN and peptide 
synthesis-grade DMF, CH2Cl2, DIEA and TFA were from Carlo Erba-SdS 
(Sabadell, Spain). All other reagents were of the highest quality commercially 
available from Sigma-Aldrich (Madrid, Spain).  
 
General peptide synthesis procedures 
 
Peptides were assembled in an ABI433 peptide synthesizer (Applied 
Biosystems, Foster City, CA) running Fmoc (FastMoc) SPPS protocols at 0.1-
mmol scale on either Fmoc-L-Arg(Pbf)-Wang resin, Fmoc-Rink-amide 
ChemMatrix resin, Fmoc-Rink-amide (MBHA) resin or aminomethyl 
ChemMatrix resin. Side chain functionalities were protected with tert-butyl 
(Glu, Ser, Thr, Tyr), N
G
-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl 
(Arg), trityl (Cys) groups. Eight-fold excess of Fmoc-L-amino acids and 
HBTU, in the presence of a double molar amount of DIEA, were used for the 
coupling steps, with DMF as solvent. After chain assembly, full deprotection 
and cleavage were carried out with TFA/H2O/EDT/TIS (94:2.5:2.5:1 v/v, 90 
min, rt). Peptide isolation was initially done by the standard procedure in 
Fmoc chemistry, namely precipitation with cold diethyl ether and 
centrifugation. However, as this practice was shown to be inadequate for 
DEF5 (see Results and Discussion), the cleavage suspension was passed 
through a syringe fitted with a polyethylene porous disk to filter off the resin, 
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which was rinsed with an additional 1 mL of TFA; the filtrate was then poured 
onto cold diethyl ether to give a white precipitate that was collected by 
centrifugation, redissolved in 0.1M acetic acid and lyophilized. 
 
Analysis and purification  
 
Analytical reversed-phase HPLC was performed on C18 columns (4.6 × 50 
mm, 3 μm, Phenomenex, Torrance, CA) in a model LC-2010A system 
(Shimadzu, Kyoto, Japan). Solvent A was 0.1% TFA in water; solvent B was 
0.1% TFA in CH3CN. Elution was done with linear 20−50% gradients of 
solvent B into A over 15 min at 1 mL/min flow rate, with UV detection at 220 
nm for the linear peptide and with  5-40% linear gradient of B into A for 
oxidized peptide. LC-MS was performed in a LC-MS 2010EV instrument 
(Shimadzu) fitted with an XBridge column (4.6 × 150 mm, 3.5 μ ,  aters, 
Cerdan ola del  all s,  pain  eluted with a 20-50% linear gradient of B into 
A for the unfolded (reduced) peptide and with a 5-40% linear gradient of B 
into A for the oxidized peptide (A = 0.1% formic acid in water; B = 0.08% 
formic acid in acetonitrile) over 15 min at a flow rate of 1 mL/min, with UV 
detection at 220 nm. Preparative HPLC runs were performed on a Luna C18 
column (21.2 mm  250   , 10 μ ; Pheno enex , using linear gradients of 
solvent B (0.1% in ACN) into A (0.1% TFA in water), as required, with a flow 
rate of 25 mL/min. Fractions of high (>95%) HPLC homogeneity and with the 





The reduced (hexathiol) forms of DEF5 or DEF5
a
 were oxidized at 5 M 
concentration in 0.1 M NH4OAc, pH 7.8, 25 °C.
15
 The peptide, with or without 
previous HPLC purification (see Results and Discussion), was dissolved at the 
specified concentration in the above buffer containing both reduced (GSH) 
and oxidized (GSSG) glutathione to give a 1:100:10 peptide:GSH:GSSG ratio. 
The solution was then placed under inert (N2) atmosphere and stirred 
overnight at 25°C. Progress of the folding reaction was monitored by 
analytical HPLC and, once completed, the target products were purified to 
homogeneity by preparative RP-HPLC and subsequently lyophilized. The 
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synthetic DEF5 thus folded and purified coeluted in analytical HPLC with an 
authentic DEF5 sample.  
 
Proteolytic stability of DEF5 
 
For proteolytic stability determination, peptides (1 mg/mL in 50 mM 
NH4HCO3) were incubated with trypsin (Promega) at 37°C in a 1:100 enzyme-
peptide ratio. Incubation was terminated by acetic acid addition. The 
remaining amount of original peptide was determined by HPLC peak 
integration (elution conditions as above). 
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